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Abstract 
A deeper insight into the structural biology of HS is key to understanding its near-
universal functional role as a co-receptor for growth factors and morphogens. Due to the 
extreme difficulty in preparing homogeneous HS oligosaccharides for structural and 
functional studies, traditionally, oligosaccharides derived from the related molecule 
heparin are used as HS structural models. In this study a number of authentic HS derived 
hexasaccharides, in addition to heparin derived hexasaccharides, have been purified in 
sufficient quantity to permit a detailed NMR and molecular modelling based analysis of 
their three dimensional structure. The primary sequence of one HS derived 
oligosaccharide has never previously been published. Studies on all oligosaccharides and 
their chemically de-2-O-sulphated derivatives have revealed additional new insights into 
the structural influence of sulphate groups. Consistent with previous studies, at the 
monosaccharide level, sulphation was found to influence iduronate conformational 
behaviour. However, with the data presented, a number of gaps in the literature have now 
been filled, and it is now possible for the first time to predict the balance of iduronate 
conformational equilibria within any HS monosaccharide sequence. Sulphation was also 
found to influence the overall topology of the oligosaccharide chains themselves. In 
particular, for the first time NMR data is presented to show that local deviations may 
occur along the helical axis of each oligosaccharide when it is free in solution. 
Polyacrylamide gel electrophoresis data and molecular dynamic modelling data are 
presented to suggest that the rate at which local deviations occur may be influenced by 
the sulphation pattern contained within a particular oligosaccharide. The functional 
implications of these and other new structural insights are discussed, and in particular are 
related to a library of HS derived decasaccharide structures previously tested for 
biological activity. 
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1. Introduction 
Heparan Sulphate (HS) is a member of a family of complex polysaccharides known as 
glycosaminoglycans (GAGs). They are made up of  repeating C1, C4- linked 
disaccharide units, that are composed of a hexuronic acid, which is one of either β-D-
glucuronic acid (GlcUA) or α-L-iduronic acid (IdoUA), and an N-acetyl (GlcNAc) or N-
sulpho-α-D-glucosamine (GlcNS). In addition to N-sulphation, many of these constituent 
disaccharides carry one or several O-sulphate substituents. Commonly O-sulphation 
occurs at C2 of IdoUA to form the monosaccharide IdoUA(2S) and/or at C6 of GlcNS or 
GlcNAc to form the monosaccharides GlcNS(6S) and GlcNAc(6S). 
HS binds to a variety of protein ligands (Esko and Selleck 2002) and has been shown to 
be involved in the regulation of a wide range of biological activities, including 
developmental processes (Lander and Selleck 2000; Perrimon and Bernfield 2000), 
angiogenesis (Robinson and Stringer 2001), blood coagulation (Marcum et al. 1986) and 
tumour metastasis (Liu et al. 2002). 
A brief description of the conformational features of the common constituent HS 
monosaccharide units is given below. 
 
1.1 The conformation of N-glucosamine monosaccharides 
The GlcNAc, GlcNAc(6S), GlcNS and GlcNS(6S) monosaccharides (collectively termed 
N-glucosamines) of HS, and a related molecule heparin, exist exclusively in the 4C1 chair 
conformation (Mulloy and Forster 2000). In common with other hexopyranose sugars 
within the 4C1 conformation, there exists an equilibrium between rotamer conformations 
about the C5-C6 bond. These rotamers are characterised by the O6-C6-C5-O5 torsion 
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angle (w-angle). Three stable staggered rotamers are possible for the w-angle and are 
termed gauche-trans (gt), trans-gauche (tg) and gauche-gauche (gg). Gauche and trans 
referring to the orientation of the w-angle and the O6-C6-C5-C4 angle respectively (see 
Figure 1). Gluco-pyranosides display approximately equal populations of the gt and gg 
rotamers, with nearly a complete absence of the tg rotamer (Kirschner and Woods 2001). 
The tendency for the w-angle to adopt gauche conformations has been termed the gauche 
effect. 
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Figure 1 C5-C6 rotamer conformations of N-acetyl-α-D-glucosamine. 
The pyranose ring of GlcNAc is stable in the 4C1 conformation, as shown in each of the 
models below. In solution there exists an equilibrium between three different 
conformations about the C5-C6 bond. The three different conformations are termed gg, gt 
and tg (see text, for explanation of this nomenclature). 
These conformations are characterised by a Cremer-Pople puckering parameter of θ = 
<10˚ and NMR coupling constants of 3J1,2 = 3.6, 3J2, 3 = 10.2, 3J3, 4 = 9.4, 3J4, 5 = 9.9, 3J5, 6a 
= 4.0, 3J5, 6b = 2.0 (van_Boeckel et al. 1987). 
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1.2 Cremer-Pople puckering parameters and NMR coupling constants 
Cremer-Pople puckering parameters are merely a mathematical measurement of pyranose 
ring conformation (Cremer and Pople 1975; Cremer 1984). Their values are, however, 
influenced by the order in which the atoms within a ring system are selected for analysis 
(Forster and Mulloy 1993). Throughout this thesis work, atoms were selected for analysis 
in the order O5-C1-C2-C3-C4-C5. The result of this is that the Cremer-Pople parameters 
given in this study, are not directly comparable to a number of previous studies (Ragazzi 
et al. 1986; Ragazzi et al. 1993), where atoms were chosen in the order C1-C2-C3-C4-
C5-O5. They are however comparable to the majority of previous work.  
It is quite common to see NMR spectra in which the signal due to a particular proton 
appears as a collection of peaks (Carey 1992). The observed splitting of NMR signals is 
known as spin-spin splitting and the physical basis for this phenomenon is spin-spin 
coupling. Protons with different chemical shift values, which are connected by three 
bonds (vicinal protons), may be spin-spin coupled and give rise to split signals. Four 
bond couplings are weaker and not normally observable. The extent to which two vicinal 
nuclei are coupled is known as the coupling constant 3J. This is equal to the separation 
between adjacent lines of the signal of a particular proton. It has been shown that the 
value of a given coupling constant depends dramatically on the value of the dihedral 
angle between the two spin-spin coupled protons (Karplus 1959). This is known as the 
Karplus relationship. By measuring a particular coupling constant, it is possible to 
propose a dihedral angle between the two protons giving rise to this constant and vice-
versa, using the Karplus equation 
3J = A + B cos θ + C cos 2θ 
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Where θ is a dihedral angle value and A, B and C are equation parameters.  
Application of the Karplus equation depends critically on the values of the parameters A, 
B and C, which are obtained empirically from a set of experimental data (Becker 2000). 
For parameterisation of the equation as originally proposed by Karplus (Karplus 1959), 
values for A, B and C were determined by the analysis of ethane like molecules. 
Variations on the original Karplus equation, such as the Hassnoot equation attempt to 
take into account the effect of electronegative atoms such as oxygen on the relationship 
between dihedral angle and coupling constant values (Haasnoot et al. 1979).   
 
1.3 The conformation of glucuronic acid and iduronate acid monosaccharides 
In common with N-glucosamine monosaccharides, glucuronic acid monosaccharides are 
also stable in the 4C1 chair conformation. However IdoUA and IdoUA(2S) residues 
(collectively termed iduronates) vary in conformation between the 4C1 chair form, an 
alternate 1C4 chair conformation, and a 2S0 skew boat conformation (see Figure 2). When 
internally positioned within an oligosaccharide the 1C4 and 2S0 conformations are thought 
to pre-dominate (Ferro et al. 1990).   
  
 
 31 
Figure 2  Equilibrium conformations of methyl-α-L-iduronic acid. 
The pyranose ring of iduronic acid exists in equilibrium between three low energy 
conformations (shown below). The 4C1 conformation is only thought to occur when 
iduronates form the terminal unit of an oligosaccharide. The 1C4 and 2S0 conformations 
are characterised by a Cremer-Pople puckering parameter of θ = >160˚ (1C4) and θ = 
approx 90˚ (2S0). For the 2S0 conformation a second parameter Φ2 can be calculated. For 
2S0, Φ2 = approx 150˚. The published NMR coupling constants for these conformations 
vary between studies (van_Boeckel et al. 1987; Forster and Mulloy 1993; Ojeda et al. 
2002; Lucas et al. 2003). The following values are taken from the earliest cited work of 
van_Boeckel et al.  
For 1C4, 3J1,2 = 2.6, 3J2, 3 = 3.5, 3J3, 4 = 3.5, 3J4, 5 = 1.1 
For 2S0, 3J1,2 = 5.9, 3J2, 3 = 10.3, 3J3, 4 = 5.8, 3J4, 5 = 4.3 
For 4C1, 3J1,2 = 7.8, 3J2, 3 = 9.7, 3J3, 4 = 9.4, 3J4, 5 = 4.6 
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1.4 The conformation of ∆UA monosaccharides 
Oligosaccharides frequently used for HS structural studies terminate at their non-reducing 
end in a ∆4,5 unsaturated uronic acid residue (∆UA or UA) (see enzymatic degradation 
of HS discussed later in this introduction). These monosaccharides exist in an equilibrium 
between the 1H2 and 2H1 half chair conformations (see Figure 3). 
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Figure 3 Equilibrium conformations of ∆4,5 unsaturated uronic acid. 
 The pyranose ring of UA exists in an equilibrium between two low energy 
conformations shown below. These are characterised by Cremer-Pople puckering 
parameters of θ = approx 50˚, Φ2 = approx 90˚ and θ = approx 130˚, Φ2 = approx 250˚ for 
1H2.  
NMR coupling constants are given as:  
For 2H1, 3J1,2 = 8.27, 3J2, 3 = 7.67, 3J3, 4 = 2.78  
For 1H2, 3J1,2 = 2.87, 3J2, 3 = 2.37, 3J3, 4 = 4.67 
(Ragazzi et al. 1993) 
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1.5 Protein core and HS chains- one functional unit 
HS chains commonly occur at the cell surface typically covalently linked to a protein 
core structure (Bernfield et al. 1992; David 1993). Proteins that are modified in this way 
are termed proteoglycans (PGs). Proteins that are specifically modified, through the 
attachment of HS chains are termed specifically Heparan Sulphate proteoglycans 
(HSPGs).  
Both the protein and HS part of HSPGs are thought to play a functional role in their 
biological activity. For example, syndecan HSPGs via their HS chains, bind growth factor 
and extra-cellular matrix molecules extra-cellularly while also interacting with the intra-
cellular cytoskeleton, via their protein core cytoplasmic domain (Bernfield et al. 1992). 
Covalently anchored to the protein core, usually several HS chains are presented for 
potential ligand binding interactions at the cell suface. By regulating the distribution of 
the core protein within the plasma membrane and the time at which core proteins are 
expressed, the cell may have a mechanism by which to limit the action of HS binding 
ligands to a place and time at the cell surface. The structure and function of the most 
common protein core units is discussed below. 
 
2. Proteoglycans 
PGs have traditionally been categorised on the basis of their cellular location, either at the 
cell surface, or within the extracellular matrix. The major cell membrane HSPGs are the 
transmembrane syndecans and the GPI anchored glypicans. Other minor forms of 
membrane HSPG include betaglycan (Andres et al. 1992), which is unusual in that it 
carries only one HS chain, and the V-3 isoform of CD44 present on keratinocytes and 
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activated monocytes (Jackson et al. 1995). In the extracellular matrix, especially 
basement membranes the multi-domain perlecan, agrin and collagen XVIII core proteins 
are the main HS-bearing species. 
 
2.1 Syndecan HSPGs 
The syndecan family of HSPGs is comprised of four members. Syndecans 1 and 3 and 
syndecans 2 and 4 comprise separate subfamilies that have arisen by gene duplication and 
divergent evolution from a single ancestoral gene (Carey 1997). The syndecan numbers 
1-4 reflect the order in which the cDNAs for each family member were cloned. All are 
small type I membrane proteins, with an N-terminal signal peptide, an ectodomain, a 
single hydrophobic transmembrane domain and a short C-terminal cytoplasmic domain 
(Bernfield et al. 1992) (see Figure 4). The ectodomains show the least amount of amino 
acid sequence homology, no more than 10-20 % (David 1993). In contrast to the 
ectodomains the transmembrane and the short cytoplasmic tail domains of the four 
syndecans contain around 60-70% sequence homology (David 1993). The 
transmembrane domains contain an unusual alanine/glycine motif while the cytoplasmic 
domain is essentially composed of two regions of conserved sequence (C1 and C2) 
separated by a central variable region that is distinct for each family member (V) (see 
Figure 4).  
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Figure 4 Syndecan structure   
The extracellular domains of the four syndecans contain several sites for HS attachment. 
The transmembrane domain is highly conserved between syndecan family members and 
contains an unusual glycine/alanine motif. The cytoplasmic domain contains two domains 
(C1 and C2) that are also highly conserved and flank a central variable (V) region. This 
Figure is reproduced with the permission of the author from the thesis of Goodger 
(Goodger 2003) 
 
 
 
 
 
 
 
 
Conserved domain (C2)
Conserved domain (C1)
Variable  (V) region
Transmembrane domain
Chondroitin sulphate (CS) chains 
found in syndecans-1 & -4
Heparan sulphate (HS) chains
....EYFA….
Proline/threonine region 
found in syndecans-1 & -3
  
 
 37 
Proposed biological roles for syndecans are diverse. A change in the level of cell surface 
hypothalamic syndecan 3, in murine models, has been linked to an increase in food intake 
and obesity. Syndecans 1 and 4 have been linked with cellular invasion of the bacterium 
Neisseria gonorrhoeae; while a further role for syndecan 1 in modulating the Wnt 
signalling pathway has been elucidated. This pathway is involved in cell proliferation and 
differentiation during both development and disease. For a review of all these biological 
roles see (Bellin et al. 2003). 
 
2.2 Syndecan ectodomains 
Conserved within the amino acid sequences of the various ectodomains are glycosylation 
signal sequences that signal the attachment sites for modifying HS chains. All syndecans 
have a similar sequence motif for HS attachment towards the amino terminus (Carey 
1997). This motif consists of a single serine-glycine amino acid sequence that is preceded 
or flanked by a sequence of acidic amino acids (Bernfield et al. 1992). In syndecans-1 
and -4 sites for additional glycanation close to the cell membrane are occasionally 
modified by a galactosaminoglycan, chondroitin sulphate (CS) (Kokenyesi and Bernfield 
1994; Shworak et al. 1994). A co-operative role between CS and HS chains has been 
shown in the binding of a number of growth factors (Deepa et al. 2004). The conservation 
of HS attachment sites within the protein structure of all members of the syndecan family 
demonstrates the vital role played by HS modification in syndecan function. 
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2.3 Syndecan transmembrane domains 
The alanine/glycine motif found within the transmembrane domain has been shown to 
have a role in the dimerisation of syndecan-3 and probably plays a similar role in the 
dimerisation of other syndecans (Asundi and Carey 1995). It is also through the 
transmembrane domain that syndecans are able, in principle, to interact with other 
membrane proteins, this may affect their positioning in appropriate plasma membrane 
compartments (Carey 1997). The transmembrane domain has also been associated with 
the internalisation of extracellular ligands (Zimmerman and David 1999). 
 
2.4 Syndecan cytoplasmic domains 
One of the best-characterised roles for a syndecan cytoplasmic domain is in the 
recruitment of syndecan-4 into focal adhesions. Syndecan-4 is a common constituent of 
focal adhesions (Woods and Couchman 1994). Its recruitment into focal adhesions is 
stimulated by the treatment of fibroblasts with activators of protein kinase C (PKC) 
(Baciu and Goetinck 1995), and a PKCα specific signalling function has been identified 
(Oh et al. 1997). The mechanism by which PKCα signalling is activated is complex (for 
an extensive review see (Rapraeger 2001)) but key to the mechanism is the dimerisation 
of the V-region of the cytoplasmic domain (Oh et al. 1997). Dimerisation appears to be 
reduced by the phosphorylation of a conserved serine residue within the C1 cytoplasmic 
domain (Horowitz and Simons 1998). Phosphorylation of this conserved serine residue 
within C1, and tyrosine residues in syndecan 1, has been detected either in-vitro or in-
vivo for all members of the syndecan family (Prasthofer et al. 1995; Reiland et al. 1996; 
Oh et al. 1997). While the inhibition of the dimerisation of the V-region of syndecan-4 
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may be a unique mechanism, it is conceivable that phosphorylation within C1, may 
represent a common mechanism for regulating V-region and cytoplasmic domain 
interactions.  
At the opposite end of the cytoplasmic domain, another family of five structurally related 
proteins has been identified that recognise the specific tetrapeptide sequence EFYA, 
which is conserved in the C2 region of all syndecans (Rapraeger 2001). The five 
members so far identified are syntenin, synectin, syndesmos, CASK/Lin-2 and synbindin 
(Asundi and Carey 1995; Cohen et al. 1998; Ethell et al. 2000; Gao et al. 2000).  
Overexpression of either synectin or syndesmos appears to result in an increased 
recruitment of syndecan-4 into focal adhesions (Baciu et al. 2000; Gao et al. 2000). 
CASK has been shown to bind syndecan-2 at synaptic junctions and is co-
immunoprecipitated with syndecan-3 from brain extracts (Hsueh and Sheng 1999). It has 
also been shown to co-localise with syndecan–1 at the basolateral borders of epithelial 
cells (Cohen et al. 1998). Synbindin binds to the EFYA motif of syndecan-2 in dendritic 
spines (Ethell et al. 2000). Syntenin, the first member of this family to be identified, has 
been reported to be a component of cell adhesion sites and of microfilament bundles 
(Zimmermann et al. 2001).  
The presence of a least one PDZ domain in all these proteins, and the experimental 
observations described above, suggests these are adaptor proteins and may connect the 
syndecans to the cytoskeleton (Rapraeger 2001). The significance of differing adaptor 
proteins binding to differing syndecans depending on their cellular location is unclear. 
While some insights have been made into the role phosphorylation plays in the functional 
relationship between the cytoplasmic C1 and V domains, mostly regarding syndecan-4, 
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questions remain as to the effect of phosphorylation within C1 on protein binding to C2 
and vice versa.  
 
2.5 Syndecan expression 
Virtually all cells express at least one form of syndecan, most express multiple forms, and 
there are distinct patterns of syndecan expression that characterise individual cell types 
and tissues (Kim et al. 1994). For example, adult mouse kidney is found to contain 
mostly syndecan-4 mRNA while liver contains high levels of all syndecan mRNAs 
except syndecan-3. This reflects syndecan expression by the various cell types that 
compose these two types of tissue (Kim et al. 1994).  
Syndecan expression is often associated with morphological transitions, or major changes 
in tissue organization. A burst of syndecan-3 expression corresponds with a period of 
oligodendrocyte differentiation and further formation of the central nervous system in 
new-born mice (Carey et al. 1997). Alterations in the levels of other syndecan family 
members, have also been shown to coincide with differentiation events in other cell types 
(reviewed by (Carey 1997)).  
 
2.6 Glypican HSPGs 
The glypican family of HSPGs are anchored to the cell surface via covalent linkage to 
glycosylphosphatidylinositol (GPI), and in contrast to the syndecans do not span the cell 
membrane (see Figure 5). Six glypicans have been identified in vertebrates, two in 
Drosophila and one in C. elegans (Filmus 2001).  
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All glypicans contain an N-terminal secretory signal peptide and a hydrophobic domain 
in the C-terminal region, required for the insertion of the GPI anchor. Comparing the 
amino acid sequences of the vertebrate glypicans to one another, the sequences vary from 
being 17% to 63% identical (De Cat and David 2001). The location of 14 cysteine 
residues is conserved between the glypicans, suggesting the existence of a highly similar 
three-dimensional structure. HS attachment is restricted to the last 50 amino acids in the 
C-terminus, placing HS chains close to the cell membrane (Saunders et al. 1997). 
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Figure 5 Glypican structure  
The glypican core protein is covalently linked to the plasma membrane at its C-terminus 
via a GPI linker or anchor. Numerous disulphide bridges organize the core protein into a 
highly compact globular structure. HS attachment is restricted to the last 50 amino acids 
in the C-terminus. This figure is reproduced with the permission of the author from the 
thesis of Goodger (Goodger 2003). 
 
 
 
 
 
 
 
 
 
C- te
rm
in
u
s 
G
ly
pi
ca
n
ethanolamine
glycan
inositol
phosphate
phosphate
Cell membrane
GPI linker
HS chains
Globular head 
C- te
rm
in
u
s 
G
ly
pi
ca
n
  
 
 43 
2.7 Glypican expression  
In terms of its cellular distribution, glypicans are predominantly expressed during 
development (De Cat and David 2001). Like the syndecans, glypican expression is also 
associated with morphological transitions or major changes in tissue organization. For 
example cerebroglycan, a member of the glypican family, is only expressed in the 
developing rat nervous system, specifically during neuronal differentiation (Stipp et al. 
1994). Mutation studies on the Drosophila glypican or Dally have identified this as being 
required for correct development of the drosophila central nervous system (Nakato et al. 
1995). While mutation of human glypican 3 leads to Simpson-Golabi-Behmel syndrome, 
characterised by pre- and post-natal overgrowth of multiple tissues and organs (Pilia et al. 
1996).  
 
3. Extracellular matrix HSPGs 
3.1 Perlecan 
The perlecan core protein consists of five-domains and has a mass of 470 kDa. It is 
located in most extracellular matrices and has been purified from a variety of human cell 
types (Knox et al. 2001). The precise role of perlecan in-vivo is unknown. Some of the 
biological functions of perlecan may be linked to the core proteins ability to interact with 
a variety of macromolecules, including β1 integrins and laminin (Brown et al. 1997; 
Hopf et al. 1999). However the HS chains are believed to be the main contributors to its 
biological action, through ligand binding (Whitelock et al. 1999), and control of 
basement membrane permeability. 
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3.2 Agrin 
The best characterised role for agrin is in the development of the neuromuscular junction 
during embryogenesis (Cole and Halfter 1996). Indeed, agrin’s name is based on its 
involvement in the aggregation of acetylcholine receptors during synaptogenesis.  
Recently, it has been shown that treatment of a cultured muscle cell line with chlorate 
reduces the spontaneous formation of acetylcholine receptor clusters (McDonnell and 
Grow 2004). Chlorate prevents the correct biosynthesis of HS and this observation 
suggests that the HS side chains of agrin may play a role in the formation of acetylcholine 
receptor clusters. 
There are three potential HS attachment sites within the primary sequence of agrin but it 
is thought that only two of these actually carry HS chains when the protein is expressed 
(Groffen et al. 1998). Some of the biological roles of agrin require interactions through 
the protein core itself. While another biological role in the retention of anionic 
macromolecules, within the vasculature, has been suggested for HS at the glomerular or 
pulmonary alveolar basement membranes (Groffen et al. 1998).  
    
3.3 Collagen XVIII 
Collagen XVIII is the only currently known collagen that carries HS side chains (Halfter 
et al. 1998). Eight potential GAG attachment sites were identified in chick collagen 
XVIII and three of these were found to carry GAGs. These were located towards the N-
terminus of the protein. In the naturally occuring protein it is believed that collagen XVIII 
is exclusively modified by HS attachment, although CS modifications were detected in- 
vitro (Dong et al. 2003). 
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Proteolytic cleavage within a C-terminal domain of collagen XVIII releases a 20 kDa 
anti-angiogenic protein, endostatin (O'Reilly et al. 1997). Endostatin has been shown to 
bind heparan sulphate along with a number of other components of the vascular basement 
membrane (Blackhall et al. 2003; Marneros and Olsen 2005). The exact details of the 
molecular interaction between endostatin and HS, is discussed in more detail under 
“section 11” of this introduction.  
  
4. Limitations of core protein analyses 
Studies into the expression of both cell membrane and extracellular matrix core proteins, 
yield useful information on the type of HSPGs present at the cell surface. These studies 
may also demonstrate how expression patterns alter. However, in the absence of a 
structural analysis of the HS chains linked to the protein core, limited information can be 
gained on their biological role. This is particularly the case with glypican core proteins.  
Since glypicans have no transmembrane or cytoplasmic domains with which to make 
intracellular connections, any signalling functions must be indirect. Glypicans, via their 
HS chains, have the potential to capture any number of extracellular ligands, which may 
then signal through transmembrane receptors; variations in HS structure being able to 
influence the range of ligands with which a glypican or other HSPGs may interact. 
  
5. HS chain structure is cell type specific 
For syndecan-1 (Kato et al. 1994; Sanderson et al. 1994) and perlecan (Knox et al. 2002) 
it has been shown that the structure of the attached HS chains are specific for a particular 
cell type. Other studies have also detailed structural differences between HS isolated from 
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different cell types and tissues. However, within the same cell, syndecans-1 and -4 have 
been shown to carry similar HS chains with similar ligand binding properties (Zako et al. 
2003). Likewise, syndecan-4 and glypican-1 proteoglycans extracted from the same cell 
type, have also been shown to possess HS chains with no major structural differences 
(Tumova et al. 2000). These extracted proteoglycans were also shown to have similar 
affinities for an extracellular ligand, the Hep II domain of fibronectin (Tumova et al. 
2000).  
Together these studies support the hypothesis that the synthesis of HS chains and core 
proteins of individual HSPGs, are independently regulated in any particular cell type and 
possibly tailored for the desired role(s) of that cell. 
 
6. Biosynthesis 
6.1 HS biosynthesis 
Many different cell types produce HS chains with many different primary structures. 
Therefore there is room for a great deal of variability in the way HS chains are 
synthesised. However, essential to the formation of HS regardless of primary sequence, is 
a range of biosynthetic enzymes (Esko and Selleck 2002).  
These enzymes consist of multiple glycosyltransferases, sulphotransferases and an 
epimerase. These enzymes also synthesise heparin, a GAG closely related in structure to 
HS, but much more heavily sulphated. Many of these enzymes have now been purified, 
molecularly cloned and their expression patterns studied. From early work on the 
fundamental stages of HS/heparin synthesis using a mouse mastocytoma cell free system 
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a lot is known about the order of enzyme reactions and enzyme specificity (Lindahl et al. 
1998). 
 
6.2 Chain initiation 
HS synthesis initiates with the transfer of xylose from UDP-xylose by xylotransferase 
(XT) to specific serine residues. Attachment of two D-galactose (Gal) residues by 
galactosyltransferases I and II (GalTI and GalTII) and GlcUA by glucuronosyltransferase 
I (GlcATI) completes the formation of a core protein linkage tetrasaccharide, βGlcUA-
1,3→βGal-1,3→βGal-1,4→βXyl (see Figure 6). Xylose attachment to the core protein is 
thought to occur in the ER with further assembly of the linkage region and the remainder 
of the chain occurring in the golgi apparatus.  
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Figure 6 HS chain initiation 
The pathways for HS and CS/DS biosynthesis diverge after the formation of a common 
core protein linkage tetrasaccharide (see text). Four separate enzymes XylT, GalT-I, 
GalT-II and GlcAT-I are responsible for the formation of this tetrasaccharide. The next 
enzyme to act either GlcNAcT-I or GalNAcT-I directs synthesis to HS/heparin or CS/DS 
(see text). This figure is reproduced with the permission of the author from the thesis of 
Goodger (Goodger 2003). 
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GlcAT-I 
GalNAcT-I 
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6.3 Chain elongation, HS vs CS/DS 
The initial linkage tetrasaccharide is the same for the attachment of glucosaminoglycans 
(HS/heparin) and galactosaminoglycans (CS/DS) (Esko and Selleck 2002). The amino 
acid sequence Ser-Gly-X-Gly is the minimal sequence for xylosylation (Bourdon et al. 
1985). After the formation of the linkage tetrasaccharide, the next step in chain formation 
is crucial to determining which of these two types of chain are synthesised. This is carried 
out by HexNAc transferases that were thought to differ from enzymes involved in chain 
polymerisation (Rohrmann et al. 1985; Fritz et al. 1994), although it has also been 
reported that a GlcNAc transferase may initiate and also elongate HS chains (Kim et al. 
2001). The attachment of GlcNAc results in the formation of HS/heparin, while the 
attachment of GalNAc results in the formation of CS/DS.  
Studies into the protein sequence surrounding the attachment sites for HS and CS in 
syndecans-1 and -4, suggest this is key to determining the type of GAG chain synthesised 
(Kokenyesi and Bernfield 1994; Shworak et al. 1994). Synthetic addition of HS to both 
serine residues in a serine glycine repeat (SGSG) is favoured when it is flanked by acidic 
residues towards the N-terminal and hydrophobic residues towards the C-terminal. 
Analysis of three CS attachment sites in syndecan-1 showed that all three shared a similar 
sequence, a single sequence of serine-glycine flanked on both sides by acidic residues 
(Kokenyesi and Bernfield 1994). The HexNAc transferase enzymes may bind to the 
tetrasaccharide linkage region and a domain may then interact with the core protein. The 
local conformation of the core protein or peptide domains adjacent to the attachment site 
will determine, which HexNAc transferase enzyme then adds the first amino sugar.  
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Just as the conserved sequence of a HS attachment site between protein cores does not 
guarantee that both proteins will be glycosylated within this sequence, neither does the 
presence of an attachment motif within an individual protein. Syndecan-1 has five 
potential GAG attachment sites, but contains different numbers of chains in different cells 
(Bernfield et al. 1992). 
 
6.4 HS chain elongation 
After attachment of the first GlcNAc residue elongation of the tetrasaccharide linker 
continues by the stepwise addition of GlcUA and GlcNAc residues. GlcUA and GlcNAc 
residues are transferred from their respective UDP-sugar nucleotides and attached to the 
non-reducing end of the growing chain. This is carried out by one or more related 
enzymes, whose genes are members of the exostoses (EXT) gene family of tumour 
supressors.  
The EXT family consists of six members in total, EXT 1-3, and three related genes 
termed EXT like, EXTL1-3. A GlcNAc transferase activity has been detected for the 
gene products of all three EXTL genes (Kim et al. 2001). However, their role in-vivo is 
unknown, as mutants lacking these enzymes have not been produced. However, murine 
mutants have been produced that lack either EXT1 or EXT2 gene products (Lin et al. 
2000; Stickens et al. 2005). Mice with either EXT1 (Lin et al. 2000) or EXT2 (Stickens 
et al. 2005) knock out mutations lack HS and die during embryogenesis as a result of 
developmental abnormalities.  
Mutations at the EXT 1-3 gene loci in humans leads to the development of hereditary 
multiple exostoses, which are characterised by multiple cartilaginous tumours, suggesting 
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an important role for HS in bone growth (McCormick et al. 2000). Sequence comparisons 
between the various EXTs suggest they contain two catalytic domains, each of the 
domains being independently responsible for GlcNAc or GlcUA transferase activity 
(Esko and Selleck 2002). It is not yet understood how chain elongation is coordinated 
between this group of enzymes. The cell free mastocytoma model was used to show that 
HS chain polymerisation can proceed in the absence of any subsequent chain 
modification reactions (Lind et al. 1998).  
 
Chain modification 
6.5 Availability of PAPS 
As the chain polymerises, it undergoes a series of modification reactions carried out by 
four classes of sulphotransferases and an epimerase. The availability of the sulphate 
donor PAPS is crucial to the activity of the sulphotransferases (Silbert 1967; Silbert 
1967). Therefore, both the enzyme systems responsible for PAPS formation, and the 
PAPS transmembrane transport system that makes PAPS available in the golgi lumen for 
HS biosynthesis (Abeijon et al. 1997), will influence the final structure of the HS/heparin 
chain.  
 
6.6 N-deacetylation/N-sulphation 
Until comparatively recently, the first polymer modification was thought to be the N-
deacetylation/N-sulphation of GlcNAc residues into GlcNS (see Figure 7 for a general 
overview of HS biosynthesis). This was thought to be prerequisite for all subsequent 
modification reactions and is carried out by one or more members of a family of four 
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GlcNAc N-deacetylase/N-sulphotransferase enzymes (NDSTs). Recent NDST genetic 
knockout studies have called the prerequisite requirement for N-deacetylation/N-
sulphation into doubt (see 6-O-sulphation section below).  
In early studies, it was shown that NDST enzymes could recognize and act on any N-
acetylated residue in the forming polymer (Lindahl et al. 1973; Hook et al. 1975). 
Therefore the modification of GlcNAc residues should occur randomly throughout the 
chain. However, HS N-sulphated residues are mainly grouped together (see HS-domain 
structure, discussed later) and separated by regions of N-acetylation where GlcNAc 
remains unmodified.  
 
6.7 Differences between heparin and HS biosynthesis 
Heparin is much more highly modified by N-sulphation than HS (∼85% GlcNS in heparin 
versus ∼40-50% in HS (Gallagher and Walker 1985)). In-vivo heparin is stored in the 
secetory granules of mast cells. NDST2 was originally cloned from mast cells (Eriksson 
et al. 1994) and was found to have a much higher N-deacetylase/N-sulphotransferase 
activity than NDST1, which had earlier been cloned from rat liver (Hashimoto et al. 
1992). A mutation in NDST2 resulted in a selective decrease in the sulphation of mast 
cell heparin (Forsberg et al. 1999). Overexpression of NDST2 in cell lines increased the 
level of GlcNS from 40% to 80%, making HS the cells produced more heparin like 
(Cheung et al. 1996). All these observations suggest that NDST2 is primarily responsible 
for the biosynthesis of heparin and that NDST1 is responsible for the biosynthesis of HS. 
NDST knock out mice have also been shown to have a defect in heparin synthesis linked 
to the failure of mast cell differentiation (Forsberg et al. 1999). However, a CHO cell 
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mutant defective for NDST1 but not NDST2 can still produce HS containing 25% GlcNS 
(Aikawa and Esko 1999). Suggesting that rather than being solely responsible for the 
biosynthesis of heparin, NDST2 also plays a role in the formation of HS. This is further 
supported by the finding that mRNAs for both enzymes, are abundantly expressed by all 
tissues and cells that make HS and heparin, all be it that cells producing heparin have a 
predominance of NDST2 (Aikawa et al. 2001). Thus it would seem that both the levels of 
enzyme expression and the specific properties of the NDST isoform apparently determine 
the extent of N-sulphation. It is not yet known what it is about NDST2 that enables it to 
catalyse the formation of the much more highly sulphated heparin polymer. 
 
6.8 NDST3 and 4 
Little is known about the significance of the expression pattern of NDST3 and 4 or their 
activities (Esko and Selleck 2002). NDST3 has a greater deacetylation activity than 
sulphotransferase activity and NDST4 has a greater sulphtransferase activity than 
deacetylation activity. Expression of both enzymes is thought to be restricted to adult 
brain and foetal tissues (Aikawa et al. 2001).  
 
6.9 Generation of GlcNH2 residues 
Due to the N-deacetylase and N-sulphotransferase activity being carried out by the same 
enzyme, N-sulphation is normally tightly coupled to N-desulphation. GlcNH2 residues 
resulting from an apparent uncoupling of the two activities have been found in heparin 
and HS (Toida et al. 1997; Westling and Lindahl 2002). The activity of NDST3 is a 
prime candidate for the generation of such residues.  
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Murine embryonic stem cells in which the NDST1 and NDST 2 genes are knocked out, 
still produce HS chains with a number of free amine groups (Holmborn et al. 2004). In 
these cells NDST3 mRNA can be detected at low levels, further supporting this as the 
enzyme responsible for the generation of GlcNH2 residues. However, the low levels at 
which it is detected, and the restricted tissue expression pattern of this protein, calls this 
into question. Possibly, there may exist an as yet un-discovered de-acetylase enzyme.  
It has been shown that a GlcNH2 unit forms part of the binding site in HS for herpes 
simplex virus glycoprotein D (Shukla et al. 1999) and is implicated in the binding of L-
selectin (Norgard_Sumnicht and Varki 1995), suggesting the occurrence of GlcNH2 may 
be under tight regulatory control. 
 
6.10 Epimerisation and 2-O- sulphation 
Epimerisation is catalysed by one enzyme, the GlcUA C5 epimerase. This enzyme 
epimerises certain GlcUA units to IdoUA. Substrate recognition requires that the GlcN 
residue linked to the non-reducing side of a potential GlcUA target be N-sulphated 
(Jacobsson et al. 1984). Studied in isolation the GlcUA C5-inversion is freely reversible. 
Prolonged incubation of either O-desulphated heparin (IdoUA, ∼90% of total HexUA) or 
N-sulpho-heparosan, (GlcUA, 100% of total HexUA) with soluble epimerase yielded 
similar products with 30-35% IdoUA, representing equilibrium (Hagner Mcwhirter et al. 
2000). In-vivo, this equilibrium is clearly not established. Heparin chains may contain 
∼90% IdoUA (Esko and Selleck 2002). It is the action of another enzyme, uronosyl-2-O-
sulphotransferase (2OST), and the resulting 2-O-sulphation of IdoUA that prevents its re-
conversion to GlcUA (Valla et al. 2001).  
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This enzyme acts on both IdoUA and GlcUA units but sulphates IdoUA at a faster rate, 
under most conditions, when substrates containing both units are provided (Rong et al. 
2001). In heparin 2-O-sulphation nearly always modifies IdoUA residues. In HS the 
extent of 2-O-sulphation ranges from 50-90% of the available IdoUA residues and as a 
result, IdoUA residues without 2-O- modification are present in the mature HS chain. It 
may be that the speed at which the HS chain is synthesised, and moved away from the 
golgi, that prevents the establishment of an equilibrium, and conversion of IdoUA units 
that escaped 2-O- modification back to GlcUA. For heparin, bio-synthesis can occur in 
less than 1 min (Hook et al. 1975). 
 
6.11 6-O- sulphation 
Three glucosaminyl 6-O-sulphotransferases (6OSTs) have been identified. In a mutant 
cell line completely lacking 2-O-sulphotransferase activity, HS chains were found to 
contain a higher level of 6-O-sulphation than HS from normal cells (Merry et al. 2001). 
This suggests that 2-O-sulphation may play a role in regulating the action of the 6-O-
sulphotransferase enzymes and occur prior to the action of the 6OST enzymes. However, 
the fact that 6-O-sulphation occured at all in the absence of 2-O-sulphation suggests that 
a strict order of 2-O- then 6-O- sulphation may not exist. In support of this, the different 
6-OST isoforms were found to have preferences for the sulphation of GlcNS linked to 
either IdoUA or GlcUA but the activity of no isoform was found to be reliant on the 
presence of 2-O-sulphation (Habuchi et al. 2000). More recently in a mutant cell line 
completely lacking 6-O-sulphotransferse activity, HS chains were found to contain a 
higher level of 2-O-sulphation than HS from normal cells (Kamimura et al. 2006).   
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In murine embryonic stem cells in which the NDST1 and NDST2 genes were knocked 
out, 6-O-sulphation was never the less detected (Holmborn et al. 2004). This result places 
6-O-sulphation at an early stage of HS bio-synthesis.  
While 6-O-sulphation is certainly not essential in order for N-sulphation to occur, it may 
influence N-sulphation levels and positioning (see HS domain structure, discussed later). 
Perhaps not surprisingly, given that N-sulphation is not required in order for 6-O-
sulphation to occur, GlcNAc units that are 6-O-sulphated are frequently found in the 
mature HS chain. 
 
6.12 3-O- sulphation 
At least five glucosaminyl 3-O-sulphotransferases (3OSTs) exist. The action of four of 
these, 3OST1, 3OST2, 3OST3A and 3OST3B have been characterised. The 2-O-
sulphation of the uronic acid, either IdoUA or GlcUA, adjacent to the target GlcNS(6S) 
prevents the action of 3OST1 (Zhang et al. 2001) while it is required for the substrate 
recognition and action of the other 3OST isoforms (Liu et al. 1999; Liu et al. 1999). The 
3OST1 enzyme requires the target GlcNS residue to be 6-O-sulphated. However the 
action of other members of the family does not require GlcNS to be 6-O-sulphated (Esko 
and Selleck 2002).  
The 3OST enzymes are of key importance in the biosynthesis of at least two 
characterised ligand binding sites, antithrombin III (Lindahl et al. 1984) and herpes 
simplex virus glycoprotein D (Shukla et al. 1999). 
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6.13 Sulfs 
Although not strictly bio-synthetic enzymes the extracellular sulphatases (Sulfs) play an 
important role in modifying HS structure. The Sulfs are a family of 6-O-endosulphatases. 
The first member of this family to be discovered was termed QSulf1; “Q” signifying 
Quail, the origin of the cDNA library from which the gene for this enzyme was identified 
(Dhoot et al. 2001). Subsequent homologs of this enzyme have been found in a range of 
species from Caenorhabditis elegans (C. elegans), to mice and humans. The original 
nomenclature for the quail derived enzyme has stuck and MSulf1 and HSulf1 refer to 
murine or human derived protein isoforms respectively.  
A related enzyme Sulf2 has been identified in vertebrates and more recently by a re-
screening of the quail cDNA library (Ai et al. 2006).  To date the QSulf1 and QSulf2 
isoforms are the most well characterised. 
Both enzymes exhibit the same substrate specificity towards disaccharides of the 
sequence -IdoUA(2S)-GlcNS(6S)-, removing the 6-O-sulphate group from the GlcNS 
monosaccharide (Ai et al. 2006). This modification could have profound consequences 
for the binding of a number of protein ligands (see FGF-2 discussed later). In contrast to 
the true HS bio-synthetic enzymes, QSulf1 does not remain localised to the golgi 
apparatus and is transported to the cell surface together with HSPGs. It has been shown 
that its sulphatase activity exists both at the cell surface and while temporarily localised 
to the golgi (Ai et al. 2003). The discovery of this family of enzymes adds an additional 
layer of complexity to the already complex picture of HS biosynthesis.  
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6.14 Biosynthetic enzyme expression patterns 
There is a differential tissue expression pattern of the various 6OSTs and 3OSTs 
(Shworak et al. 1999; Habuchi et al. 2000). Brain tissue contains large amounts of 
6OST2 and 3OST1, 2 and 4 while liver contains mostly 6OST1 and 3OST3A and 3B. 
Variations in the level of expression of 6OST may also influence the level of N-
sulphation and in turn 2-O-sulphation. Changes in the level of Sulf expression may also 
influence HS primary structure. It is conceivable that individual cell types express 
different levels of different isoforms of the HS biosynthetic enzymes, allowing the 
creation of unique patterns of N-, 2-O-, 6-O- and 3-O-sulphation.  
         
6.15 Chain heterogeneity 
In the absence of a ‘code’ that specifies the synthesis of particular saccharide sequences, 
a great deal of research has been undertaken in order to characterise the action of the 
enzymes involved in HS biosynthesis (as detailed above). The modifications that occur 
are non-random and to an extent interdependent. To add further complexity to the system 
they are also quantitatively incomplete.  
In mature HS, possible substrates for the O-sulphotransferase enzymes can be found that 
have escaped sulphation (bearing in mind that some 6-O-sulphates may have been 
removed by the action of the Sulf enzymes). The end result is a very high level of 
structural complexity within any individual HS chain. 
A simplified scheme for HS biosynthesis is given in Figure 7. 
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Figure 7 A simplified scheme of heparan sulphate biosynthesis 
In mature HS 40-50% of the GlcNAc residues present in the heparan precursor are 
modified to GlcNSO3. All other potential modifications to heparan, as shown below, are 
also quantitatively incomplete and result in heparan sulphate chains with a highly 
complex primary structure.  
Not shown are the rare modifications carried out by the 3OST enzymes, the formation of 
GlcNH2 residues and 6-O-sulphatase modifications carried out by Sulf enzymes. 
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7. De-polymerisation techniques 
Either chemical or enzymatic de-polymerisation techniques or a combination of the two 
underlie the vast majority of analyses carried out on the structure of HS and heparin. 
 
7.1 Enzymatic 
The enzymes traditionally used to digest heparin or HS for structural studies are naturally 
produced by the soil bacterium Flavobacterium heparinum. This bacterium is capable of 
utilizing either heparin or HS as its sole carbon and nitrogen source. In order to do this it 
produces a range of enzymes such as lyases, glucuronidases, sulphoesterases and 
sulphamidases (Galliher et al. 1981). It is the lyases that have mainly been used in 
HS/heparin structural studies. The bacterium produces three lyases, heparinases I, II and 
III and each has distinct substrate specificities as detailed below (Linhardt et al. 1990; 
Desai et al. 1993). 
 
Heparinase I  GlcNSO3(+6S) – IdoUA(2S) 
Heparinase II  GlcNSO3/Ac(+6S) – IdoUA(+2S) 
  or GlcNSO3/Ac(+6S) – GlcUA   
Heparinase III  GlcNSO3/Ac(+6S) – GlcUA/IdoUA (with a preference for GlcUA) 
 
The lyases cleave the HS/heparin chain by a β-elimination mechanism. This action 
generates an unsaturated double bond between C4 and C5 of the non reducing terminal 
uronate residue (Linker and Hovingh 1972; Linhardt et al. 1988). This C4-C5 unsaturated 
uronate is termed ∆UA or UA. It is a sensitive UV chromaphore (max absorption at 232 
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nm) and allows the rate of an enzyme digest to be followed as well as providing a 
convenient method for detecting the fragments produced by enzyme digestion.  
Due to their substrate specificities there are a limited number of cleavage sites for each 
enzyme within heparin/HS chains. An individual enzyme can be used to either cleave the 
chain at all the possible cleavage sites, or its action can be controlled so that only a partial 
number of cleavage sites will be acted upon. When used in combination, the enzymes 
will digest a HS/heparin chain into its component disaccharide units. The various 
component disaccharides can then be identified by their position of elution on HPLC or 
capillary electrophoresis. In this way the complete disaccharide composition of the chain 
can be established.  
Unfortunately, by generating an unsaturated uronate residue, asymmetry at C5 of the 
uronic acid is lost. This asymmetry distinguishes IdoUA from GlcUA and so it is not 
possible to identify the uronic acid component of the disaccharides. It is only possible to 
define the proportion of mono-, di- and tri- sulphated disaccharides and not proportions 
of IdoUA and GlcUA.  
 
7.2 Chemical 
Nitrous acid can be used to chemically depolymerise heparin/HS and avoids the loss of 
uronate asymmetry. Nitrous acid can be used at pH 1.5 or at a higher pH of 4. Under both 
conditions nitrous acid effects deaminative cleavage of the chain (Shively and Conrad 
1976). At both ‘high’ (4) and ‘low’ (1.5) pH, deaminative cleavage occurs between 
GlcNSO3-HexA units, all be it at a slower rate at the higher pH, but deaminative cleavage 
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between GlcNH2-HexUA units only occurs at high pH. The deamination reaction, and 
therefore chain cleavage, is regardless of O-sulphation carried by either unit.  
At low pH deaminative cleavage results in the release of inorganic SO4, and the 
convertion of GlcNSO3 to anhydromannose (aMan). The preference for cleavage of the 
chain at either GlcNSO3-HexUA or GlcNH2-HexUA, depending on pH, can be exploited 
in HS structural studies (Edge and Spiro 1985). Low pH nitrous acid treatment is also an 
excellent method to distinguish N-sulphated polysaccharides such as HS and heparin 
from non N-sulphated polysaccharides such as CS and DS; CS and DS polysaccharides 
being un-susceptible to nitrous acid cleavage. 
 
8. HS and heparin structural distinct molecules 
When HS chains become highly modified, the boundary between what is classed as HS 
and heparin becomes unclear. It is only through the use of agents that can cleave either 
HS or heparin at specific linkages, and the subsequent analysis of the fragments 
generated, that major differences in the structures of the two molecules becomes clear. It 
is the domain structure of HS that distinguishes it from heparin. 
 
8.1 Domain structure of HS 
Heparin is almost completely depolymerised by nitrous acid at low pH to di- or 
tetrasaccharides (Cifonelli and King 1977). Regions of the HS chain under the same 
conditions remain intact. A 1985 study analysed the size of the nitrous acid cleavage 
products of HS from a number of different sources (Gallagher and Walker 1985). It was 
shown that in the HS analysed most N-sulphated units were present in alternating or 
  
 
 63 
contiguous sequences, and that there was therefore a strong tendency for N-acetylated 
and N-sulphated disaccharides to be separated, generating domains (see Figure 8). Due to 
the substrate specificities of the biosynthetic enzymes, epimerised and 2-O-sulphated 
disaccharides are predominantly located within the N-sulphated domains. These have 
subsequently been termed S-domains and the regions of consecutive N-acetylation 
termed N-Ac domains.  
Within the S-domains 50-60% of the hexosamine residues were identified as IdoUA and 
most of these were 2-O-sulphated. This domain structure is typical of all HS chains 
analysed subsequently. The disaccharides that form the heparin chain are much more 
extensively modified and as a result heparin lacks the distinctive domain structure of HS 
(see Figure 8). 
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Figure 8 HS/heparin domain structure 
The domain structure of HS is made up of blocks of highly modified sequence (S-
domains) separated by blocks of unmodified sequence (N-Ac domains).  
Heparin is essentially one continuous S-domain interrupted by the odd region of low 
sulphation. 
 
Heparan sulphate 
 
 
Heparin 
 
 
 
 
NAc domain S-domain
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8.2 Alternating sequences and K5 lyase 
Typically blocks of N-acetylation and N-sulphation were also detected in HS purified 
from a number of bovine organs by Maccarana et al. (Maccarana et al. 1996). This study 
also demonstrated that a great deal of variability exists within blocks of alternating N-
acetylated and N-sulphated disaccharides, termed NA/NS or alternating domains 
previously identified by Gallagher and Walker (1985) (Gallagher and Walker 1985). 
These sequences frequently contained none sulphated IdoUA residues and more than half 
of the total number of 6-O-sulphate groups within the chain. These alternating domains 
were presumed to occur at the boundary between the S-domains and N-acetylated 
domains. This presumption was proved correct by the structural analysis of 
oligosaccharides generated by the use of the K5 lyase enzyme (Murphy et al. 2004). 
This enzyme cleaves the HS chains where contiguous un-interupted regions of eight or 
more N-acetylated disaccharides occur. In the resulting oligosaccharides, alternating 
sequences were only found in conjunction with S-domain type sequences. This led to a 
refinement of the model for the domain structure of HS that was presented in Figure 8 
(see Figure 9).  
In this refined model S-domains are flanked on either side by alternating domains. From 
the initial K5 lyase study is was not possible to establish whether this is actually the case. 
It may be that alternating domains only occur to one side or are more extended to one 
side of the S-domains.  
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Figure 9 A refined model of the molecular structure of HS.  
The S-domains and the N-acetylated sequences are arranged in an alternating and 
equidistant manner, with solitary N-sulphated disaccharides scattered within the NAc-
domains. Flanking the S-domains and forming the border between the S-domains and 
NAc-domains are the NA/NS domains. Only two S-domains are shown. 
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9. Ligand binding 
All ligands that have been found to bind heparin also bind HS. The S-domains within HS 
resemble heparin in structure, although less 6-O-sulphated. The majority of protein 
interactions analysed have been found to occur via the S-domains (Gallagher and Lyon 
2000; Coombe and Kett 2005).  
The number of protein ligands that have been shown to bind HS/heparin is considerable. 
Including all members of individual protein families that interact with HS/heparin, the 
number of protein ligands is probably around 30 to 40. The discussion below focuses on 
specific proteins. For these proteins the HS/heparin structural requirements for the 
interaction have been particularly well characterised, or their interaction with HS 
illustrates the role HS domain structure may play in ligand binding.   
 
9.1 Protein binding sites for HS 
The binding sites for HS/heparin within a protein ligand are usually characterised by 
extensive regions of positive charge on the surface of the protein. These result from the 
close positioning of basic amino acid side chains in the secondary or tertiary structure of 
a protein or protein complex. As an illustration of this, two such regions of positive 
charge can be seen on the surface of a FGF-2 monomer in complex with a heparin 
hexasaccharide (see Figure 10).   
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Figure 10 The crystal structure of a heparin hexasaccharide in complex with a 
FGF-2 monomer. 
The coordinates for this crystal structure were taken from the protein data base, code 
1BFC (Faham et al. 1996).  
For both models A and B the molecular surface of the FGF-2 protein was calculated 
using the surf algorithmn as implemented in the VMD molecular graphics program 
(Humphrey et al. 1996). In model A the entire surface of the protein is coloured blue, in 
model B all basic amino acid residues at the protein surface are marked out in red. In 
model B a number of electrostatic contacts can be seen between two clusters of basic 
amino acids at the protein surface and the hexasaccharide structure. 
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 69 
It can be clearly seen in Figure 10 that the heparin binding site consists of two regions of 
basic amino acids, separated by a region of neutral amino acids over which the heparin 
oligosaccharide spans. This type of binding site makes it difficult to definitively identify 
a consensus amino acid sequence within proteins for HS/heparin binding. Amino acid 
sequences separated by great distances within the primary structure of a protein, may fold 
to form a HS/heparin binding site. Never the less the sequences XBBXBX and 
XBBBXXBX have been suggested as consensus sequences to which HS/heparin binding 
may occur (Cardin and Weintraub 1989). “B” representing an amino acid with a basic 
charge (usually arginine or lysine) and “X” an uncharged or hydrophobic amino acid. In 
most cases these sequences will not form the whole, but part of a HS binding site. 
 
10. A footprinting approach 
A ‘footprinting’ approach has been adopted in the study of HS interactions with a number 
of proteins (Lortat_Jacob et al. 1995; Stringer and Gallagher 1997; Spillmann et al. 1998; 
Stringer et al. 2002). Footprinting involves enzymatic depolymerisation of the HS chain 
in the presence of a high concentration of ligand. Regions of the HS chain that are then 
protected from enzymatic cleavage by ligand binding are structurally examined. The first 
protein for which a footprinting approach was adopted was interferon-γ (Lortat_Jacob et 
al. 1995). 
 
10.1 Interferon-γ 
Interferon-γ (IFN-γ) is a cytokine secreted by many cells involved in an immune response 
(Schroeder et al. 2004). The first stage of biological activity involves its binding to a 
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specific cell membrane receptor, IFN-γR (Sadir et al. 1998). In contrast to many other HS 
binding ligands, where HS binding promotes biological activity. The binding of IFN-γ to 
HS actually inhibits its biological activity (Sadir et al. 1998). 
 
10.2 Interferon-γ structure 
The IFN-γ monomer is comprised of a core of six α-helices and an extended, unfolded 
region towards the C-terminal of the protein (see Figure 11). It is thought to be 
biologically active in a dimeric form, the dimer forming by anti-parallel interlocking of 
the two monomers (Thiel et al. 2000) (see Figure 11).  
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Figure 11 The crystal structure of human interferon-γ 
The coordinates for this crystal structure and the crystal structure shown subsequently in 
Figure 12 were taken from the protein data base, code 1FG9 (Thiel et al. 2000). Models 
were then generated using the VMD molecular graphics program (Humphrey et al. 1996). 
Monomeric interferon-γ 
In model A a single protein monomer is shown by a line representation. In the cartoon 
representation shown in model B the six α-helices that comprise the core of the structure 
are numbered. 
  
  
 
 
 
Dimeric interferon-γ 
The biologically active IFN-γ dimer is formed through the anti-parallel interlocking of the 
two monomers as shown in models C-E 
C D E
A B
C-terminal 
unfolded sequence
1
2
3
4
5 6
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The models shown in Figure 11 are all truncated at their C-termini by 17 amino acids; 
full length IFN-γ being 143 amino acids in length, the models being 126 amino acids in 
length.  
 
10.3 Interferon-γ, HS binding sites 
Affinity for HS resides solely within the deleted sequence of 17 amino acids 
(Vanhaverbeke et al. 2004). In this sequence two clusters of basic amino acids occur, 125 
KTGKRKR131 and 137RGRR140, termed D1 and D2 respectively. HS interacts with both 
of these sequences, with the D1 sequence contributing most to the interaction (Lortat-
Jacob and Grimaud 1991). 
 
10.4 The domain structure of Interferon-γ binding oligosaccharides  
Using the footprinting approach, the binding of dimeric IFN-γ was found to protect a HS 
fragment 21-24 disaccharide units in length. This consisted of two S-domains (each 3-4 
units in length) separated by a region rich in N-acetylated residues (15-16 units in length). 
Each S-domains is thought to interact with a separate HS binding site, one at each C-
terminal of either protein monomer, with the N-acetylated region acting to span the 
distance between the two binding sites (Lortat_Jacob et al. 1995).  
 
10.5 HS binding prevents receptor binding possibly by steric hinderance 
If the models shown in Figure 11 are expanded to include the co-ordinates of two of the 
three IFN-γ receptor molecules also incuded in the 1FG9 protein data base file (pdb), it 
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becomes clear why HS binding inhibits the biological activity of IFN-γ (Sadir et al. 1998) 
(see Figure 12). 
 
  
 
 74 
Figure 12 The crystal structure of human interferon-γ in complex with two 
identical interferon-γ receptor molecules. 
For both models the molecular surface of the two IFN-γ receptors, and for model B the 
IFN-γ dimer, was calculated using the surf algorithmn as implemented in the VMD 
molecular graphics program (Humphrey et al. 1996).  
In model A the IFN-γ dimer is shown in a cartoon representation. The enlargement shows 
the close proximity of the red C-terminal domain of one IFN-γ monomer and the grey 
receptor molecule. In this close proximity a number of electrostatic interactions may 
occur between the two molecules (see text for exact residues involved). Similar 
interactions may occur between the C-terminal domain of the blue IFN-γ monomer and 
the receptor shown in green. In model B the view of this interaction is obscured by the 
front edge of the receptor molecule and is not enlarged. 
 
 
 
 
 
 
 
 
 
 
 
IFN-γ receptor BIFN-γ receptor A
A B
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It should be noted that the authors of the 1FQ9 pdb file, note that the electron density 
beyond residue 120 of each IFN-γ was weak (Thiel et al. 2000). The enlarged C-terminal 
interactions between lysine 125 and a number of glutamic acids (173 and 175) within the 
receptor protein, may represent one of many partially populated conformational states. 
Despite this, it can be seen how HS binding to an extended C-terminal domain may 
compete with, and block receptor binding for the same region of IFN-γ.  
 
10.6 Biological implications of HS- IFN-γ binding 
The functional significance of the HS- IFN-γ complex is unclear. It has been shown that 
the presence of the D1 amino acid sequence, in the absence of HS, increases the rate at 
which IFN-γ-IFN-γR complexes form (Sadir et al. 1998). Interaction between the D1 
sequences and receptor molecules may be the first step in complex formation. Binding of 
HS protects the D1 sequence from proteolytic cleavage (Lortat-Jacob and Grimaud 
1991), possibly saving it for a later interaction with a receptor molecule. After protection, 
how IFN- γ or specifically the D1 sequences are then freed from HS binding in order to 
interact with receptor molecules remains to be determined.  
 
11. Other cytokines 
The most well known function of the cytokines is their regulation of leukocyte migration, 
but they also play a role in controlling other biological functions such as development, 
angiogenesis and neuronal patterning to name a few (Lortat_Jacob et al. 2002). Under 
conditions required for structural studies, like IFN-γ, other cytokines are dimeric or 
tetrameric in structure. In-vivo it is unclear whether it is the multimeric or monomeric 
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form of the protein that binds cell surface receptors as the individual monomeric units 
may dissociate faster than receptor binding occurs. However, a role has been suggested in 
the stabilisation of the multimeric state for HS at the cell surface; multimerisation 
apperars to be strongly enhanced by the presence of HS (Lortat_Jacob et al. 2002). 
 
11.1 The domain structure of chemokine binding oligosaccharides  
Similar fragments of variable length and sulphation to the fragments with high affinity for 
IFN-γ, have been isolated using a footprinting approach from cytokines such as platelet 
factor 4 (PF-4) (Stringer and Gallagher 1997), interleukin 8 (IL-8) (Spillmann et al. 1998) 
and macrophage inflammatory protein 1α (MIP1α) (Stringer et al. 2002). It has been 
suggested that binding to this type of extended HS sequence may be a common feature of 
mutimeric cytokines (Gallagher and Lyon 2000). 
 
11.2 The role of sulphation patterns within IFN-γ and cytokine binding 
oligosaccharides 
Little is known about the specific sulphation features of these saccharides, only a general 
overview of their organisation into various sulphation domains. Within these 
oligosaccharides the function of the N-Ac domain may be to space the S-domains 
correctly for binding to multiple binding sites at the protein surface to occur. Little is 
known about how variations in the sulphation patterns within the NA/NS domains or the 
S-domains themselves effect protein binding.  
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Endostatin is another protein that binds to a similar type of HS sequence. However in this 
case many of the saccharide structural features that influence endostatin binding have 
been examined. 
 
12. Endostatin 
As mentioned earlier under the general introduction to collagen XVIII, endostatin is 
derived from the C-terminal of collagen XVIII by proteolytic cleavage (O'Reilly et al. 
1997). Collagen XVIII/endostatin is a common component of almost all epithelial and 
endothelial basement membranes.  
 
12.1 The oligomerisation state of endostatin influences its biological activity  
At the C-terminal of collagen XVIII lies a 38 kDa NC1 domain (“NC” for None 
Collagenous). This domain contains the 20kDa endostatin domain but also a trimerisation 
domain. Without cleavage of the so called ‘hinge region’ in between the trimerisation 
domain and the start of the endostatin domain, the endostatin domain is trimerised 
(Sasaki et al. 1998). Cleavage within the hinge region by elastase and/or cathepsin L 
releases monomeric endostatin which has been shown to have an anti-angiogenic effect 
in-vitro and in-vivo (O'Reilly et al. 1997). Opposing this, trimeric endostatin is a potent 
motogen (Kuo et al. 2001) and this biological activity could actually be described as pro-
angiogenic.  
The loss of endostatin, due to genetic mutation in mice and humans, does not lead to a 
major increase or decrease in angiogenic activity (Marneros and Olsen 2005). Suggesting 
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endostatin is one of many pro-angiogenic and anti-angiogenic factors that work together 
to regulate this process.  
 
12.2 HS binding sites within endostatin 
The HS component of a glypican proteoglycan has been identified as an endothelial cell 
surface binding site for endostatin (Karumanchi et al. 2001). Six arginine residues, R155, 
R158, R193, R194, R184 and R270, have been identified as being crucial for HS/heparin 
binding to endostatin; loss of either of these groups resulting in a loss of heparin binding 
(Sasaki et al. 1999).  
Within the tertiary structure of endostatin these arginine residues form two distinct 
clusters. R155, R158, R184 and R270 forming one cluster and R193 and R194 forming 
the other (see Figure 13). These two clusters are in marked contrast to the single cluster 
observed at the protein surface of FGF-2 (see Figure 10). 
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Figure 13 The crystal structure of human endostatin. 
Coordinates for this structure were taken from the protein database file code 1KOE 
(Hohenester et al. 1998).  
The molecular surface of the molecule was calculated as in Figure 10. Basic amino acid 
residues are coloured red. The six specific arginine residues crucial for HS/heparin 
binding are labelled. 
 
R 193
R 194
R 158
R 155
R 270
R 184
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12.3 The domain structure of endostatin binding oligosaccharides 
As can be seen in Figure 13, in order to interact with both arginine clusters a single 
HS/heparin oligosaccharide must span across a considerable area of the protein surface. 
This is reflected in a minimal length, of dp12, for heparin oligosaccharides found to bind 
efficiently to endostatin (Sasaki et al. 1999). Subsequently it has been shown that binding 
oligosaccharides need not be composed of contiguously N-sulphated disaccharides. Both 
Kreugar et al. (Kreuger et al. 2002), and Blackhall et al. (Blackhall et al. 2003), have 
shown that HS derived oligosaccharides, composed of two short S-domain type 
sequences separated by NA/NS and N-acetylated type sequences, bind with a similar 
affinity to heparin derived oligosaccharides. 
 
12.4 Specific sulphation requirements for endostatin binding oligosaccharides 
Several apparently conflicting reports have been published as to the importance of HS 
sulphation on endostatin binding. Blackhall et al. have shown, through a filter binding 
study, that HS completely devoid of 2-O-sulphation displays an identical affinity for 
endostatin when compared to HS containing a normal level of 2-O-sulphation (Blackhall 
et al. 2003). Contradictory to this Ricard-Blum et al. have shown, through a BIAcore 
study, that de-2-O-sulphated heparin displays a marked decrease in affinity for endostatin 
when compared to intact heparin (Ricard-Blum et al. 2004). Endostatin also fails to bind 
a melanoma cell line displaying a 90% reduction in normal 2-O-sulphation levels 
(Karumanchi et al. 2001). To date however, perhaps the most comprehensive study on 
the role of HS sulphation on endostatin binding has been carried out by Clamp et al. 
(Clamp et al. 2006).  
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In their studies a panel of Chinese hamster ovary cells (CHO cells) with specific defined 
defects in their HS biosynthetic processes were utilised. Oligomeric endostatin was found 
to induce morphological changes in the same CHO cells producing normal cell surface 
HS. By comparing the morphological features of mutant and normal CHO cells in 
reponse to added oligomeric endostatin, the effect of specific HS structural defects could 
be investigated. In this study it was found that 2-O-sulphation was not required in order 
for oligomeric endostatin to elicit a morphological response from mutant CHO cells. A 
50% reduction in N-sulphation was also not detrimental to an endostatin morphological 
response. Within this reduced N-sulphated cell line an increase in the proportion of O-
sulphate groups found within NA/NS type sequences was detected. Previous studies had 
already implicated these type of sequences in endostatin binding (Kreuger et al. 2002; 
Blackhall et al. 2003). Endostatin is the first protein for which it has been proposed that 
NA/NS domains rather than S-domains form the principal binding site within HS.  
Clamp et al have also shown that binding of the oligomeric form of endostatin to cell 
surface HS may be essential for its biological activity. Competition between monomeric 
endostatin and oligomeric endostatin for the same HS binding site may regulate their 
biological activities. 
 
13. Fibroblast growth factors (FGFs) 
The fibroblast growth factor family of proteins, in humans, encompasses 23 members. 
These control the proliferation, migration, differentiation and survival of a wide variety 
of cell types (Ornitz and Itoh 2001). Most fibroblast growth factors (FGFs) have a high 
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affinity for HSPGs and require HS to activate one of five types of cell surface receptor 
(Ornitz and Itoh 2001; Sleeman et al. 2001).  
 
13.1 The domain structure and minimal sulphation requirements of FGF binding 
oligosaccharides 
Oligosaccharides composed solely of S-domain type sulphation sequences have been 
found to bind many members of the FGF family. Specifically HS binding sequences for 
FGF-1 and 2 have been particularly well characterised (Ishihara 1994; Faham et al. 1996; 
Kreuger et al. 2001).  
A minimal HS binding sequence for FGF-2 has been deduced from x-ray crystallography 
studies on a heparin-FGF2 complex (Faham et al. 1996). The structure of this complex 
was shown earlier in Figure 10. The minimal HS binding sequence consists of a 
pentasaccharide sequence GlcNS-IdoUA(2S)-GlcNS-IdoUA-GlcNS. Interestingly this 
sequence contains only a single O-sulphate group (see next section 12.2). 
FGF-1 interacts with a similar minimal sequence although it also appears to recognise 6-
O- sulphate groups (Ishihara 1994). An O-sulphated tri-saccharide motif consisting of 
IdoUA(2S)-GlcNS(6S)-IdoUA(2S) has been shown to be present in all saccharides of six 
to eight disaccharides in length that bind with high affinity to FGF-1 (Kreugar et al., 
1999).   
 
13.2 Different FGFs interact with different HS sulphation sequences? 
The rationale behind many HS-FGF binding studies has been to demonstrate that 
different members of the FGF family bind to different sulphation sequences within the 
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HS polymer. Support for this rationale has recently come from a comprehensive screen of 
the HS binding structures for FGFs-2, 4, 7, 10 and 18 (Ashikari-Hada et al. 2004). FGF-8 
was also screened, however this was shown not to bind any of the oligosaccharides 
analysed. It has been suggested that this was due to the choice of a none heparin binding 
isoform of this protein (Kreuger et al. 2005). The binding affinity of a number of variably 
O-sulphated, entirely N-sulphated octasaccharides, for these FGFs was assessed 
(Ashikari-Hada et al. 2004).  The FGFs could be divided into 4 groups, as detailed below. 
  
Group 1 FGF-2  requires 2-O-sulphation but not 6-O-sulphation 
Group 2 FGF-10 requires 6-O-sulphation but not 2-O-sulphation 
Group 3 FGF-18 requires 2-O-sulphation or 6-O-sulphation 
Group 4 FGF-4 and FGF-7  require both 2-O- and 6-O-sulphation 
The group 4 classification of FGF-7 is not supported by the previous study of Ostrovsky 
et al., which places FGF-7 in group 3 (Ostrovsky et al. 2002).  
 
The specific number of each O-sulphate group required varied between the FGFs. FGF-2 
bound to an octasaccharide carrying a lone 2-O-sulphate group with appreciable affinity, 
as predicted from x-ray crystallography studies (Faham et al. 1996). FGF-10 required the 
presence of three 6-O- sulphate groups. FGF-18 also required three 6-O-sulphate groups 
or alternatively two or three 2-O-sulphate groups. Results for FGFs -4 and -7 were not 
reported.  
The different requirements for O-sulphate groups can be interpreted as a difference in the 
HS sulphation patterns that binds to each FGF. 
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13.3 Biologically active, FGF binding, HS oligosaccharides 
With many FGFs, a saccharide sequence longer than the minimal FGF binding sequence 
is required in order for them to elicit a biological response. With FGF-2 it has also been 
shown that additional O-sulphate groups are also required.  
The HS sequence of a biologically active FGF-2-HS decasaccharide complex must 
comprise a minimum core of three IdoA(2S)-GlcNS
 
repeats substituted with one or at 
most two 6-O-sulphate groups (Guimond et al. 1993; Ishihara et al. 1995; Pye et al. 
2000). The 6-O- sulphate groups are not required for FGF-2 binding to HS and it has 
been proposed that they may be involved in interactions with a receptor molecule 
(Gallagher and Lyon 2000).  
 
13.4 Fibroblast growth factor receptors (FGFRs) 
The FGFRs are members of the receptor tyrosine kinase family of proteins. When a 
ligand binds to the extracellular domain of these receptors, receptor dimerisation occurs. 
Each monomer then phosphorylates a number of conserved tyrosines within the 
cytoplasmic domain of it dimeric partner. This then leads to a series of downstream intra-
cellular signalling events. FGFR dimerisation is therefore a key feature in initiating a 
biological response (Ornitz and Itoh 2001). Alternative splicing of four FGFR genes 
(FGFR1-4) results in the production of over 48 different isoforms of the FGFR receptors 
that vary in their ligand binding properties and kinase domains (Coutts and Gallagher 
1995; Duchesne et al. 2006). All share a common extracellular region composed of three 
immunoglobulin (Ig) like domains (D1-D3).  
  
 
 85 
Interactions with FGFs occur via FGFR domains D2 and D3. Each receptor can be 
activated by several FGFs. In many cases the FGFs themselves can also activate more 
than one receptor, this is not the case with FGF-7 however which can only activate 
FGFR2b. A gene for a fifth FGFR protein, FGFR5, has also been identified (Sleeman et 
al. 2001). In contrast to FGFRs 1-4 it lacks a cytoplasmic tyrosine kinase domain and one 
isoform, FGFR5γ, only contains the extracellular domains D1 and D2. Due to its later 
discovery, little is known about the ligand binding activity of this protein. A 
comprehensive review of FGF receptors and which FGFs are able to activate individual 
splice variants here is not warranted, for such a review for FGFRs 1-4 see (Ornitz et al. 
1996). 
In the presence of either FGF-1 or -2 various ectodomain splice variants (FGFRs 1-4) 
have been shown to have an affinity for HS derived oligosaccharides. In some cases the 
affinity being enhanced by the presence of one or other of the FGFs (Jastrebova et al. 
2006). This and the previous work detailed (Guimond et al. 1993; Ishihara et al. 1995; 
Pye et al. 2000), supports the hypothesis that biologically active oligosaccharides must 
interact with both receptor molecules, in addition to the FGF protein itself. This has been 
shown to be the case in 2 crystal structures of FGF-FGFR-heparin complexes (Pellegrini 
et al. 2000; Schlessinger et al. 2000).   
 
13.5 FGF-FGFR-heparin complexes 
Two crystal structures have been published that show how HS may interact with both 
receptor and FGF at the cell surface to stabilise a ternary complex (see Figures 14 and 15) 
(Pellegrini et al. 2000; Schlessinger et al. 2000). 
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Figure 14 The crystal structure of a 2:2:1 FGF1:FGFR2c:heparin dp10 
complex. 
The co-ordinates for this structure were taken from the protein data bank file 1E0O 
(Pellegrini et al. 2000). Molecular surfaces for the FGFs (green) and FGF receptors (grey 
and purple respectively) were calculated as in Figure 10. The heparin oligosaccharide is 
shown by a line representation. The whole complex is shown in model A.  
Within the complex and due to their close proximity, a number of electrostatic 
interactions may exist between various negatively charged heparin carboxyl groups and 
sulphate groups and positively charged basic amino acid residues exposed at the surface 
of both FGF molecules and the single FGFR molecule coloured grey.  The close 
proximity of these groups can be seen more clearly in enlargements B and C. The side 
chains of all basic amino acids are coloured red in enlargement C. 
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Figure 15 The crystal structure of a 2:2:2 FGF2:FGFR1c:heparin complex. 
The co-ordinates for this structure were taken from the protein data bank file 1FQ9 
(Schlessinger et al. 2000).  
Molecular surfaces for the FGFs (green) and FGF receptors (grey and purple 
respectively) were calculated as in Figure 10. The heparin oligosaccharide is shown by a 
line representation. 
From model A it is not immediately obvious that a two oligosaccharides run along the top 
edge of the complex. This can be more clearly seen in the transparent representation of 
model B. For model C, model B was rotated to a postion where the two heparin 
oligosaccharides could be more clearly viewed from above. In enlargements D and E the 
non-reducing end of each oligosaccharide can clearly be seen positioned in the centre of 
the complex. In enlargement E basic residues are again marked out in red, due to their 
close proximity again a number of electrostatic interactions are possible between these 
and various heparin carboxyl and sulphate groups. Two 6-O-sulphate groups which have 
been shown to be essential for biological activity (see text) are marked with arrows. 
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The models shown in Figures 14 and 15 are for different FGFs (FGF-1 and -2) and 
different receptor ectodomains (FGFR2c and FGFR1c). The Pelligrini model (Figure 14) 
puts HS/heparin oligosaccharides at the heart of complex formation and biological 
activity. It can be seen how without stabilisation by the centrally positioned 
oligosaccharide FGFR dimerisation may not occur and a biological reponse not initialted.  
The Schlessinger model (Figure 15) gives heparin/HS less of a key role. An extensive 
area of contact exists between both FGFRs and it is doubtful whether the presence of an 
oligosaccharide in the complex stabilises this interaction still further. Differences 
between these models may be due to experimental procedure. For example Schlessinger 
et al diffused heparin oligosaccharides into pre-formed crystals of the FGF and FGFR. 
While the crystals analysed by Pelligrini et al. were formed with oligosaccharides in-situ. 
Differences may also simply be the result of using different FGFs and splice variant 
FGFR ectodomains.  
It has recently been suggested that the binding of a single FGF-1 ligand alters the local 
conformation of oligosaccharide chain. The altered conformation then has an increased 
affinity for the binding of a second FGF-1 ligand and in this way facilitates the formation 
of a 2:2:1 Pelligrini type complex (Robinson et al. 2005). 
 
13.6a Different FGFs and FGFRs do not interact with different HS sulphation 
sequences or specific sulphation sequences? Part 1 
The long held assumption that different FGFs interact with different sulphation sequences 
has recently been challenged (Kreuger et al. 2005; Kreuger et al. 2006). A number of 
sequenced HS derived oligosaccharides were analysed for their binding affinity to various 
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FGFs (FGFs -1, -2 , -4, -7 and -8b). A considerable degree of overlap was detected in 
many of their binding characteristics. It was also found that rather than interacting with 
specific sequences the affinity of the FGFs for the oligosaccharides was mainly due to the 
charge density of the oligosaccharide. Similar charge density rather than sequence effects 
have also recently been shown for receptor binding interactions (Jastrebova et al. 2006). 
The first conclusion that FGFs share binding sites is not too controversial. It can be 
imagined how competion between the various growth factors for a limited number of HS 
binding sites might provide a type of regulatory mechanism. This is similar to the 
proposal for competition to exist between the endostatin monomer and trimer in the 
regulation of endostatin biological activity. The second conclusion that binding is related 
to charge density rather than sequence cannot fit with studies where specific sequences of 
sulphation have been shown to either possess or not possess biological activity (Pye et al. 
1998; Guimond and Turnbull 1999). A good example of a study of this type being the 
thesis work of Goodger (Goodger 2003).  
From this work, a decasaccharide carrying 7 sulphate groups,  
UA-GlcNAc-IdoUA-GlcNS-IdoUA(2S)-GlcNS(6S)-IdoUA(2S)-GlcNS-HexUA-
GlcNAc(6S)  
was unable to elicit a biological response from FGF-2 in combination with the FGFR1 
IIIc receptor. A decasaccharide carrying 6 sulphate groups was however,  
UA-GlcNAc-IdoUA-GlcNS-IdoUA(2S)-GlcNS(6S)-IdoUA-GlcNS-HexUA-
GlcNAc(6S).  
This result directly contradicts the new charge density theory.  
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A possible explaination for this apparent contradiction may lie in the conformational 
flexibility of iduronate residues. This issue will be re-examined in the light of a 
discussion of another HS binding protein antithrombin III. 
 
14. Antithrombin III and Factor Xa 
Historically the first and most well characterised ligand-binding interaction is that of 
antithrombin III (AT-III). When bound to heparin, the rate at which AT-III inactivates 
thrombin and other proteases involved in blood clotting, most notably factor Xa, 
dramatically increases (Bjork and Lindahl 1982). However, it is the HS present at the cell 
surface of vascular endothelial cells that is one of the factors responsible for maintaining 
the non-thrombogenic properties of blood vessel walls, rather than heparin (Marcum et 
al. 1986).  
A sequence of five monosaccharides within a heparin derived AT-III binding 
octasaccharide (underlined in the octasaccharide sequence shown in Figure 16) was found 
to be the minimal sequence required for AT-III binding (Lindahl et al. 1984). Any loss of 
sulphation or alteration of any of these five residues resulted in a dramatic drop in the 
affinity of the octasaccharide for AT-III, although N-acetylation or sulphation was 
subsequently found to be tolerated at position 2 (Conrad 1998).  
 
  
 
 93 
Figure 16 
The sequence of an octasaccharide with high affinity for ATIII (Lindahl et al. 1984). The 
minimal antithrombin-binding pentasaccharide (units 2-6) is underlined in red. 
 
 
 
 
IdoUA-GlcNAc(6S)-GlcUA-GlcNS(3S,6S)-IdoUA(2S)-GlcNS(6S)-IdoUA(2S)-aMan(6S)
1            2                 3                 4              5                6                7                 8
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Inactivation of factor Xa by an activated antithrombin–HS complex requires only the 
specific pentasaccharide able to bind antithrombin (Danielsson et al. 1986). However, 
inactivation of thrombin requires the pentasaccharide to be part of a much longer 
sequence that is then thought to bind both thrombin and antithrombin bringing them into 
close proximity and facilitating their interaction (Danielsson et al. 1986).  
An extended highly sulphated ‘biologically active’ sequence encompassing both a 
thrombin binding site and the antithrombin binding pentasaccharide would be relatively 
common within a heparin chain. However, within HS, such a long consecutive sequence 
of sulphation would be rare and it is more likely that the thrombin and antithrombin 
binding sites occur within two separate S-domains, linked by a region of alternating or N-
acetylated sequence.  
 
14.1 Synthetic Factor Xa inhibiting pentasaccharides 
The potential application of a Factor Xa inhibiting pentasaccharide as a clinical anti-
coagulant has prompted much research into its synthesis using synthetic chemistry 
techniques. This research has culminated in the marketing of the anticoagulant product 
Arixtra® by Sanofi-Aventis. Arixtra® contains a synthetic pentasaccharide almost 
identical in structure to the minimal antithrombin III binding sequence. A number of 
derivatives of this pentasaccharide have also been produced and these have shed new 
light on the functional role of a number of specific sulphate groups within this sequence 
(Sisu et al. 2003).   
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14.2 Conformationally locked iduronate residues 
The minimal AT-III binding pentasaccharide contains a single iduronate residue at 
postion 5 (see Figure 16). This can be synthetical locked into the 1C4 or 2S0 
conformations (Das et al. 2001). Only oligosaccharides containing the locked 2S0 
conformation
 
were able to bind and activate AT-III. If the iduronate is retained locked in 
this conformation but the N- and 6-O- sulphate groups removed from the N-glucosamine 
residue to its reducing side, AT-III binding and biological activity is maintained (Sisu et 
al. 2003).  
The conclusion here is that the removed sulphate groups are not required to directly 
interact with AT-III. The role of these sulphate groups, may be to influence the 
conformational equilibrium of the adjacent iduronate more towards the 2S0 conformation 
necessary for binding to AT-III to occur. 
 
13.6b Different FGFs and FGFRs do not interact with different HS sulphation 
sequences or specific sulphation sequences? Part 2 
A similar iduronate influencing role could be envisioned for strategically positioned 
sulphate groups within biologically active HS/heparin oligosaccharide sequences. It may 
be that the apparent correlation between an increase in charge density, (or more 
specifically an increase in the number of sulphate groups) is related to an increase in the 
chance that one or several of the additional sulphate groups is able to influence the 
conformational equilibria of a conformationally critical iduronate residue.  
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15. The balance of iduronate equilibria, a critical influence on oligosaccharide 
binding? A purification problem 
Typically iduronate conformational details are not available for HS oligosaccharides 
screened in binding or biological assays. These details can only be gained through the use 
of NMR techniques, which require a minimum of 0.5mg of material for analysis. Typical 
functional analysis studies can work with <10µg of material. 
Although HS itself has been available in bulk quantities for a number of years (Griffin et 
al. 1995), few authentic HS oligosaccharides larger than dp4 have been well 
characterised by NMR techniques that are needed, not only for iduronate, but for more 
general conformational studies (Hileman et al. 1997).  
This is due to the extreme difficulty in obtaining a homogeneous sample in the quantities 
required for NMR analysis. The number of potential sulphation sequences and 
consequently sample heterogeneity, increases dramatically as the chain length increases 
(Hileman et al. 1997). 
 
16. Iduronate and terminal ∆4,5 uronic acid conformational analysis of heparin and 
synthetic oligosaccharides 
Due to the purification problem, iduronate conformation has only been analysed within 
synthetic or heparin derived oligosaccharides (reviewed by (Ferro et al. 1990)) Due to 
heparins high level of sulphation it is much easier to purify homogeneous 
oligosaccharides in high quantities for NMR analysis and other structural studies.  
The conformational equilibrium has been shown to be influenced by the sulphation state 
of neighbouring N-glucosamine residues on both sides of the iduronate as well as 2-O-
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sulphation of the iduronate residue itself (Ferro et al. 1990). For example iduronate in the 
tetrasaccharide sequence GlcUA-GlcNS(6S,3S)-IdoUA(2S)-GlcNS(6S) has a 
conformational equilibrium of 32%:68% 1C4: 2S0. While in the tetrasaccharide sequence 
GlcUA-GlcNS(6S)-IdoUA(2S)-GlcNS(6S) the conformational balance is altered to 
56%:44% 1C4: 2S0. 
Like iduronates the balance of terminal ∆ 4,5 uronic acid conformational equilibrium is 
influenced by the sulphation state of adjacent glucosamines and by 2-O- sulphation. For 
example, the sequence UA-GlcNS(6S) exists as 46%:54% 2H1: 1H2, while the sequence 
UA(2S)-GlcNS(6S) exists as 8%:92% 2H1: 1H2 (Ragazzi et al. 1993). 
A survey of the literature reveals that for both iduronate and terminal uronic acid 
residues, there are significant gaps in the sequences within which their conformational 
equilibrium has been studied. For example, no reference could be found to the balance of 
the iduronate conformational equilibrium in the sequence -GlcNS-IdoUA(2S)-GlcNAc-. 
 
17. Theoretical coupling constants  
The 1990 review by Ferro et al. (Ferro et al. 1990) used a least squares fitting technique, 
to fit experimental coupling constant data to theoretical coupling constant values, and 
derive the percentage of iduronate in each of its three low energy conformations. This 
technique has subsequently been used in a number of similar studies. However, all of 
these studies use different theoretical values to fit to their experimental data (Forster and 
Mulloy 1993; Ojeda et al. 2002; Lucas et al. 2003). Still more theoretical values were 
published prior to 1990 (van_Boeckel et al. 1987), although these were not used in a 
least-squares fitting analysis.  
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It is not clear to what extent the results of a least-squares analysis are influenced by the 
choice of theoretical coupling constants. Nor was it clear which should be the correct 
choice of theoretical values for a least squares analysis of the data presented in this thesis. 
In order to examine these two issues, as part of this thesis work a three conformational 
least squares fit was performed to previously published data. The conformational fit was 
calculated as detailed below. 
Using the solver add-in of Microsoft Excel the sum of the squares of the differences 
between each of the experimentally observed coupling constants and a weighted average 
of the theoretical coupling constants was minimised. The weighted average of the 
theoretical constants was represented by the formula 
a 3Jx,y 1C4 + b 3Jx,y 4C1 + c 3Jx,y 2S0  
where 3Jx,y = the theoretical value for each coupling constant 3J1,2, 3J2,3, 3J3,4 and 3J4,5. 
The sum of the squares of the differences was minimised by varying parameters a, b and 
c subject to the constraints that their sum should equal 1 and each could take a value >=  
0 but <=1. The percentages of each conformation reported are parameters a, b or c 
expressed as a percentage of their sum total 1. The spread sheet to carry out this analysis 
was set out by Professor John Pezzulo, Georgetown University, Washington DC. 
Table 1 shows the distribution of iduronate conformations best-fitting the measured 
experimental coupling constants for a number of previously published oligosaccharide 
structures.  
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Table 1.  A comparison of the conformational distribution of iduronate residues 
within a number of previously published oligosaccharide sulphation sequences.  
A three conformation least-squares fit was carried out for experimentally determined 
coupling constants taken from (Ferro et al. 1990) (oligosaccharides 1, 2, 3, 5 and 6) and 
(Lucas et al. 2003) (oligosaccharide 4). The fit was to theoretical values as published by 
(van_Boeckel et al. 1987; Ferro et al. 1990; Forster and Mulloy 1993; Ojeda et al. 2002; 
Lucas et al. 2003).  
The iduronate residue to which the coupling constants refer are marked in red.  
Note, the sequences of oligosaccharides 1 and 3 were published incorrectly by Ferro et al. 
by reference to the original work cited by them of van Boeckel et al.(van_Boeckel et al. 
1987) 
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Oligosaccharide Coupling constants 
Contribution of conformer to equilibrium 
(%) 
Reference for theoretical 
values 
  
3J1,2 3J2,3 3J3,4 3J4,5 1C4 2S0 4C1     
                    
1. GlcNS-IdoUA-GlcNS 3.3 5.4 3.6 2.4 73 27 0   van Boeckel et al. (1987) 
        63 29 8   Ferro et al. (1990) 
        62 38 0   Forster and Mulloy (1993) 
        76 24 0   Ojeda et al. (2002) 
          71 29 0   Lucas et al. (2003) 
2. GlcNAc-IdoUA-GlcNAc 3.9 6.6 3.6 3.2 56 44 0   van Boeckel et al. (1987) 
        46 47 7   Ferro et al. (1990) 
        45 55 0   Forster and Mulloy (1993) 
        58 42 0   Ojeda et al. (2002) 
          57 43 0   Lucas et al. (2003) 
3. GlcNAc(6S)-IdoUA(2S)-GlcNS 1.4 3.2 2.8 2.1 100 0 0   van Boeckel et al. (1987) 
        95 1 4   Ferro et al. (1990) 
        94 6 0   Forster and Mulloy (1993) 
        100 0 0   Ojeda et al. (2002) 
          99 0 1   Lucas et al. (2003) 
4. GlcNS-IdoUA(2S)-GlcNS- 3.6 4.2 3.6 3.5 78 22 0   van Boeckel et al. (1987) 
IdoUA(2S)-GlcNS 
    74 2 24   Ferro et al. (1990) 
      64 24 8   Forster and Mulloy (1993) 
      80 20 0   Ojeda et al. (2002) 
      78 0 21   Lucas et al. (2003) 
5. GlcNS(6S)-IdoUA(2S)-GlcNS 2.8 5.4 3.1 2.5 76 24 0   van Boeckel et al. (1987) 
        65 35 0   Ferro et al. (1990) 
        65 35 0   Forster and Mulloy (1993) 
        79 21 0   Ojeda et al. (2002) 
          74 26 0   Lucas et al. (2003) 
6. GlcNS(6S,3S)-IdoUA(2S)- 3.9 7.3 3.9 3.3 48 52 0   van Boeckel et al. (1987) 
GlcNS  
      40 53 7   Ferro et al. (1990) 
        38 62 0   Forster and Mulloy (1993) 
        49 51 0   Ojeda et al. (2002) 
          49 51 0   Lucas et al. (2003) 
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As can be seen in Table 1, the choice of theoretical coupling constants can have an effect 
on the results of the least-squares fitting procedure. This is most dramatically seen for 
oligosaccharide 4. 
The study of Forster and Mulloy (Forster and Mulloy 1993) cited in Table1, examined 
the molecular dynamics of iduronates using a computational model. The coupling 
constants then published and used to produce the conformational percentages given in 
Table 1, were an average over the structures observed during the course of a 200ps 
molecular dynamic simulation. This approach eliminates the high level of bias introduced 
by choosing to fit to an arbitrary single set of coupling constants. These results are, 
however, by their nature dependent on the charge model and molecular dynamic force 
field used. It was felt that an improvement on the accuracy of these values might be 
offered by repeating this work using the modern carbohydrate specific Glycam04 
molecular dynamics force field (Case et al. 2005). 
 
18. Heparan Sulphate, three-dimensional structure 
Many NMR studies of polymeric heparin or heparin derived, rather than HS derived 
oligosaccharides have been published, again due to the ease of heparin oligosaccharide 
purification  (Loganathan et al. 1990; Yamada et al. 1992; Mulloy et al. 1993; Yamada et 
al. 1993; Mulloy et al. 1994; Larnkjaer et al. 1995; Pervin et al. 1995; Mikhailov et al. 
1996; Mikhailov et al. 1996; Tsuda et al. 1996; Yates et al. 1996; Cros et al. 1997; 
Mikhailov et al. 1997; Yamada et al. 1998; Hricovini et al. 1999; Yates et al. 2000; 
Chuang et al. 2001; Guerrini et al. 2001; Hricovini et al. 2001; Chuang et al. 2002; 
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Guerrini et al. 2002; Hricovini et al. 2002; Hakansson and Caffrey 2003; Vanhaverbeke 
et al. 2004; Angulo et al. 2005).  
Most NMR studies are limited to proton assignment however two 3D-models have been 
produced for a heparin dodecasaccharide using a combination of NMR and molecular 
modelling techniques (see Figure 17) (Mulloy et al. 1993). 
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Figure 17 Two, three dimensional models of heparin dodcasaccharides. 
The coordinates for both structures were taken from the protein data base, code 1HPN 
(Mulloy et al. 1993). The models are composed of 6 repeats of a GlcNS(6S)-IdoUA(2S) 
disaccharide unit.  
In model A all IdoUA(2S) monosaccharides are in the 2S0 conformation. In model B all 
IdoUA(2S) monosaccharides are in the 1C4 conformation. 
 A
B
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NMR studies on chemically de-sulphated heparin derivatives suggest that removal of 
specific types of sulphate group does not unduly affect the overall helical conformation 
of the oligosaccharides presented in Figure 17 (Mulloy et al. 1994). On this basis the 
helical conformations of these models are assumed to be adopted by all HS S-domain 
type sequences (Mulloy and Forster 2000).  
Chemical de-sulphation techniques though, lack the subtlety to reproduce many of the 
sulphation sequences found within authentic HS derived sequences (Merry et al. 1999; 
Vives et al. 1999; Kreuger et al. 2001). It may be that subtle sulphational differences 
produce subtle conformational differences within authentic HS oligosaccharides.  
 
18.1 The torsional angles Φ and Ψ, and the exo-and endo-anomeric effect 
Defining the relative orientation of each monomeric unit in the Figure 17 models are the 
Φ and Ψ torsion angles across each glycosidic linkage. The authors of these models 
defined these torsional angles as Φ = H1-C1-O-C4 and Ψ = C1-O-C4-H4 (see Figure 18).  
Definition of these torsional angles is an area of inconsistency in HS/heparin 
oligosaccharide modelling. Some authors define these angles as Φ = O5-C1-O-C4 and Ψ 
= C1-O-C4-C5 (Verli and Guimaraes 2004; Becker et al. 2005) (see Figure 18). While 
others use a torsion angle of Ψ = C1-O-C4-C3 (Imberty and Perez 2000) or Φ = C2-C1-
O-C4 and Ψ = C1-O-C4-C3 (Raman et al. 2003) (see Figure 18). Occasionally how these 
angles were defined is not declared (Mikhailov et al. 1996; Mikhailov et al. 1997). While 
each definition is equally valid, the lack of consistency makes a comparison of data 
between studies a difficult if not impossible task, particularly when definitions are not 
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declared. The definition adopted by Mulloy et al. slightly predominates in the literature 
and was adopted throughout this study. 
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Figure 18 Φ and Ψ torsion angles defining the relative special orientation of 
each monosaccharide across a glycosidic linkage. 
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The exo-anomeric effect is reported to cause a considerable barrier to free rotation about 
the Φ and Ψ torsion angles (Collins and Ferrier 1998). The exo-anomeric effect causes 
axial or equatorial groups attached to C1 to prefer differing rotamer states. These rotamer 
states are presented as a Newman projection along the C1-glycosidic oxygen bond in 
Figure 19. The exo-anomeric effect is the result of the glycosidic oxygen preferring to 
adopt a conformation in which its lone pair orbitals overlap with the non-bonded 
electrons of the endocyclic O5-C1 bond (Bubb 2003). 
The intra-ring equivalent of the exo-anomeric effect is the endo-anomeric effect. For 
pyranoses, the usually energetically preferred equatorial orientation of substituents in six 
membered ring systems, is opposed by interactions between lone pair electrons of the 
endo-cyclic oxygen (O5) and electronegative substituents attached to C1; these 
substituents favouring an axial orientation (see Figure 19) (Bubb 2003).  
According to this effect, all C1 substituents within HS/heparin have a preference for an 
axial orientation. This may be the cause of the formation of αC1-C4 glycosidic linkages 
between all HS/heparin structural units as opposed to βC1-C4. (note, through a quirk of 
carbohydrate naming nomenclature C1-C4 bonds between glucuronic acid and a N-
glucosamine are classed as βC1-C4. The C1 substituent of β-glucuronic acid is actually 
axially orientated, as with all other internal HS/heparin structural units).  
For axially orientated systems the endo- and exo- anomeric effects oppose each other 
(Collins and Ferrier 1998). This makes the exo- anomeric effect less of a barrier to 
rotation about the Φ and Ψ torsion angles of HS/heparin. By how much this barrier is 
lowered is unclear. 
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Figure 19 Axial and equatorial orientations of C1 substituents and their 
preferred rotamer conformations due to the exo-anomeric effect. 
Lone pair orbitals on the oxygen substituent are represented as       and       
 
 
 
 
 
 
 
Prefered rotamer conformations due to the endo-anomeric effect: 
        
  For axial substituents                   For equatorial substituents 
 
 
 
 
 
 
The R group from the above two structures is a single hydrogen atom. However, the R 
group in an oligosaccharide, will be the C4 of a linking monosaccharide. 
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19. Molecular dynamic studies 
NMR derived structures represent an average of many structures that occur in solution. 
This is particularly the case with oligosaccharide structures, which are known to be 
particularly flexible in solution (Imberty and Perez 2000). An idea can be gained as to 
how much a modelled structure may sample alternate conformations, through the use of 
molecular dynamic modelling techniques.  
A review of the insights gained and the problems with HS/heparin molecular dynamic 
modelling is discussed below. 
 
19.1 Dynamic modelling of N-glucosamine monosaccharides 
The gauche effect is notoriously hard to replicate in molecular dynamic modelling 
simulations. It has been shown that for methyl α-D-glucopyranside (essentially GlcNAc 
but with a hydroxyl group in place of the NAc substituent) a simulation time of 50ns is 
required to produce conformational ensembles that display the correct, experimentally 
determined, rotamer populations (38:5:57, gt:tg:gg) (Kirschner and Woods 2001). 
Explicit solvent molecules must also be included in the calculation. A 50ns explicit 
solvent simulation, for any modelled system, is only realistically possible through the use 
of expensive muti-processor hardware.  
In the modelling of N-glucosamines, within HS/heparin oligosaccharides rotamer 
populations are usually assigned as ‘gg’ where static models are produced (Mulloy et al. 
1993) (see Figure 17), or initiated in the ‘gg’ conformation when molecular dynamic 
simulations are carried out (Mikhailov et al. 1997; Ojeda et al. 2002; Lucas et al. 2003; 
Verli and Guimaraes 2004). In all these studies the rotamer conformation remained in the 
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‘gg’ conformation throughout the length of the simulation. The modelled preference for a 
‘gg’ conformation is mainly based on the experimentally observed rotamer equilibrium 
for methyl α-D-glucopyranside.  
 
19.2 Dynamic modelling of iduronate monosaccharides 
To date, no molecular dynamic simulation has been able to reproduce experimentally 
determined iduronate conformer populations. In one study, a single transition from the 
2S0 to the 4C1 conformation was reported (Forster and Mulloy 1993), while in another 
study torsional angle restraints were employed to actively prevent ‘ring flipping’ (Verli 
and Guimaraes 2004). The presumption here is that the applied restraints do not 
artificially influence the dynamics of the modelled system. However, in many studies 
iduronates remain in their starting conformation throughout a molecular dynamic 
simulation, without the application of additional torsion angle restraints (Ojeda et al. 
2002; Angulo et al. 2003; Lucas et al. 2003). A clear advance in the field would be the 
demonstration that models may sample alternate iduronate ring conformations, at a rate 
consistent with experimental data. The influence of sulphation pattern on the rate of 
sampling could then be assessed. 
 
19.3 Molecular modelling of terminal uronate monosaccharides   
Few models have been generated that terminate in this unit. However, Mikhailov et al. 
(Mikhailov et al. 1996) carried out a number of molecular dynamic simulations of a 
tetrasaccharide terminating in UA(2S). The starting conformation for this residue in all 
simulations was 1H2. Only in one simulation was a conformational change observed to 
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2H1. In other simulations the conformation remained un-altered or an intermediate 
conformation between the two half chair conformations became stabilised. The fact that 
an intermediate conformation existed for almost the entire duration of one simulation, 
suggests there was a parameterisation problem with this residue in this model system. 
 
20. Aims of this study 
Over many years of study, a great deal of NMR structural information has been gathered 
for heparin or heparin derived oligosaccharides (see section 16, for a comprehensive 
reference list from 1990-2005). Only one previous HS-NMR study has characterised 
authentic HS derived, di-, tetra- and a single hexasaccharide. This study was limited to 
just proton assignment (Hileman et al. 1997). The primary aim of the work presented in 
this thesis was to address this inbalance.  
A preliminary SAX-HPLC analysis of authentic HS hexasaccharides derived from a bulk 
source of commercial porcine HS was carried out. This revealed that the considerable 
peak overlap, observed on HPLC analysis by Hileman et al., did not occur with these 
samples. It should, therefore, have been possible to purify more than the single 
hexasaccharide isolated by Hileman et al. and possibly longer oligosaccharides for NMR 
analysis. This would represent a first in the field of HS conformational analysis.  
Once a number of authentic HS oligosaccharides had been purified and sequenced by 
NMR, it became clear that an analysis of their iduronate and terminal UA conformations 
could fill a number of gaps in the literature. For a comparison a number of heparin 
derived hexasaccharides were also produced. Chemical de-2-O-sulphation of these 
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heparin and HS oligosaccharides were carried out in order provide a greater insight into 
the role 2-O-sulphate groups play in influencing conformational equilibria.  
It was also sought to produce an improved set of coupling constants for iduronate 
conformational analysis, using computational molecular dynamic modelling, in a way 
similar to the coupling constant set previously produced by Forster and Mulloy (Forster 
and Mulloy 1993). 
The second aim of the work presented, was to use the NMR structural data gathered to 
provide new information on the relationship between HS structure and function. 
Molecular models were produced for all HS oligosaccharides on which NMR structural 
data had been gathered. It was found that static models could only provided limited new 
structure/functional information. In particular static molecular modelling could not 
explain the basis on which a number of decasaccharide structures either possessed or did 
not possess biological activity (Goodger 2003). Molecular dynamic modelling was then 
used to try and account for the significant degree of conformational flexibility all 
oligosaccharides possess in solution (Imberty and Perez 2000). By analysing the data 
from dynamic studies in was hoped to provide a link between oligosaccharide sulphation 
pattern and biological activity that was missing from the thesis work of Goodger 
(Goodger 2003).  
 
21. Molecular dynamic partial charge assignment 
Partial charge assignments are a problem area for the field of molecular dynamic 
modelling. They are necessary in order for through space interactions between atoms to 
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be considered in dynamic simulations. In reality, however, partial charges are a fictitious 
concept and as such cannot be measured experimentally.  
Many different methods and variations of methods exist with which to assign partial 
charges (reviewed in (Leach 2001)). Usually, molecular modelling force-field torsional 
parameters are calculated using a single set of partial charges calculated by a given 
method. Changing partial charge values from the values at which torsion parameters 
where derived, should strictly require a re-evaluation of the torsional parameters to fit 
with these new values, this is seldom however carried out. For use with a particular force 
field, it is thought good practice to calculate partial charges for new systems using a 
method similar to, if not identical to, the original method used in the force fields 
development, although this is not always carried out, see (Verli and Guimaraes 2004). 
Verli and Guimaraes applied Lowdin type partial charges to a force field originally 
parameterised using a different partial charge calculation method. 
Partial charge values for the HS oligosaccharide models of this study are particularly 
problematic. While a majority of the torsional parameters needed for the models are 
contained in the glycam04 parameter set, which is available on line at 
http://www.glycam.com/gl_params.html and distributed free with the AMBER 8 
molecular modelling software suite (Case et al. 2004), parameters needed to cover 
sulphate, carboxyl and the C4-C5 double bond of UA are not. Parameters for these are 
available in the literature or from other force fields, but have been developed using 
alternate partial charge calculation methodologies. Ideally, what is needed is a new force 
field, or a further development of the glycam parameter set to cover these missing 
parameters.  
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Using existing parameters an evaluation of three different partial charge sets was made in 
this thesis work, on HS dp6-2 and -3 structural models. Partial charge calculation method 
one is the most similar in principal to that employed by the glycam04 developers 
(Professor. Karl. Kirschner, personal communication). Partial charge methods two and 
three are significantly more rigorous and represent an early stage in the development of a 
new force field with which to model HS/heparin oligosaccharides (under development in 
collaboration with Dr. Francois Dupradeau, University of Amien, Amien, France). 
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EXPERIMENTAL MATERIALS AND PROCEDURES 
1. Experimental Materials 
Bio-Gel P-10 (fine grade) was purchased from Bio-Rad (Hemel Hempsted, Herts, UK). 
PD-10 prepacked, disposable Sephadex G-25 columns were purchased from Amersham 
Pharmacia Biotech. ProPac PA-1 semi-preparative strong anion-exchange HPLC columns 
were from Dionex (Camberley, Surrey, UK). The TSK3000PW gel filtration column was 
purchased from phenomenex (Macclesfield, UK). Heparinase I (Flavobacterium 
heparinum; EC 4.2.2.7), heparinase II (F. heparinum; no EC number assigned) and 
heparinase III (F. heparinum; EC 4.2.2.8) were purchased from Grampian Enzymes 
(Orkney, UK). The disaccharide standard ∆UA(2S)-GlcNS(6S) was also purchased from 
Grampian Enzymes. Porcine intestinal mucosal Heparan Sulphate was purchased from 
Celsus laboratories (Cincinnati, OH, USA). Tinzaparin Sodium (Innohep®) was 
purchased from Leo Pharmaceuticals (Princes Risbourgh, UK). D2O was purchased from 
GOSS scientific (Essex, UK). Acrylamide and HPLC grade sodium chloride were 
purchased from VWR international (Poole, UK). Trizma-base, Glycine, Azure A, DEAE-
Sephacel and sodium hydroxide were purchased from Sigma (Dorset, UK) as was the 
Shigemi NMR microtube. 
 
EXPERIMENTAL PROCEDURES  
2. Enzymatic depolymerisation of HS. 
Porcine intestinal mucosal HS was depolymerised using the enzyme Heparinase III. To 
200mg of HS 2ml of 0.1mM sodium acetate, 0.1mM calcium acetate, pH 7.0 and 10mU 
of heparinase III was added. For preparative digests a further three additions of 10 mU of 
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heparinase were made at 16hr intervals. In total 50 identical digests were carried out 
using 10g of HS starting material. All digestions were carried out at 25˚C. 
 
3. Gel filtration chromatography. 
3.1 Analytical gel filtration chromatography 
A 10µl aliquot containing 200µg of HS was applied to a TSK3000PW gel filtration 
column. The column was pre-equilibrated with 0.15M NaCl, 20mM Na2HPO4, at pH 7.2 
(phosphate buffered saline (PBS)) and the sample eluted from the column using the same 
PBS at a flow rate of 0.4ml/min. The eluant was monitored in-line for absorbance at 
232nm. 
 
3.2 Preparative gel-filtration chromatography 
Each 200mg digest was applied to a Bio-Gel P10 column (3 x 120cm) eluted with 0.25 M 
NH4HCO3 at a flow rate of 9ml h-1. Likewise 3 vials of tinzaparin sodium were applied 
and eluted from the column. Fractions of 3ml were collected, their absorbance at 232nm 
measured and relevant fractions pooled. After initial evaporation to dryness the 
concentration of NH4+ ions was further reduced by repeatedly re-dissolving the samples 
in 10ml H2O and evaporating to dryness using rotary evaporation.  
 
4. Strong Anion-exchange HPLC (SAX-HPLC). 
HS tetrasaccharide, hexasaccharide and heparin hexasaccharide samples were applied to a 
ProPac PA-1 column (9 x 250mm) pre-equilibrated with distilled water adjusted to pH 
3.5 with HCl. Elution was effected with an NaCl gradient of 0-1M NaCl over 80 mins at 
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a flow rate of 4ml min-1. The NaCl gradient for the HS octasaccharides was 0-1.2M NaCl 
over 90 mins and the gradient for the HS decasaccharides was 0-1.2M NaCl over 180 
mins. All gradients were identical to those used by Merry et al. (Merry et al. 1999). The 
eluate was monitored in-line for absorbance at 232nm and 4ml fractions were collected. 
Relevant fractions were pooled and added to identical fractions from previous separation 
runs. These were concentrated by rotary evaporation, desalted on a PD10 column eluted 
with water, concentrated and then lyophilised. 
 
5. Quantification. 
Initial quantification was carried out using the following method.  
A known quantity of the disaccharide standard ∆UA(2S)-GlcNS(6S) (molecular weight 
664 Da) was applied to a TSK3000PW gel filtration column. The column was pre-
equilibrated with PBS and the sample eluted from the column using the same PBS at a 
flow rate of 0.4ml min-1. The eluate was monitored in-line for absorbance at 232nm. The 
area under the ∆UA(2S)-GlcNS(6S) peak was calculated to obtain a nmoles/ml per area 
unit.  
The purified samples were re-dissolved in 100µl of water and 5µl then applied and eluted 
from the TSK column. The amount of material applied to the column was calculated by 
dividing the area under the sample peak by the previously calculated nmoles/ml per area 
unit. From this the concentration and total quantity of purified material could be 
calculated. 
Later in the study enough material had been purified to allow direct quantification of the 
sample, after lyophilisation to dryness, by weight on a standard laboratory balance. 
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6. Polyacryamide gel electrophoresis (PAGE). 
To each well 10µg of HS hexasaccharide or octasaccharide in 20µl of a 20 % glycerol, 
1% phenol red solution was loaded. Samples were initially ran through a 1.5 cm stacking 
gel (5% acrylamide/ 2% cross-linker). Then through a 16cm x 12cm x 0.75cm resolving 
gel (30% acrylamide / 5% cross-linker) at a constant voltage of 200V until the phenol red 
marker reached the bottom of the gel. The discontinuous buffer system of Laemmli was 
used (Laemmli 1970) with 0.375M Tris/HCl in the resolving gel and 0.125M Tris/HCl in 
the stacking gel at pHs of 8.5 and 6.5 respectively. Tank buffer consisted of 25mM Tris/ 
0.192M glycine pH 8.3. Oligosaccharide bands were visualised by staining with 0.25% 
aqueous Azure A for 5 mins under constant agitation. Gels were de-stained by repeated 
washing in water for up to 30mins. 
 
7. Recovery of HS oligosaccharides dp6-5 and dp6-6 from polyacrylamide gels 
This was done using a variation of the method published by Vives et al. (Vives et al. 
2001). For preparative purposes bands corresponding to HS dp6-5 and HS dp6-6 were cut 
out from the gel and pooled into a single tube. To this 5mls of 2M NaCl was added and 
the sample left overnight. The 5mls was then applied to a Bio-Gel P2 column (1.5cm x 5 
cm) equilibrated with distilled water. The sample was then washed through the column 
until the blue Azure A colour was 1cm from the bottom. The large sample volume 
collected was then concentrated by rotary evaporation and further desalted by passage 
over PD-10 desalting columns eluted with water, and lyophilised to dryness. Removal of 
the Azure A organic dye in this way meant that PD10 columns were not contaminated 
and could be easily re-used. 
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8. DEAE ion-exchange chromatography 
DEAE-Sephacel columns (1.5cm x 3.5 cm) were equilibrated with PBS. Dry lyophilised 
samples were re-dissolved in 1ml H2O and applied to the column. Acrylamide 
contaminants were then eluted from the column using 10-20ml of PBS. Oligosaccharides 
were then eluted from the column using 1M NaCl, 20mM Na2HPO4, at pH 7.2. 
Oligosaccharide samples were concentrated by rotary evaporation, desalted by passage 
over PD-10 desalting columns eluted with water, and lyophilised to dryness before 
further analysis.   
 
9. Disaccharide Analysis. 
A volume corresponding to 100µg of sample was lyophilised to dryness. The sample was 
then re-dissolved in 20µl of 0.1mM sodium acetate, 0.1 mM calcium acetate, pH 7.0 and 
2 milliunits of heparinases I, II and III were added. All digests were incubated at 37 ˚C 
for 16 hrs and the total digest volume was 50µl. After digestion into their component 
disaccharides, all samples were made up to a volume of 1ml by the addition of water-
adjusted to a pH of 3.5 with HCl, and applied to a Pro-Pac PA-1 SAX-HPLC column (9 x 
250mm) pre-equilibrated in water adjusted to pH 3.5 with HCl. Elution was effected by 
an increasing NaCl gradient of 0-1M over 45 mins at a flow rate of 4ml min-1. Peak 
identification was made by comparison to the elution position of known disaccharide 
standards.  
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10. Chemical de-2-O sulphation 
The total quantity of sample available was lyophilised down to dryness. A 1M solution of 
sodium hydroxide was prepared and the sample re-dissolved at a ratio of 1:4 sodium 
hydroxide to water, to a final volume of 1ml and a final concentration of sodium 
hydroxide of 0.2M. The sample was then lyophilised to dryness and re-dissolved in 900µl 
of water. The sodium hydroxide present was neutralised by the addition of 100µl of 
glacial acetic acid and the sample de-salted by passage over a PD-10 de-salting column 
before lyophilisation to dryness.  
This procedure constituted one round of de-2-O- sulphation, samples were then subjected 
to NMR spectroscopy analysis (see below) before additional rounds of de-sulphation 
were undertaken on some samples.  
 
11. NMR spectroscopy.  
All NMR spectra were recorded by Dr. Neil McLay (Dept. of Chemical and Biological 
Sciences, University of Huddersfield). 
For NMR measurements, the total quantity of material available was dissolved in 250µl 
0.15M NaCl, 20mM Na2HPO4 (PBS), 2H2O at pH 7.2 and then repeatedly exchanged in 
1ml 2H2O with intermediate lyophilization. For analysis samples were contained in a 5-
mm Shigemi tube at a sample volume of 250µl.  
The 1H-NMR spectra were acquired on a 500 MHz. Bruker NMR spectrometer. Reported 
chemical shifts are in ppm relative to tetramethylsilane. The TOCSY and NOESY spectra 
were recorded in phase sensitive mode using states-TPPI. A total of 256 experiments of 
2048 data points were recorded with 128 scans over a spectral width of 2741 KHz in both 
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dimensions. The FIDs were zero filled in F1 and multiplied by phase shifted sine 
functions in both dimensions to give data sets of 1024x1024 points. 
The DQF-COSYs were recorded in magnitude mode using the same size data set as 
above but with the number of scans reduced to 64. The FIDs were zero filled in F1 and 
multiplied by sine functions in both dimensions prior to transformation. 
HSQC spectra were recorded in phase-sensitive acquisition mode using Echo-anti-echo 
with sensitivity improvement. A total of 256 experiments of 1024 data points were 
recorded, using 16 scans and a spectral width of 2480Hz (1H) in F2 and 20833Hz (13C) in 
F1. The FIDs were multiplied by phase shifted sine functions in both dimensions and 
linear prediction applied to the F1 dimension to give final data sets of 1024 x 1024 data 
points. 
 
12. Coupling constant measurement 
In most cases it was possible to measure multiplet coupling constants directly from the 
recorded transformed 1D-NMR spectra. In cases where it was not possible, due to peak 
overlap, using the MestRe-C NMR analysis program the following procedure was 
adopted. 
The first derivative of the spectrum was calculated and a Hilbert transformation applied 
to re-generate the imaginary part of the spectrum. Phase correction was then applied to 
make all analysed peaks positive. Line fitting (de-convolution) was then used to optimise 
peak numbers, positioning and shape composing an individual multiplet. By default, 
MestReC uses the Levenberg-Marquardt and Downhill Simplex fitting methods in 
combination. Optimisation was deemed to be successful when the sum of the areas of the 
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optimised peaks reproduced the peak shape of the analysed multiplet to a high degree of 
accuracy. Coupling constants were then measured between optimised de-convoluted 
peaks. 
 
13. Molecular modelling 
Molecular modelling was carried out using the AMBER 8 molecular modelling suite 
(Case et al. 2004). Generously provided free of charge by Professor David Case (The 
Scripps Research Institute, California. USA). For modelling purposes all carboxyl, 
sulphate and sulphamate groups were modelled in their de-protonated form and all charge 
models calculated accordingly. 
 
13.1 Iduronate Coupling constant analysis 
Initial coordinates for the methyl glycosides of IdoUA and IdoUA(2S) in the 1C4 
conformation were based on geometries taken from the protein data bank file 1HPN 
(Mulloy et al. 1993).  These structures were then submitted to the antechamber module of 
AMBER 8 and AM1-BCC charges (Jakallan et al. 2002) and GAFF atom types assigned 
(Wang et al. 2004). The 2S0 and 4C1 geometries were taken from a 5ns generalized Born 
implicit solvent molecular dynamic (MD) simulation of the 1C4 models at a temperature 
of 400K. At this temperature a number of transitions occur between all three 
conformations (data not shown). AM1-BCC charges were then re-assigned for randomly 
chosen 2S0 and 4C1 structures. 
For explicit water simulations, each conformation was placed in a truncated octahedral 
box of explicit TIP3P water molecules. An 8Å buffer of water was generated around the 
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monosaccharide to the edge of the water box in each dimension. The charge on the 
monosaccharides was then neutralised through the addition of sodium ions using the 
addions method implemented in the xleap module. Standard molecular modelling 
techniques were then used to equilibrate the system prior to a 1ns 300K molecular 
dynamics (MD) run, as follows.  
During equilibration the initial position of water molecules and sodium ion(s) were 
minimised, while the conformation of the sugar was restrained (50 Kcal mol-1 Å-1) (1500 
steps steepest descent minimisation, 1500 steps conjugate gradient minimisation). The 
restraints were then removed and the whole system minimised (1000 steps steepest 
descent minimisation, 1500 steps conjugate gradient minimisation) before weak restraints 
were re-applied to the sugar (10 Kcal mol-1 Å-1) and the system allowed to heat up to 
300K at constant volume for 20ps. Restraints were again removed and the density of the 
water was then allowed to relax during 100ps of MD using a constant pressure periodic 
boundary with an average pressure of 1 atm. During this final equilibration step and the 
subsequent MD run the temperature was maintained at 300K. In all equilibration steps 
and MD runs the Particle Mesh Ewald electrostatic treatment was implemented using the 
sander default settings and a cut off distance of 6Å. The SHAKE algorithm was also 
applied to all bonds involving hydrogen and a 2fs MD time step was used. The system 
coordinates were output to a trajectory file every pico-second, resulting in a final 
trajectory file for each MD run consisting of 1000 frames/structures. 
The program mdXvu (see http://sourceforge.net/projects/mdxvu) was used to analyse the 
explicit water MD trajectories and extract theoretical coupling constants for the sugar in 
each frame according to the Haasnoot et al. equation (Haasnoot et al. 1979). It was also 
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used to monitor values of the Cremer-Pople ring puckering parameters θ and ф2 
(pyranose ring atoms were selected in the order O5-C1-C2-C3-C4-C5). 
 
13.2 Partial charge calculation methods- Method 1 (partial charge set 1) 
Initial coordinates for all monosaccharides were based on geometries taken from the 
protein data bank file 1HPN (Mulloy et al. 1993). All monosaccharides were modelled 
with a hydroxyl group capping carbons-1 and -4 of the pyranose ring, where a glycosidic 
linkage normally occurs. These structures were then submitted to the antechamber 
module of AMBER 8 and AM1-BCC charges assigned (Jakallan et al. 2002). The 
hydroxyl group from carbon position 1 (except for units needed to form a non-reducing 
end terminus), and the hydrogen of the hydroxyl group attached to carbon position 4 were 
then deleted from each monosaccharide structure. Their charges were then spread equally 
among the remaining atoms, adjusting each charge slightly. 
 
13.3 Calculation of potential energy surfaces across glycosidic linkages 
Calculations were carried out using the Glycam04 force field for carbohydrates, supplied 
with the AMBER software suite. Additional parameters for O- and N-sulphates groups 
were added (Huige and Altona 1995) and parameters for the C4 to C5 double bond of 
non-reducing end uronates were taken from the General Amber Force Field (GAFF). All 
1-4 and greater, electrostatic interactions and van der Waals interactions were treated 
equally (SCEE=SCNB=1) (Kirschner and Woods 2001). 
Conformational energy maps were calculated for each glycosidic linkage as a function of 
the Φ and Ψ torsion angles as defined in the introduction (section 17.1). A dielectric 
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constant of 4 was used (Chuang et al. 2000). Φ and Ψ were varied from –160˚ to +180˚ 
and disaccharide structures were energy minimised every 20˚ with an Φ and Ψ torsion 
restraint of 10000 Kcal mol-1 Å-1 until the RMS derivative for the whole structure was 
less than 0.01. 
 
13.4 Whole molecule molecular dynamic simulations 
Molecular dynamic simulations were carried out using the same modified version of the 
glycam04 parameter set used in the potential energy surface calculations (see section 13.3 
above). 
The hexasaccharides were neutralised, through the addition of sodium ions, using the 
addions method implemented in the xleap module, and placed in a truncated octahedral 
box of explicit TIP5P water molecules. The use of TIP5P water necessitates the addition 
of parameters to describe the oxygen lone pairs present in this water model. These were 
taken from the general amber force field (GAFF). An 8Å buffer of water was generated 
around the hexasaccharide to the edge of the water box in each dimension.  
Each system was then equilibrated prior to a 1ns production molecular dynamics (MD) 
simulation. The equilibration and production molecular dynamic protocol were 
essentially the same as described under section 13.1. The only difference being that 
minimisation of the whole system without restraints (1000 steps steepest descent 
minimisation, 1500 steps conjugate gradient minimisation) was repeated twice. This was 
due to the fact that the TIP5P water box generated by xleap/AMBER is not pre-
equilibrated, unlike the TIP3P water box. 
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14. Additional computational modelling  
14.1 Partial charge calculation method - Method 2 (partial charge set 2) 
Partial charge calculation methods 2 and 3 were carried out in collaboration with Dr. 
Francois-Yves Dupradeau (University of Amien, France).  
Initial coordinates for all monosaccharides were based on geometries taken from the 
protein data bank file 1HPN (Mulloy et al. 1993). All monosaccharide structures were 
capped with an O-Methyl group at carbon position 1 and a hydroxyl group at carbon 
position 4. For all monosaccharide structures, N-acetyl, sulphamate and sulphate groups 
were then replaced by hydroxyl groups. Quantum mechanical geometry optimisation of 
these structures was then carried out at the HF/6-31G* level of theory, using the Gaussian 
98 software package. No dihedral angle restraints were applied during the optimisation. 
This results is structures containing a maximum number of intra-molecular hydrogen 
bonds. The geometry of N-methyl amide, N-methyl sulphamate and methyl sulphate were 
optimised independently. 
For each optimised monosaccharide conformation a molecular electrostatic potential 
(MEP) computation was carried out at the HF/6-31G* level, using the CHELPG 
algorithm as implemented in the Gaussian package. Using the RESP program (part of the 
AMBER 8 molecular modelling suite) partial charges were then calculated for all atoms 
that reproduce the calculated MEP.  
For this calculation four molecular orientations based on the rigid body re-orientation 
algorithm (RBRA) implemented in the R.E.D. program were used (atom sets used in the 
RBRA approach were C1, C3, C5 and C5, C3, C1 and C2, C4, O5, and O5, C4, C2). Two 
molecular orientations based on the RBRA approach were also used for N-methyl amide, 
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(atom sets were; N-methyl carbon, N-methyl nitrogen, carbonyl carbon and carbonyl 
carbon, N-methyl nitrogen, N-methyl carbon), N-methyl sulphamate (atom sets were; N-
methyl carbon, N-methyl nitrogen, sulphamate sulphur, and sulphamate sulphur, N-
methyl nitrogen, N-methyl carbon) and methyl sulphate (atom sets were; methyl carbon, 
ester oxygen, sulphate sulphur, and sulphate sulphur, ester oxygen, methyl carbon). 
As specified by the Glycam04 force field developers, the charge value of the hydrogen 
atoms linked to any sp3 carbon atoms were set to zero during the fitting procedure using 
intra-molecular charge constraints.  
The charge values for atoms involved in potential glycosidic linkages were calculated 
using an inter-molecular charge constraint where the charge values of the C1-methyl and 
HO4-O4 hydroxyl groups of the two considered monosaccharides were required to have a 
net charge of zero. Likewise, the N-acetyl, sulphamate, and sulphate groups were linked 
to the correct position of their monosaccharides using an inter-molecular charge 
constraint set to a net charge of zero. These were between the target monosaccharide 
hydroxyl group and the N-methyl group of N-methyl amide or the methyl group of N-
methyl sulphamate or alternatively methyl sulphate, respectively.  
The whole procedure was automatically carried out using a beta version of the R.E.D. IV 
program, currently under development in the laboratory of Dr. Dupradeau (University of 
Amien, Amien, France). 
 
14.2 Partial charge calculation method - Method 3 (partial charge set 3) 
Partial charge calculation method 3 was similar to method 2. The only difference being 
that during the initial quantum mechanical geometry optimisation of the structures, care 
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was taken to avoid the formation of any intra-molecular hydrogen bonds. This was done 
by constraining a number of dihedral angles during the initial quantum mechanical 
geometry optimisation.  
For ∆UA, a dihedral constraint of -60˚ was used for the HO3-O3-C3-H3 dihedral angle in 
the 2H1 conformation. For the α-methyl glycoside of glucose (gg rotamer) a dihedral 
constraint of 180˚ was used for the HO4-O4-C4-H4 dihedral angle. All other dihedral 
angles involving hydroxyl groups, in all structures, were initially set to 180˚ and allowed 
to move freely during optimisation. 
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RESULTS  
1. Initial studies into the degradation of HS by the heparinase III enzyme. 
Trial heparinase III digests were carried out in order to ascertain the minimum amount of 
enzyme needed to digest 200mg of celsus HS to completion. Progress of digestion was 
monitored through changes in the gel-filtration profile of the sample. These profiles are 
shown in Figure 20.    
After 4 additions of 10mU of heparinase III and incubation for an 88 hour period (total) 
digestion can be said to be complete. The addition of a further 10mU of enzyme and 
incubation for a further 24 hour period did not alter the gel filtration profile significantly 
(compare Figure 20, panels D and E). Incubation time as opposed to amount of enzyme 
added was also investigated. See Figure 21. Incubation with 30 mU of enzyme for a time 
period additional to 64 hrs was not sufficient to bring about a significant amount of 
further digestion. This result also verified the approach of adding the enzyme in 10 mU 
aliquots to the sample. The addition of a further 10mU of enzyme at 64 hrs did result in 
further digestion (compare Figure 20, Panel D with Figure 21, Panel A). 
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Figure 20 Analytical TSK3000PW gel-filtration profiles of HS after cleavage 
with heparinase III.  
Samples of 10µg from a 200mg total digest of Celsus HS by the heparinase III enzyme 
were chromatographed on a TSK3000PW analytical gel-filtration column (30 x 0.75 cm).  
Panel A, 16 hrs after the addition of 10mU of heparinase III; Panel B, 24 hrs after the 
addition of a further 10mU of heparinase III; Panel C, 24 hrs after the addition of a 
further of 10mU of heparinase III; Panel D, 24 hrs after the addition of a further of 10 mU 
heparinase III; Panel E, 24 hrs after the addition of a further of 10mU of heparinase III. 
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Figure 20 
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Figure 21 
 
 
 
 
 
 
 
 
 
 
Figure 21 Comparison of the analytical gel-filtration profiles of HS digested with 
30mU of heparinase III for 64 or 160 hours.  
Celsus HS (200mg total) was digested with 30mU of heparinase III for 64 or 160 hrs. 
Samples of 10µg were then chromatographed on a TSK3000PW analytical gel-filtration 
column (0.75cm x 30cm). Panel A shows the gel filtration profile after 64 hrs of 
incubation and panel B after 160 hrs incubation.  
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2. Bio-gel P10 gel filtration chromatography of HS digested to completion with 
heparinase III. 
A typical Bio-Gel P10 filtration profile is shown in Figure 22 (panel A) for HS digested 
to completion with heparinase III. A typical Bio-Gel P10 filtration profile for the 
commercial low molecular weight heparin product Tinzaparin Sodium (Innohep®) is also 
shown (Figure 22, panel B).  
A series of oligosaccharides ranging in size from dp2 up to dp18 were separable for the 
HS sample. In comparison to the heparin profile the oligosaccharide peaks for HS are 
considerably broader. The elution position for HS and heparin derived oligosaccharides 
of the same length are also different. Vo and Vt remained un-altered for both profiles 
corresponding approximately to fractions 50 and 165 respectively.   
Fractions corresponding to separate peaks were either pooled and stored (dp2 and >dp10), 
or taken on for further analysis (dp4-dp10). 
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Figure 22 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 Preparative Bio-Gel P10 gel filtration profiles of HS digested to 
completion with heparinase III and the commercially available low molecular 
weight heparin product Tinzaparin sodium.  
HS (200 mg) digested to completion by the addition of 40mU of heparinase III over an 88 
h period and Tinzaparin sodium (1 vial, approx 300 mg) were chromatographed on a Bio-
Gel P10 gel-filtration column (3cm x 120cm). Panel A, heparinase III digested HS; Panel 
B, Tinzaparin sodium. 
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3. SAX-HPLC chromatography of sized HS dp4-dp10 oligosaccharides. 
In order to examine the number of charged species of oligosaccharide within the HS dp4-
dp10 size pools, a sample of each was applied to a ProPac PA-1 SAX-HPLC column. 
Elution gradients are as described under experimental procedures. These results are 
shown in Figure 23. 
Due to the large amount of previous work undertaken on the dp4 oligosaccharides 
(Hileman et al. 1997), their predicted lack of biological activity (see introduction) and the 
high degree of heterogeneity encountered in the dp10 pool, further analytical efforts 
where directed towards the dp6 and dp8 peaks numbered in Figure 4, panels B and C. 
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Figure 23  SAX-HPLC chromatography of sized HS oligosaccharides.  
The dp4-dp10 oligosaccharide pools generated by heparinase III digestion of HS and 
purified by Bio-Gel P10 chromatography (see Figure 22) were individually applied to a 
ProPac PA-1 SAX-HPLC column (250mm x 9cm) (see experimental procedures for 
gradients used). Each peak or groups of peaks collected and taken on further analysis by 
PAGE are numbered (panels B and C). 
Panel A, dp4 pool; Panel B, dp6 pool; Panel C, dp8 pool; Panel D, dp10 pool. 
 
 
  
 
 137 
Figure 23 
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4. PAGE analysis of dp6 and dp8 SAX-HPLC peaks.  
Dp6 peaks 1 to 7 and dp8 peaks 1 to 8 were analysed by PAGE. These results are shown 
in Figure 24. 
In the cases of dp6-2, dp6-3, dp8-1 and dp8-3 the SAX-HPLC profile indicated two 
charged species to be present, these pools were made up of two closely eluting peaks (see 
Figure 23, panels B and C). On PAGE analysis only one charged species was detected. In 
other cases, most clearly seen in Figure 24 for dp8-7, a single peak from the SAX-HPLC 
profile was separated into more than one charged species on PAGE analysis. For dp8-7, 
one major and one minor band were observed. Similarly, more than one band could be 
seen for dp6-4 and dp8-2 on initial de-staining of the gel.  
Based on these results, peaks containing predominantly a single charged oligosaccharide 
species were analysed for their disaccharide composition. 
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Figure 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 PAGE analyses of selected peaks from the HS dp6 and dp8 SAX-
HPLC profile. 
 Individual peaks or groups of peaks from the dp6 and dp8 SAX-HPLC profile (see 
Figure 23) were pooled, desalted and quantified (see experimental methods). 
Approximately 20µg of material was applied to each lane.  
Panel A shows the dp6 analysis, panel B the dp8 analysis. Lane numbers correspond to 
the peaks labelled in Figure 23, panels B and C.  
 
1                2                3               4           5                6                7
Panel A
1            2            3              4            5       6            7            8
Panel B
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5. Disaccharide analysis of selected dp6 and dp8 SAX-HPLC peaks.  
The disaccharide analysis of selected dp6 and dp8 SAX-HPLC peaks shown to contain 
predominantly a single charged oligosaccharide species by PAGE, are shown in Table 2.  
These results clearly indicate that although a single species is indicated on the PAGE 
analysis of the dp8 pools, a significant number of minor species must also be present, 
warranting their further purification. In contrast all dp6 pools analysed were shown to 
contain mainly a single charged species of oligosaccharide (see discussion). 
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Table 2 Disaccharide analyses of selected peaks from the HS dp6 and dp8 
SAX-HPLC profile.   
Individual peaks or groups of peaks from the dp6 and dp8 SAX-HPLC profile (see Figure 
23), that were indicated to contain predominantly one charged species of oligosaccharide 
by PAGE analysis (see Figure 24), were analysed for their disaccharide composition. 
Oligosaccharides were broken down into their component disaccharides by combined 
heparinase digestion and analysed by SAX-HPLC (see experimental procedures).  
 
dp6- 2 dp6- 3 dp6- 5 dp6- 6 dp8- 1 dp8- 3 dp8- 7
Disaccharide
UA-GlcNAc 37 34 0 37 48 40 8
UA-GlcNS 34 33 38 36 14 26 39
UA-GlcNAc(6S) 0 0 62 0 7 6 24
UA(2S)-GlcNAc 0 0 0 0 0 0 0
UA-GlcNS(6S) 0 0 0 0 11 3 7
UA(2S)-GlcNS 28 34 0 0 7 9 7
UA(2S)-GlcNS(6S) 0 0 0 26 13 16 16
Oligosaccharide size and pool number
Disaccharide as a % of total disaccharides
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6. Variation between SAX-HPLC profiles. 
The peaks dp6-2, dp6-3, dp6-5 and dp6-6 here after referred to as oligosaccharides dp6-2, 
dp6-3, dp6-5 and dp6-6 were deemed suitable initial targets for purification in the 
quantities required for NMR analysis.  
However, on initiating large scale purification of these oligosaccharides, significant 
variation was observed in the quantities of dp6-5 and dp6-6, present in dp6 size pools 
from different digests. These results are shown in Figure 25. Frequently accurate pooling 
of dp6-5 and dp6-6 without a high level of cross contamination was un-achievable (see 
Figure 25, panel B).  
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Figure 25 
 
 
 
 
 
 
 
 
 
 
Figure 25 Variation of the SAX-HPLC profile of dp6 size pools purified from 
different heparinase III digests of HS.  
Dp6 oligosaccharides generated by heparinase III digestion of HS and purified by Bio-
Gel P10 chromatography (see Figure 22) were applied to a ProPac PA-1 SAX-HPLC 
column (250mm x 9cm). Panel A and panel B show the SAX-HPLC profile of dp6 size 
pools purified from two different 200mg HS digests. 
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7. Purification strategy. 
The strategy adopted was to target the purification of oligosaccharides dp6-2 and dp6-3. 
When dp6-5 and dp6-6 were clearly resolved into two peaks, which was in a minority of 
cases, these peaks were pooled separately otherwise a single peak was pooled for later 
further purification using PAGE. 
In total to produce 2mg each of dp6-2 and dp6-3, fifty identical 200mg HS digests were 
carried out using a total of 10 grams of HS and 40 mU of enzyme per digest (2 U total).  
 
8. PAGE purification of dp6-5 and dp6-6.  
Where a single peak had been pooled containing both oligosaccharides dp6-5 and dp6-6 
these samples were concentrated, desalted and subjected to PAGE (see experimental 
procedures). An example of the banding pattern observed is shown in Figure 26.  
Bands corresponding to oligosaccharides dp6-5 and dp6-6 were cut out from the gel, 
extracted from the polyacryamide and the azure A stain removed (see experimental 
procedures). The PAGE separated oligosaccharides were then added to the 
oligosaccharides separated by SAX-HPLC alone.  
In total approximately 1mg of dp6-5 was produced and 0.5mg of dp6-6. 
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Figure 26 
 
 
 
 
Figure 26 Further purification of dp6-5 and dp6-6 by PAGE.  
Single broad peaks containing both oligosaccharides dp6-5 and dp6-6 (see Figure 25, 
panel B) were pooled, desalted and quantified (see experimental procedures). 
Approximately 20µg of material was applied to each lane. Bands corresponding to 
oligosaccharides dp6-6 and dp6-5 are labelled.  
   
 
 
 
 
 
 
 
 
 
 
 
 
Oligosaccharide 6-6
Oligosaccharide 6-5
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9. Preliminary NMR analysis of dp6-2 and dp6-3. 
Oligosaccharides dp6-2 and dp6-3 were analysed by 1H 1-D NMR spectroscopy. These 
results are shown in Figure 27. By reference to literature chemical shift values, reported 
mainly for heparin derived oligosacharides (Chuang et al. 2001), a number of chemical 
shifts could be putatively assigned. These are labelled in Figure 27. 
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Figure 27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 One-dimensional 500 mHz 1H-NMR spectra of hexasaccharides 6-2 
and 6-3.  
Spectra were recorded in PBS at 25oC.  
Panel A, dp6-2: Panel B, dp6-3. 
Chemical shifts that could be putatively assigned by reference to reported literature 
values are labelled. 
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6.0 5.0 4.0 3.0 2.0
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GlcNAc, CH3
Panel A
Panel B
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10. Full spectral assignment of dp6-2 and dp6-3. 
Two dimensional COSY, TOCSY and NOESY NMR spectra were recorded for both 
oligosaccharides, these are shown in appendix I. The chemical shifts at around 2ppm, 
which correspond to the methyl protons of any N-acetyl groups, are not shown for all 
spectra in appendix I. No through-bond cross-peaks were detected in the COSY and 
TOCSY spectra for these three protons. Notably, also no through-space connectivity’s 
were detected in all NOESY spectra. 13C DEPT-135 and 13C HSQC spectra were also 
recorded for these oligosaccharides and are shown in appendix II (see discussion). 
 
COSY spectra (dp6-2, Figure 82, page 331, dp6-3, Figure 83, page 332),  
TOCSY spectra (dp6-2, Figure 84, page 333, dp6-3, Figure 85, page 334)   
NOESY spectra (dp6-2, Figure 86, page 335, dp6-3, Figure 87, page 336) 
DEPT-135/HSQC spectra (dp6-2, Figure 103, page 352, dp6-3, Figure 104, page 353)  
 
As a demonstration of the assignment process a detailed breakdown of the proton 
assignment of dp6-2 (Figures 28-33 ) and dp6-3 (Figures 34-37) are given.  
Assignment of proton chemical shifts using 2D-NMR experiments is generally regarded 
as standard practice, and a detailed breakdown of the process is not given for all 
subsequently characterised oligosaccharides.  
For assignment purposes the non-reducing terminal uronic acid residue in each case was 
lettered residue “a” with each subsequent residue lettered accordingly, ending at the 
reducing terminus in residue number “f”. 
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Figure 28 Assignment of the non-reducing terminal uronic acid, residue “a” of 
oligosaccharide dp6-2.  
Using the COSY spectrum (Panel A) starting at the chemical shift for H4 assigned to 
5.814ppm, H3 was assigned to 4.314ppm, H2 to 3.801ppm and H1 to 5.11ppm.  
The coloured arrows (Panel A) correspond to cross-peaks involving a particular proton or 
the track of this proton across the spectrum. Cross-peaks forming the UA ring system are 
sequentially linked by the arrows.  
   H4  
  H3  
  H2  
  H1  
A single trans-glycosidic cross-peak was then identified in the NOESY spectrum (Panel 
B) from H1 of UA to an unassigned proton of the linking glucosamine residue at 
3.866ppm. This cross-peak is circled in Panel B 
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Figure 28 
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Figure 29 Assignment of glucosamine, residue ”b”  of oligosaccharide dp6-2.  
Using the TOCSY spectrum (Panel A) the anomeric proton H1 for the ring system 
containing the 3.866ppm unassigned glucosamine proton (circled in Figure 28, Panel B) 
was identified. This anomeric proton was assigned to 5.336ppm. Using the COSY 
spectrum (Panel B) H2 was then assigned to 3.314ppm, H3 to 3.761ppm and H4 to 
3.866ppm, identifying this as the proton involved in the trans-glycosidic NOE from 
residue “a”. H5 was later assigned to 3.837ppm and both H6 protons to a range between 
3.837ppm and 3.925ppm, by analysis of a subsequently recorded HSQC spectrum (see 
discussion). Assignment of H2 to 3.314ppm identified this glucosamine as being N-
sulphated.  
The coloured arrows (Panel A and B) again correspond to cross-peaks involving a 
particular proton or the track of this proton across the spectrum. Cross-peaks for protons 
H1 to H4 forming part of the GlcNS ring system are sequentially linked by the arrows. 
   H4 
  H3 
  H2 
  H1 
Two trans-glycosidic cross-peaks were identified in the NOESY spectrum (Panel C) from 
H1 of GlcNS to unassigned protons in the proceeding IdoUA residue at 4.059ppm and 
4.266ppm. These cross-peaks are circled. 
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Figure 29 
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Figure 30 Assignment of iduronic acid, residue “c” of oligosaccharide dp6-2.  
Using the TOCSY spectrum (Panel A) the anomeric proton H1 for the ring system 
containing the 4.059ppm and 4.266ppm unassigned iduronic acid protons (circled in 
Figure 29, Panel C) was identified. This anomeric proton was assigned to 5.285ppm. 
Using the COSY spectrum (Panel B) H2 was then assigned to 4.356ppm, H3 to 
4.266ppm, H4 to 4.059ppm and H5 to 4.885ppm, identifying H3 and H4 respectively as 
the protons involved in the trans-glycosidic NOE from residue “b”. For clarity only 
assignments originating from H1 on the horizontal axis are tracked (Panel B). 
Assignment of H2 to 4.356ppm identified this iduronic acid as being 2-O-sulphated.  
The correspondence of the coloured arrows (Panel A and B) are with cross-peaks 
involving a particular proton or the track of this proton across the spectrum, as in Figures 
28 and 29, with the addition of a H5 proton label/track.   
   H5 
Cross-peaks forming the IdoUA(2S) ring system are sequentially linked. 
 
Two trans-glycosidic cross-peaks were identified in the NOESY spectrum (Panel C) from 
H1 of IdoUA(2S) to two unassigned protons in the proceeding glucosamine residue at 
3.72ppm and 3.889ppm. These cross-peaks are circled.  
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Figure 30  
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Figure 31 Assignment of glucosamine, residue “d” of oligosaccharide dp6-2.  
Using the TOCSY spectrum (Panel A) the anomeric proton H1 for the ring system 
containing the 3.72ppm and 3.889ppm unassigned glucosamine protons (circled in Figure 
30, Panel C) was identified. This anomeric proton was assigned to 5.391ppm. Using the 
COSY spectrum (Panel B) H2 was then assigned to 3.247ppm, H3 to 3.743ppm and H4 
to 3.72ppm, identifying H4 as one of the two protons involved in trans-glycosidic NOEs 
from residue “c”. H5 was later assigned to 3.854ppm and both H6 protons to a range of 
between 3.889-3.905ppm (by HSQC analysis, see discussion). This assignment of H6 
identified one of the H6 protons as involved in a trans-glycosidic NOE with residue “c”. 
Assignment of H2 to 3.247ppm identified this glucosamine as being N-sulphated. The 
correspondence of the coloured arrows (Panel A and B) are with cross-peaks involving a 
particular proton or the track of this proton across the spectrum as in Figures 28-30, with 
the addition of a H6 label. 
   H6 
Cross-peaks for protons H1 to H4 forming part of the GlcNS (residue 4) ring system are 
sequentially linked. 
 
Two trans-glycosidic cross-peaks were identified in the NOESY spectrum (Panel C) from 
H1 of GlcNS to unassigned protons in the proceeding IdoUA residue at 4.079ppm and 
4.128ppm. These cross-peaks are very close together in the spectrum and circled.    
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Figure 31  
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Figure 32 Assignment of iduronic acid, residue “e” of oligosaccharide dp6-2.  
Using the TOCSY spectrum (Panel A) the anomeric proton H1 for the ring system 
containing the 4.079ppm and 4.128ppm un-assigned iduronic acid protons (circled in 
Figure 31, Panel C) was identified. This anomeric proton was assigned to 4.989ppm. 
Using the COSY spectrum (Panel B) H2 was then assigned to 3.743ppm, H3 to 
4.128ppm, H4 to 4.079ppm and H5 to 4.767ppm, identifying H3 and H4 respectively as 
the protons involved in the trans-glycosidic NOE from residue “c”. For clarity only 
assignments originating from H1 on the horizontal axis are tracked (Panel B).  
See Figures 28-31 for a key to the coloured arrows annotation scheme used in panels A 
and B. Cross-peaks forming the IdoUA ring system are sequentially linked by the arrows. 
 
A single trans-glycosidic cross-peak was identified in the NOESY spectrum (Panel C) 
from H1 of IdoUA(2S) to an unassigned proton in the proceeding glucosamine residue at 
3.86ppm. This is circled. 
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Figure 32  
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Figure 33 Assignment of the reducing terminal glucosamine, residue “f” of 
oligosaccharide dp6-2.  
Using the TOCSY spectrum (Panel A) two ring systems were identified containing the 
3.86ppm unassigned glucosamine proton (circled in Figure 32, Panel C). These ring 
systems correspond to the presence of the terminal GlcNAc residue in both the α and β 
anomeric configurations. The anomeric proton for each configuration was assigned to 
5.224ppm (α) and 4.734ppm (β). Using the COSY spectrum (Panel B) H2 was then 
assigned to 3.905ppm (α), 3.725 (β) and H3 to 3.837ppm (α), 3.86ppm (β). Assignment 
of H2 to these values confirmed the glucosamine to be N-acetylated. H4 were later 
assigned to 3.86ppm (α), 3.931 (β) as were H5 to 3.979ppm (α) and 3.561ppm (β) and 
H6s to 3.725-3.754ppm (α) and 3.808-3.837 (β) (by HSQC analysis, see discussion). This 
identified H3 (β) and H4 (α) as involved in the trans-glycosidic NOE with residue “e”.   
See Figures 28-31 for a key to the coloured arrows annotation scheme used in panels A 
and B. Cross-peaks for protons H1 to H3 forming part of both ring systems respectively 
are sequentially linked by the arrows. 
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Figure 33  
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These 2-D-NMR analyses established the primary sequence of dp6-2 to be 
UA-GlcNS-IdoUA(2S)-GlcNS-IdoUA-GlcNAc(α or β) 
  a.           b.         c.                    d.           e.              f. 
Letters signify residue designation and relative position within the oligosaccharide to the 
non-reducing end (lettered ‘a’). 
 
11. Proton assignment of dp6-3. 
A detailed proton assignment of the first 3 residues of dp6-3 established these residues to 
be identical in nature and sequence to those of dp6-2. Chemical shift assignments are 
summarised at the end of this section in Table 3.  
Variation between the two oligosaccharides occurred in the nature of the uronic acid 
residue at position “e” and in the chemical shift values of residue “d”. A detailed 
breakdown of the proton assignment of dp6-3, residues d-f is given in Figures 34-37.  
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Figure 34   
 
 
 
 
 
 
 
 
Figure 34 Identification of trans-glycosidic NOEs between IdoA(2S), residue “c” 
of dp6-3 and the proceeding glucosamine residue “d”.  
Two trans-glycosidic cross-peaks were identified in this NOESY spectrum, from H1 of 
IdoA(2S) to two unassigned protons in the proceeding glucosamine residue at 3.741ppm 
and 3.891ppm. These cross-peaks are circled.         
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Figure 35 Assignment of glucosamine, residue “d” of oligosaccharide dp6-2. 
Using the TOCSY spectrum (Panel A) the anomeric proton H1 for the ring system 
containing the 3.741ppm and 3.891ppm unassigned glucosamine protons (circled in 
Figure 34) was identified. This anomeric proton was assigned to 5.613ppm (contrast this 
with an assignment of 5.391ppm for the equivalent proton of dp6-2). Using the COSY 
spectrum (Panel B) H2 was then assigned to 3.288ppm, H3 to 3.683ppm and H4 to 
3.741ppm, identifying H4 as one of the two protons involved in trans-glycosidic NOEs 
from residue “c”. H5 was later assigned to 3.823ppm and both H6 protons to a range of 
between 3.891-3.966ppm (by HSQC analysis, see discussion). This assignment of H6 
identified one of the H6 protons as forming a trans-glycosidic NOE with residue “c”. 
Assignment of H2 to 3.288ppm identified this glucosamine as being N-sulphated.  
See Figures 28-31 for a key to the coloured arrows annotation scheme used in  panels A 
and B. Cross-peaks for protons H1 to H4 forming part of the GlcNS ring system are 
sequentially linked by the arrows. 
 
A single trans-glycosidic cross-peaks were identified in the NOESY spectrum (Panel C) 
from H1 of GlcNS to an unassigned protons in the proceeding GlcUA residue at 
3.828ppm. This cross-peak is circled. 
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Figure 35 
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Figure 36 Assignment of glucuronic acid, residue “e” of oligosaccharide dp6-3. 
Using the TOCSY spectrum (Panel A) the anomeric proton H1 for the ring system 
containing the 3.828ppm unassigned uronic acid proton (circled in Figure 35, Panel C) 
was identified. This anomeric proton was assigned to 4.596ppm identifying this residue 
as GlcUA not IdoUA as in dp6-2. Using the COSY spectrum (Panel B) H2 was then 
assigned to 3.428ppm, H3 to 3.895ppm and H4 to 3.828ppm, identifying H4 as the proton 
involved in the trans-glycosidic NOE from residue “d”.  H5 was subsequently assigned to 
3.813ppm (by HSQC analysis).  
See Figures 28-31 for a key to the coloured arrows annotation scheme used in panels A 
and B. Cross-peaks for protons H1 to H4 forming part of the GlcUA ring system are 
sequentially linked by the arrows.  
 
A single trans-glycosidic cross-peak was identified in the NOESY spectrum (Panel C) 
from H1 of GlcUA to an unassigned proton in the proceeding glucosamine residue at 
3.726ppm. This is circled. 
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Figure 37 Assignment of the reducing terminal glucosamine, residue “f” of 
oligosaccharide dp6-3.  
Using the TOCSY spectrum (Panel A) two ring systems were identified containing the 
3.726ppm unassigned glucosamine proton (circled in Figure 36, Panel C). These ring 
systems, as with oligosaccharide dp6-2, correspond to the presence of the terminal 
GlcNAc residue in both the α and β anomeric configurations. The anomeric proton for 
each configuration was assigned to 5.242ppm (α) and 4.757ppm (β). Using the COSY 
spectrum (Panel B) H2 was then assigned to 3.905ppm (α), 3.735 (β) and H3 to 
3.934ppm (α), 3.721ppm (β). Assignment of H2 to these values confirmed the 
glucosamine to be N-acetylated. H4 were later assigned to 3.726ppm (α), 4.0 (β) as were 
H5 to 3.996ppm (α) and 3.644ppm (β) and H6s to 3.842-3.939ppm (α) and 3.847-3.89 (β) 
(by HSQC analysis, see discussion). This identified H3 (β) and H4 (α) as involved in the 
trans-glycosidic NOE with residue “e”.   
See Figures 28-31 for a key to the coloured arrows annotation scheme used in panels A 
and B. Cross-peaks for protons H1 to H3 forming part of both ring systems respectively 
are sequentially linked by the arrows. 
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Figure 37  
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These 2-D-NMR analyses established the primary sequence of dp6-3 to be 
UA-GlcNS-IdoUA(2S)-GlcNS-GlcUA-GlcNAc(α or β) 
  a.          b.           c.                   d.           e.            f. 
Letters again signifying residue designation and relative position within the 
oligosaccharide to the non-reducing end (lettered ‘a’). 
For both dp6-2 and dp6-3, the NMR monosaccharide sequencing results are in perfect 
agreement with the disaccharide analysis results for each oligosaccharide (see Table 2). 
 
12. Summary of chemical shift assignments for dp6-2 and dp6-3. 
The chemical shift assignments for dp6-2 and dp6-3 are summarised in Figure 38 and in 
the proceeding Table (Table 3). The coupling constants for each proton were measured as 
described under experimental procedures and are shown in brackets along with chemical 
shift values in Table 3. 
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Figure 38 A summary of the 1H chemical shift assignments for dp6-2 and dp6-3. 
For assignment of the non-anomeric chemical shifts grouped                         see Table 3. 
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Figure 38  
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Table 3 1H and 13C chemical shifts assignments (ppm)  for hexasaccharides 6-2 
and 6-3. 
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Residue
1. ∆UA H1 5.11 (6.9) C1 100.947 H1 5.122 (6.6) C1 101.108
H2 3.801 (6.3) C2 70.694 H2 3.813 (6.0) C2 70.693
H3 4.314 (3.1) C3 67.296 H3 4.325 (3.4) C3 67.296
H4 5.814 C4 107.903 H4 5.825 C4 107.741
C5 n.d. C5 n.d.
C6 n.d. C6 n.d.
2.
  GlcNS H1 5.336 (3.4) C1 97.226 H1 5.343 (3.5) C1 97.063
H2 3.314 (10.7) C2 57.913 H2 3.327 (10.7) C2 57.913
H3 3.761 C3 n.d. H3 3.77 C3 n.d.
H4 3.866 C4 n.d. H4 3.885 C4 n.d.
H5 3.837 C5 n.d. H5 3.85 C5 n.d.
H6 3.837-3.925 C6 n.d. H6 3.797-3.966 C6 n.d.
H6' 3.837-3.925 H6' 3.797-3.966
3.  IdoUA(2S) H1 5.285 (1.6) C1 99.167 H1 5.297 (1.6) C1 99.167
H2 4.356 (4.1) C2 74.415 H2 4.368 (4.1) C2 74.576
H3 4.266 (3.15) C3 67.62 H3 4.279 (3.15) C3 67.458
H4 4.059 (2.2) C4 75.547 H4 4.068 (1.5) C4 75.547
H5 4.885 C5 68.105 H5 4.896 C5 68.267
C6 n.d. C6 n.d.
4.
  GlcNS H1 5.391 (3.4) C1 95.446 H1 5.613 (3.7) C1 97.549
H2 3.247 (10.1) C2 58.075 H2 3.288 (10.1) C2 58.236
H3 3.743 C3 n.d. H3 3.683 C3 n.d.
H4 3.72 C4 n.d. H4 3.741 C4 n.d.
H5 3.854 C5 n.d. H5 3.823 C5 n.d.
H6 3.889-3.905 C6 n.d. H6 3.891-3.966 C6 n.d.
H6' 3.889-3.905 H6' 3.891-3.966
5. HexUA H1 4.989 (2.5) C1 101.755 H1 4.596 (7.8) C1 102.24
H2 3.743 (5.0) C2 69.238 H2 3.428 C2 72.797
H3 4.128 (3.3) C3 68.429 H3 3.895 C3 n.d.
H4 4.079 (2.8) C4 74.9 H4 3.828 C4 n.d.
H5 4.767 C5 69.238 H5 3.813 C5 n.d.
C6 n.d. C6 n.d.
6. GlcNAc (α) H1 5.224 (3.4) C1 90.593 H1 5.242 (3.1) C1 90.431
H2 3.905 C2 n.d. H2 3.905 C2 n.d.
H3 3.837 C3 n.d. H3 3.934 C3 n.d.
H4 3.86 C4 n.d. H4 3.726 C4 n.d.
H5 3.979 C5 n.d. H5 3.996 C5 n.d.
H6 3.725-3.754 C6 n.d. H6 3.842-3.939 C6 n.d.
H6' 3.725-3.754 H6' 3.842-3.939
NAc 2.064 NAc 21.998 NAc 2.075 NAc 21.998
6. GlcNAc (β) H1 4.734 (8.1) C1 94.961 H1 4.757 C1 94.799
H2 3.725 C2 n.d. H2 3.735 C2 n.d.
H3 3.86 C3 n.d. H3 3.721 C3 n.d.
H4 3.931 C4 n.d. H4 4 C4 n.d.
H5 3.591 C5 n.d. H5 3.644 C5 n.d.
H6 3.808-3.837 C6 n.d. H6 3.847-3.89 C6 n.d.
H6' 3.808-3.837 H6' 3.847-3.89
NAc 2.064 NAc 21.998 NAc 2.075 NAc 21.998
Coupling constants (in Hz) to proton directly below are given in parentheses
n. d. Not determined because of overlapping signals
 6-2  6-3
Oligosaccharide Oligosaccharide
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13. Preliminary NMR analysis of oligosaccharide HS 6-5.  
Oligosaccharide 6-5 was analysed by 1H 1-D NMR spectroscopy. This result is shown in 
Figure 39, Panel A.  
Unexpectedly, a large number of aliphatic protons were detected (chemical shift values 
ranging between 1.0 and 2.5ppm) in the original sample (see Figure 39, panel A). With 
the exception of the chemical shift detected at 2.08ppm, which could be assigned to the 
methyl protons of the two N-acetyl groups present (see Table 2). These aliphatic 
chemical shifts were assumed to have arisen from contaminating polyacrlyamide, which 
had carried through into the NMR analysis. This was removed by the use of an additional 
DEAE gel chromatography purification step (see experimental procedures). The results of 
the further purification, on the 1-D NMR spectrum of HS dp6-5 are shown in Figure 39, 
panels B and C. Similar results were obtained with oligosaccharide 6-6 (data not shown). 
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Figure 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39 One-dimensional 500 mHz 1H-NMR spectra of hexasaccharide 6-5.  
Spectra were recorded in 0.15M NaCl, 20mM Na2HPO4, 2H2O at pH 7.2 and 25oC. Panel 
A, dp6-5 prior to DEAE chromatography: Panel B, material that did not bind to the 
DEAE column; Panel C, material bound to the DEAE column and eluted using 1M NaCl.  
See experimental procedures for exact experimental detail of the DEAE chromatographic 
procedure. 
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14. Spectral assignment of dp6-5 and dp6-6. 
Two dimensional COSY, TOCSY and NOESY NMR spectra were recorded for 
oligosaccharides dp6-5 and dp6-6. These are presented in appendix I 
  
COSY spectra (dp6-2, Figure 88, page 337, dp6-3, Figure 89, page 338),  
TOCSY spectra (dp6-2, Figure 90, page 339, dp6-3, Figure 91, page 340)   
NOESY spectra (dp6-2, Figure 92, page 341, dp6-3, Figure 93, page 342) 
 
The additional loss of material as a result of the PAGE and DEAE purification steps 
meant it was not possible to acquire 13C spectra for these saccharides (see discussion).  
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Proton chemical shifts were assigned as has been outlined in detail for oligosaccharides 
dp6-2 and dp6-3 (see Figures 28-33 and 34-37) these results are summarised in Figure 40 
and the proceeding Table (Table 4). These assignments established the primary sequence 
of dp6-5 to be: 
UA-GlcNAc(6S)-GlcUA-GlcNS-IdoUA-GlcNAc(6S)(α) 
  a.           b.                   c.            d.             e.              f. 
Letters signify residue designation and position within the monosaccharide sequence.  
See discussion on the placement of GlcUA and IdoUA at residues “c” and “e” 
respectively within this sequence. The primary sequence of dp6-6 was established to be: 
UA-GlcNS-IdoUA(2S)-GlcNS(6S)-IdoUA-GlcNAc(α) 
  a.           b.         c        .             d.                  e.            f. 
Due to the low amount of material present for dp6-6 and the close proximity of the 
anomeric protons of residues “a” and “e” to the water peak, an NOE could not be directly 
established across the glycosidic linkages “a-b” and “e-f”.  However the identity of these 
residues could be clearly ascertained and their position in the sequence then deduced. 
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Figure 40 A summary of the 1H chemical shift assignments for dp6-5 and dp6-6. 
A low level of cross contamination of dp6-5 with dp6-6 and vice-versa was detected. This 
is most clearly seen around the chemical shift for residue “a” H4 when comparing both 
spectra. Contaminating peaks are not labelled. For assignment of the non-anomeric 
chemical shifts grouped                         see Table 4. With both saccharides only the α 
anomeric configuration of residue “f” could be detected. 
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Figure 40  
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Table 4 1H chemical shifts assignments (ppm) for hexasaccharides 6-5 and 6-6 
Oligosaccharide 6-5 Oligosaccharide 6-6
Residue Chemical Shift (ppm) Residue Chemical Shift (ppm)
1. ∆UA H1 5.202 (6.0) 1. ∆UA H1 5.088(6.9)
H2 3.858(5.0) H2 3.791(6.0)
H3 4.279(3.4) H3 4.336(3.5)
H4 5.849 H4 5.806
2.  GlcNAc(6S) H1 5.459(3.8) 2.  GlcNS H1 5.448(3.5)
H2 3.986(9.8) H2 3.326(10.4)
H3 3.872 H3 3.749
H4 3.754 H4 n.d.
H5 4.219 H5 n.d.
H6 4.492(10.7) H6 n.d.
H6' n. d. H6' n.d.
3.  GlcA H1 4.538(7.9) 3.  IdoUA(2S) H1 5.251(2.8)
H2 3.42 H2 4.36(5.6)
H3 3.722 H3 4.257(2.2)
H4 3.819 H4 4.123
H5 n. d. H5 4.773
4.  GlcNS H1 5.388(3.8) 4. GlcNS(6S) H1 5.417(3.5)
H2 3.267 H2 3.295(10.4)
H3 3.738 H3 3.67
H4 3.894 H4 3.81
H5 n. d. H5 4.012
H6 n. d. H6 4.452(10.1)
H6' n. d. H6' n. d.
5. IdoUA H1 5.044(2.5) 5. IdoUA H1 5.009
H2 3.814(5.3) H2 3.728
H3 4.17(4.1) H3 4.157
H4 4.097(3.4) H4 4.152
H5 4.785 H5 4.767
6. GlcNAc(6S) (α) H1 5.248 6. GlcNAc (α) H1 5.364(3.4)
H2 3.961 H2 3.889
H3 3.906 H3 n. d.
H4 4.082 H4 n. d.
H5 4.098 H5 n. d.
H6 4.492 H6 n. d.
H6' n. d. H6' n. d.
NAc 2.08 NAc 2.08
Where determined coupling constants (in Hz) to proton directly below are given in brackets
n. d. Not determined
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15. Purification of two heparin derived hexasaccharides. 
The dp6 size pool from a Bio-Gel P10 gel filtration profile of Tinzaparin sodium (see 
Figure 22) was applied to a SAX-HPLC column, and the oligosaccharides eluted using a 
linear salt gradient (see experimental procedures). A typical SAX-HPLC elution profile is 
shown in Figure 41. Consistent with a number of previous studies two dominant peaks 
were detected in this size pool (numbered 1 and 2 in Figure 41) (Larnkjaer et al. 1995; 
Pervin et al. 1995; Chuang et al. 2001). These peaks have been shown to be due to the 
presence of a single oligosaccharide species here after referred to as hep dp6-1 and hep 
dp6-2.  
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Figure 41 
 
 
 
 
 
 
Figure 41 SAX-HPLC chromatography of heparin derived hexasaccharides.  
The dp6 oligosaccharides of Tinzaparin sodium (generated by partial heparinase I 
digestion of heparin) were purified by Bio-Gel P10 chromatography (see Figure 22) then 
applied to a ProPac PA-1 SAX-HPLC column (250mm x 9cm) and eluted using a linear 
salt gradient (see experimental procedures for gradient used). Column eluate was 
monitored for absorbance at 232nm. Peaks numbered 1 and 2 were collected and taken on 
for further analysis by NMR spectroscopy. 
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16. NMR and spectral assignment of hep dp6-1 and dp6-2. 
Two dimensional COSY, TOCSY and NOESY NMR spectra were recorded for 
oligosaccharides hep dp6-1 and hep dp6-2. These are presented in appendix I. 13C DEPT-
135 and 13C HSQC spectra were also recorded for these oligosaccharides and are shown 
in appendix II (see discussion). 
  
COSY spectra (hep dp6-1, Figure 94, page 343, hep dp6-2, Figure 95, page 344)  
TOCSY spectra (hep dp6-1, Figure 96, page 345, hep dp6-2, Figure 97, page 346)   
NOESY spectra (hep dp6-1, Figure 98, page 347, hep dp6-2, Figure 99, page 348) 
DEPT-135/HSQC spectra (hep dp6-1, Figure 105, page 354, hep dp6-2, Figure 106, page 
355) 
 
These 2-D-NMR analyses enabled the primary sequence of hep dp6-1 to be confirmed as: 
UA(2S)-GlcNS(6S)-IdoUA(2S)-GlcNS(6S)-GlcUA-GlcNS(6S)(α) 
    a.                   b.                    c.                        d.             e.               f. 
As established in the literature (Larnkjaer et al. 1995; Pervin et al. 1995; Chuang et al. 
2001) Letters again signifying residue designation and position within the 
monosaccharide sequence. 
Hep dp6-2 was established to be: 
UA(2S)-GlcNS(6S)-IdoUA(2S)-GlcNS(6S)-IdoUA(2S)- GlcNS(6S)(α) 
   a.                b.                  c.                      d.                  e.                    f 
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17. Summary of chemical shift assignments for hep dp6-1 and dp6-2. 
The chemical shift assignments for hep dp6-1 and dp6-2 are summarised in Figure 42 and 
in the proceeding Table (Table 5). The coupling constants for each proton were 
measured, as described under experimental procedures, and are shown in brackets along 
with chemical shift values in Table 5. 
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Figure 42 A summary of the 1H chemical shift assignments for hep dp6-1 and 
dp6-2.  
For assignment of the non-anomeric chemical shifts grouped                      see Table 
5.With both saccharides only the α anomeric configuration of residue “f” could be 
detected.
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Figure 42 
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Table 5 1H chemical shifts assignments (ppm) for hep 6-1 and 6-2 
Residue
1. ∆UA(2S) H1 5.542(2.2) C1 97.387 H1 5.555(1.9) C1 96.902
H2 4.652 C2 74.415 H2 4.649 C2 74.414
H3 4.341(5.4) C3 62.928 H3 4.357(6.1) C3 62.766
H4 6.02 C4 105.962 H4 6.081 C4 106.77
C5 n. d. C5 n. d.
C6 n. d. C6 n. d.
2.
  GlcNS(6S) H1 5.433(3.4) C1 97.064 H1 5.429(3.7) C1 97.282
H2 3.332 C2 57.428-58.237 H2 3.336(11.6) C2 58.075
H3 3.682 C3 69.723 H3 3.698 C3 69.237
H4 3.864 C4 n. d. H4 3.882 C4 77.812
H5 4.07 C5 68.914 H5 4.033 C5 69.076
H6 4.291 C6 n. d. H6 n. d. C6 66.325
H6' or 4.401 H6' n. d.
3.  IdoUA(2S) H1 5.254(2.5) C1 99.167 H1 5.28 C1 99.167
H2 4.367(5.6) C2 75.547 H2 4.357 C2 75.062
H3 4.245(4.1) C3 68.914 H3 4.307 C3 68.267
H4 4.123(3.2) C4 76.194 H4 4.139 C4 76.356
H5 4.847 C5 68.914 H5 4.951 C5 68.914
C6 n. d. C6 n. d.
4.
  GlcNS(6S) H1 5.613(3.8) C1 97.387 H1 5.45(3.7) C1 96.74
H2 3.315 C2 57.428-58.237 H2 3.313(11.6) C2 57.913
H3 3.686 C3 69.561 H3 3.726 C3 69.237
H4 3.798 C4 n. d. H4 3.792 C4 n. d.
H5 3.984 C5 69.076 H5 4.341 C5 n. d.
H6 4.262 C6 n. d. H6 4.347-4.419 C6 n. d.
H6' or 4.424 H6' 4.347-4.419 n. d.
5. IdoUA(2S) or H1 4.632(9.8) C1 102.079 H1 5.28 C1 99.167
GlcUA H2 3.322(8.2) C2 72.797 H2 4.357 C2 75.547
H3 3.882 C3 n. d. H3 4.265 C3 68.59
H4 3.828 C4 n. d. H4 4.156 C4 75.87
H5 n. d. C5 n. d. H5 4.951 C5 68.914
C6 n. d. C6 n. d.
6. GlcNS(6S) (α) H1 5.483(3.7) C1 91.078 H1 5.472(3.1) C1 90.916
H2 3.309 C2 n. d. H2 3.291(11.6) C2 57.589
H3 3.759 C3 69.4 H3 3.754 C3 77.03
H4 4.192 C4 n. d. H4 4.161 C4 n. d.
H5 4.378 C5 n. d. H5 4.269 C5 n. d.
H6 4.248-4.305 C6 n. d. H6 4.318-4.408 C6 n. d.
H6' 4.248-4.305 n. d. H6' 4.318-4.408 n. d.
Coupling constants (in Hz) to proton directly below are given in brackets
n. d. Not determined
 Hep 6-1  Hep 6-2
Oligosaccharide Oligosaccharide
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18. De-2-O-sulphation. 
After establishing the primary sequence of HS dp6-2, dp6-3 and hep dp6-1 and hep dp6-
2., these oligosaccharides were subjected to chemical de-2-O-sulphation. As mentioned in 
the aims section of the introduction, this was done in order provide a greater insight into 
the role 2-O-sulphate groups play in influencing monosaccharide conformational 
equilibria.  
The efficiency and selectivity of this procedure was evaluated using heparin 
oligosaccharide dp6-2. After initially undergoing one round of de-sulphation (see 
experimental procedures) samples were then analysed by 1-D NMR spectroscopy before 
being re-subjected to additional rounds of de-sulphation. The 1-D NMR spectrum 
recorded after each round of de-sulphation is shown in Figure 43. After the second round 
of de-sulphation a 2-D COSY spectrum was recorded (see Appendix I, Figure 102, page 
351) and the chemical shifts assigned (see Table 6). 
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Figure 43 NMR analysis of heparin dp6-2 after successive rounds of chemical 
de-2-O-sulphation.  
Panel A, heparin dp6-2 prior to the de-sulphation procedure; Panel B, after one round of 
de-sulphation; Panel C, after two rounds of de-sulphation; Panel D, after three rounds of 
de-sulphation; Panel E, after four rounds of de-sulphation. 
The peak area of the resonance at 6.02 is given as a percentage of its area plus that of the 
resonance at 5.83 ppm in each panel (see text). 
The most significant changes in the chemical shifts after de-2-O-sulphation involved 
protons within the UA and IdoUA residues (see Table 6) and these are marked with 
arrows.
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Figure 43 
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Table 6.  The 1H  chemical shifts assignments (ppm) for heparin dp6-2 prior to 
and after undergoing de-2-O-sulphation.  
The difference column refers to the difference between the protons original chemical shift 
value and the chemical shift value after de-2-O-sulphation. 
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Residue  Original (ppm)  After de-2-O-sulphation (ppm) Difference (ppm)
1. ∆UA(2S) H1 5.555(1.9) H1 5.26 -0.295
H2 4.649 H2 3.853 -0.796
H3 4.357(6.1) H3 4.407 +0.05
H4 6.081 H4 5.83(3.4) -0.251
2.  GlcNS(6S) H1 5.429(3.7) H1 5.373(3.4) -0.056
H2 3.336(11.6) H2 3.322 -0.014
H3 3.698 H3 3.701 +0.003
H4 3.882 H4 3.882 0
H5 4.033 H5 4.012 -0.021
H6 n. d. H6 n. d. n. d.
H6' n. d. H6' n. d. n. d.
3.  IdoUA(2S) H1 5.28 H1 5.046 -0.234
or IdoUA H2 4.357 H2 3.803 -0.554
H3 4.307 H3 4.17 -0.137
H4 4.139 H4 4.096 -0.043
H5 4.951 H5 4.848 -0.103
4.  GlcNS(6S) H1 5.45(3.7) H1 5.385(3.7) -0.065
H2 3.313(11.6) H2 3.26 -0.053
H3 3.726 H3 3.69 -0.036
H4 3.792 H4 3.746 -0.046
H5 4.341 H5 4.181 -0.16
H6 4.347-4.419 H6 4.26-4.36 -0.087--0.059
H6' 4.347-4.419 H6' 4.26-4.36
5. IdoUA(2S) H1 5.28 H1 5.046 -0.234
or IdoUA H2 4.357 H2 3.803 -0.554
H3 4.265 H3 4.17 -0.137
H4 4.156 H4 4.096 -0.043
H5 4.951 H5 4.848 -0.103
6. GlcNS(6S) (α) H1 5.472(3.1) H1 5.481(3.7) +0.009
H2 3.291(11.6) H2 3.3 +0.009
H3 3.754 H3 3.752 -0.002
H4 4.161 H4 4.187 +0.026
H5 4.269 H5 4.243 -0.026
H6 4.318-4.408 H6 4.351-4.492 +0.033-+0.084
H6' 4.318-4.408 H6' 4.351-4.492 +0.033-+0.084
Coupling constants (in Hz) to proton directly below are given in brackets
n. d. Not determined
 
 
 
 
  
 
 193 
The 2-O-sulphate group of UA(2S) (residue “a”) was found to be resistant to removal 
using this de-sulphation procedure; removal of the 2-O-sulphate group resulting in a shift 
in the H4 resonance from 6.02ppm to 5.83ppm, among other resonance shifts (see Figure 
43). After each round of de-sulphation a resonance at 6.02ppm could be clearly detected 
(see Figure 43, Panels B-E). However, each successive round of de-sulphation resulted in 
an increase in the strength of the signal at 5.83ppm relative to the strength of the signal at 
6.02ppm (labelled in Figure 43). This corresponds to an increase in the number of H4 
protons from a non-2-O-sulphated UA residue and a fall in the number of H4 protons for 
a sulphated IdoUA. This infers partial rather than total resistance of UA(2S) to de-2-O-
sulphation. 
In contrast, the 2-O-sulphate groups of non-terminal IdoUA(2S) residues were highly 
susceptible to removal. All 2-O-sulphate groups could be said to have been removed by 
one round of the procedure (compare IdoUA(2S) H1 resonance in Figure 43, Panels A 
and B). Slight changes occurred in the chemical shifts of all glucosamine protons. These 
changes were small in comparison to changes in the UA and IdoUA(2S) chemical shifts 
and indicates that the de-sulphation procedure targeted selective removal of 2-O-sulphate 
groups. As concluded in previous studies (Jaseja et al. 1989; Piani et al. 1993), N- and 6-
O-sulphate groups were not removed by this chemical procedure. 
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19. Further evaluation of the de-2-O-sulphation procedure and de-sulphation of 
oligosaccharide, hep dp6-1. 
All hep dp6-2 material was used in the initial evaluation of the de-2-O-suphation 
procedure described above. Further evaluation of the procedure was carried out using 
heparin oligosaccharide dp6-1. This oligosaccharide sample was subjected to a variation 
of the chemical de-2-O-sulphation procedure used in the initial evaluation with heparin 
dp6-2 (see section 20 above).  
After one round of de-sulphation as carried out for heparin dp6-2, the concentration of 
NaOH used to form an alkaline solution of the oligosaccharide for the next round of 
lyophlisation was increased by 4 times, from 0.2M to 0.8M (see experimental 
procedures). After lyophilisation to dryness the sample was analysed by 1-D NMR 
spectroscopy. The 1-D NMR spectra prior to de-2-O-sulphation and after two rounds of 
de-sulphation at 0.2M and 0.8M NaOH are shown in Figure 44. A 2-D COSY spectrum 
was recorded (see Appendix I, Figure 101) and the proton chemical shifts assigned (Table 
7).  
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 Figure 44 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44 NMR analysis of heparin dp6-1 after chemical de-2-O-sulphation.  
Panel A, heparin dp6-1 prior to the de-sulphation procedure; Panel B, after one round of 
de-sulphation using 0.2M NaOH and a subsequent round using 0.8M NaOH. The peak 
area of the resonance at 6.02 is given as a percentage of the its area plus that of the 
resonance at 5.83 ppm in each panel (see text). The most significant changes in the 
chemical shifts after de-2-O-sulphation involved protons within the UA and IdoUA 
residues (see Table 7) and these are marked with arrows. 
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Table 7.  1H  chemical shifts assignments (ppm) for heparin dp6-1 prior to and 
after undergoing de-2-O-sulphation. The difference column refers to the difference 
between the protons original chemical shift and the chemical shift value after de-2-O- 
sulphation.
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Residue  Original (ppm)  After de-2-O-sulphation (ppm) Difference (ppm)
1. ∆UA(2S) H1 5.542(2.2) H1 5.277(1.8) -0.265
H2 4.652 H2 3.86 -0.792
H3 4.341(5.4) H3 4.41(2.8) +0.069
H4 6.02 H4 5.832 -0.188
2.  GlcNS(6S) H1 5.433(3.4) H1 5.37(3.4) -0.063
H2 3.332 H2 3.315 0.017
H3 3.682 H3 3.689 +0.007
H4 3.864 H4 3.759 -0.105
H5 4.07 H5 4.042 -0.028
H6 4.291 H6 4.243 -0.048
H6' or 4.401 H6' or 4.364 -0.037
3.  IdoUA(2S) H1 5.254(2.5) H1 5.055(1.6) -0.199
or IdoUA H2 4.367(5.6) H2 3.83(5.3) -0.537
H3 4.245(4.1) H3 4.168(3.4) -0.77
H4 4.123(3.2) H4 4.102(2.8) -0.021
H5 4.847 H5 4.859 +0.012
4.  GlcNS(6S) H1 5.613(3.8) H1 5.626(4.4) +0.013
H2 3.315 H2 3.321 +0.006
H3 3.686 H3 3.684 +0.002
H4 3.798 H4 3.759 -0.039
H5 3.984 H5 4.042 +0.058
H6 4.262 H6 4.243 -0.019
H6' or 4.424 H6' or 4.364 -0.06
5. GlcUA(2S) H1 4.632(9.8) H1 4.652(7.2) +0.02
H2 3.322(8.2) H2 3.426(9.1) +0.104
H3 3.882 H3 3.9 +0.018
H4 3.828 H4 n. d. n. d.
H5 n. d. H5 n. d. n. d.
6. GlcNS(6S) (α) H1 5.483(3.7) H1 5.489(4.1) +0.006
H2 3.309 H2 3.321 -0.012
H3 3.759 H3 3.764 +0.005
H4 4.192 H4 4.188 -0.004
H5 4.378 H5 4.203 -0.175
H6 4.248-4.305 H6 4.354-4.42 +0.106-+0.115
H6' 4.248-4.305 H6' 4.354-4.42 +0.106-+0.115
Coupling constants (in Hz) to proton directly below are given in brackets
n. d. Not determined
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As monitored through the relative intensity of the H4 signals at 6.02 and 5.83 (see Figure 
44, above) with hep dp6-1 a second round of de-sulphation using 0.8M NaOH did not 
result in the removal of an additional number of sulphate groups. This was over an 
equivalent two rounds of de-sulphation using 0.2M NaOH. Compare percentages of 37% 
of the 2-O-sulphate groups removed after two rounds of de-sulphation using 0.2M NaOH 
(see Figure 43, panel C) and 35% removed using one round of 0.2M NaOH and one 
round of 0.8M NaOH (see Figure 44, panel B).  
This suggests there is a limit to the number of UA(2S) 2-O-sulphate groups that can be 
removed in one pass of this well established procedure, and that this limit can not simply 
be overcome by increasing the concentration of NaOH used (see discussion). 
 
20. De-2-O-sulphation of HS dp6-2 and dp6-3. 
De-2-O-sulphation of HS dp6-2 and dp6-3 were carried out using two rounds of the 
procedure at 0.2M NaOH. The 1D-NMR spectra before and after de-2-O-sulphation are 
shown in Figure 45. A full assignment of HS dp6-2 was not carried out as it was clear 
from the comparison to 1-D spectrum, prior to de-sulphation, that severe overlap 
occurred between resonances for the two non-sulphated iduronic acid residues that were 
now present in this sequence (see Figure 45). A COSY spectrum was recorded only for 
dp6-3 (see Appendix I, Figure 100) and chemical shifts only assigned for this 
oligosaccharide (Table 8). Changes in the chemical shifts of HS dp6-2 on de-2-O-
sulphation as shown in Figure 45 are inferred from a comparison to the 1D-spectra of the 
sample prior to de-2-O-sulphation. 
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Figure 45 NMR analysis of HS dp6-2 and dp6-3 after chemical de-2-O-
sulphation.   
Panel A, HS dp6-2 prior to the de-sulphation procedure; Panel B, HS dp6-2 after one 
round of de-sulphation using 0.2M NaOH;  Panel C, HS dp6-3 prior to the de-sulphation 
procedure; Panel D, HS dp6-3 after one round of de-sulphation using 0.2M NaOH. The 
most significant changes in the chemical shifts after de-2-O-sulphation involved protons 
within the IdoUA residue (see Table 8 for dp6-3 changes) and these are marked with 
arrows. 
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Figure 45  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 . 0 03 . 5 04 . 0 04 . 5 05 . 0 05 . 5 06 . 0 0
3 . 0 03 . 5 04 . 0 04 . 5 05 . 0 05 . 5 06 . 0 0
3.03.54.04.55.06.0 6.5 ppm
3.03.54.04.55.06.0 6.5 ppm
3 . 0 03 . 5 04 . 0 04 . 5 05 . 0 05 . 5 06 . 0 0
3.03.54.04.55.06.0 6.5 ppm
3 . 0 03 . 5 04 . 0 04 . 5 05 . 0 05 . 5 06 . 0 0
3.03.54.04.55.06.0 6.5 ppm
Panel A
Panel B
Panel C
Panel D
IdoUA(2S),
H1
IdoUA(2S),
H2
IdoUA(2S),
H4
IdoUA(2S),
H3
IdoUA(2S),
H1
IdoUA(2S),
H2
IdoUA(2S),
H3
IdoUA(2S),
H4
  
 
 201 
Table 8.  1H  chemical shifts assignments (ppm) for HS dp6-3 prior to and after 
undergoing de-2-O-sulphation.  
The difference column refers to the difference between the protons original chemical shift 
and the chemical shift value after de-2-O- sulphation. 
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Residue  Original (ppm)  After de-2-O-sulphation (ppm) Difference (ppm)
1. ∆UA H1 5.122 (6.6) H1 5.15(6.6) +0.028
H2 3.813 (6.0) H2 3.836(6.0) +0.023
H3 4.325 (3.4) H3 4.357(3.5) +0.032
H4 5.825 H4 5.854 +0.029
2.  GlcNS H1 5.343 (3.5) H1 5.447(3.8) +0.104
H2 3.327 (10.7) H2 3.345 +0.018
H3 3.77 H3 3.738 -0.032
H4 3.885 H4 3.894 +0.009
H5 3.85 H5 n. d. n. d.
H6 3.797-3.966 H6 n. d. n. d.
H6' 3.797-3.966 H6' n. d. n. d.
3.  IdoUA(2S) or H1 5.297 (1.6) H1 5.009(2.5) -0.288
IdoUA H2 4.368 (4.1) H2 3.789(5.3) -0.579
H3 4.279 (3.15) H3 4.164(4.4) -0.115
H4 4.068 (1.5) H4 4.128(2.8) +0.06
H5 4.896 H5 4.842 -0.054
4.  GlcNS H1 5.613 (3.7) H1 5.64(4.1) +0.027
H2 3.288 (10.1) H2 3.326 +0.038
H3 3.683 H3 3.686 +0.003
H4 3.741 H4 3.748 +0.007
H5 3.823 H5 3.863 +0.04
H6 3.891-3.966 H6 n. d. n. d.
H6' 3.891-3.966 H6' n. d. n. d.
5. GlcUA H1 4.596 (7.8) H1 4.614(7.9) +0.018
H2 3.428 H2 3.439 +0.011
H3 3.895 H3 3.909 +0.014
H4 3.828 H4 3.862 +0.034
H5 3.813 H5 n. d. n. d.
6. GlcNAc (α) H1 5.242 (3.1) H1 5.27(3.2) +0.028
H2 3.905 H2 3.95 +0.045
H3 3.934 H3 3.919 -0.045
H4 3.726 H4 3.752 +0.026
H5 3.996 H5 3.966 0
H6 3.842-3.939 H6 n. d. n. d.
H6' 3.842-3.939 H6' n. d. n. d.
NAc 2.075 2.091 +0.016
Coupling constants (in Hz) to proton directly below are given in brackets
n. d. Not determined
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21. Molecular dynamic simulations of iduronate residues. 
As mentioned in the aims section of the introduction, it was also sought to produce an 
improved set of coupling constants for iduronate conformational analysis. This was done 
using computational molecular dynamic modelling, in a manner similar to Forster and 
Mulloy (Forster and Mulloy 1993). 
Molecular dynamic simulations were carried out for 1000ps on IdoUA and IdoUA(2S) 
monosaccharide models in explicit water at a temperature 300K and a pressure of 1atm 
(see experimental procedures). Over the course of the simulation, variations in the 
Cremer-Pople ring puckering parameters, θ and where warranted ф2 (see introduction) 
monitored. Different simulations were started with models in each of the three low 
energy conformations of iduronate, 1C4, 2S0 and 4C1 (see introduction). Variations in the 
Cremer-Pople parameters during the simulations are shown in Figures 46 and 47. 
For both IdoUA and IdoUA(2S) the 4C1 and 2S0 starting conformation were stable over 
the course of the simulation , the Cremer-Pople parameters averaging out at the following 
values: 
IdoUA 4C1    θ = 8.98˚ 
IdoUA(2S)  4C1 θ = 9.17˚ 
IdoUA 2S0   θ = 92.8˚ ф2 = 154.1˚  
IdoUA(2S) 2S0  θ = 92.99˚ ф2 = 160.67˚  
The 2S0 and 4C1 constants shown in Table 9 were therefore averaged over all 1000 
structures sampled during the MD simulation. For both IdoUA and IdoUA(2S) the 1C4 
conformation showed a single major conformational transition during the MD simulation. 
This occurred at 99ps for IdoUA (see Figure 46, Panels D and E) and 599ps for 
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IdoUA(2S) (see Figure 47, Panels D and E). The average values for θ and ф2 after the 
transition occurred to the end of the simulation were 93.4˚ and 155˚ for IdoUA and 92.9˚ 
and 152.2˚ for IdoUA(2S). These average values established the conformational change 
to be in both cases from the 1C4 conformation to the 2S0 conformation. These 
conformational transitions validated that the glycam force field was able to make correct 
structural predictions with regard to the low energy conformations of the iduronate ring. 
This is important, because if transitions were made between conformations that were 
known to be of high energy and not exist experimentally, this would seriously undermine 
the credibility of any modelling studies undertaken using this force-field. The 1C4 
constants shown in Table 9 were averaged over 99 frames for IdoUA and 599 frames for 
IdoUA(2S).
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Figure 46 Cremer-Pople ring puckering parameters for the methyl glycoside of 
IdoUA during a 1000ps  molecular dynamic simulation.  
Panel A, θ values for models starting in the 4C1 conformation; Panel B, θ values for 
models starting in the 2S0  conformation;  Panel C, ф2 values for models starting in the 2S0  
conformation; Panel D, θ values for models starting in the 1C4  conformation;  Panel D, ф2 
values for models starting in the 1C4  conformation. See experimental procedures for 
experimental detail. 
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Figure 46  
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Figure 47 Cremer-Pople ring puckering parameters for the methyl glycoside of 
IdoUA(2S) during a 1000ps  molecular dynamic simulation.  
Panel A, θ values for models starting in the 4C1 conformation; Panel B, θ values for 
models starting in the 2S0  conformation;  Panel C, ф2 values for models starting in the 2S0  
conformation; Panel D, θ values for models starting in the 1C4  conformation;  Panel D, ф2 
values for models starting in the 1C4  conformation. See experimental procedures for 
experimental detail. 
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Figure 47 
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Table 9.  The average value and standard deviation of the theoretical iduronate 
coupling constants as obtained by explicit water molecular dynamic simulations.  
The program mdXvu was used to analyse the explicit water MD trajectories and extract 
theoretical coupling constants for the sugar in each frame according to the Haasnoot et al 
equation (Haasnoot et al. 1979).  The 2S0 and 4C1 constants were averaged over 1000 MD 
trajectory frames. 1C4 constants were averaged over 99 frames for IdoUA and 599 frames 
for IdoUA(2S) (see text). 
 
1C4 2S0 4C1
3J 1,2 IdoUA 1.71 ± 0.53 IdoUA 4.36 ± 1.5 IdoUA 7.34 ± 0.64
IdoUA(2S) 1.78 ± 0.53 IdoUA(2S) 3.99 ± 1.39 IdoUA(2S) 7.28 ± 0.69
3J 2,3 IdoUA 1.56 ± 0.99 IdoUA 9.25 ± 1.04 IdoUA 9.05 ± 1.02
IdoUA(2S) 1.82 ± 0.94 IdoUA(2S) 9.26 ± 1.04 IdoUA(2S) 8.86 ± 1.1
3J 3,4 IdoUA 2.01 ± 0.93 IdoUA 5.78 ± 2.1 IdoUA 9.06 ± 0.79
IdoUA(2S) 2.32 ± 0.99 IdoUA(2S) 6.36 ± 1.94 IdoUA(2S) 9.12 ± 0.77
3J 4,5 IdoUA 1.23 ± 0.7 IdoUA 4.26 ± 1.89 IdoUA 5.41 ± 1.06
IdoUA(2S) 1.1 ± 0.71 IdoUA(2S) 4.73 ± 1.91 IdoUA(2S) 5.15 ± 1.09
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22. Molecular modelling. 
Static models were produced for all four HS derived oligosaccharides using the 
established strategy employed by Mulloy et al. (Mulloy et al. 1993) and Mikhailov et al. 
(Mikhailov et al. 1996; Mikhailov et al. 1997). 
 
22.1 Static molecular modelling of HS dp6-3 
In order to derive inter-proton distance restraints NOESY spectra were recorded on HS 
dp6-3 with mixing times of 50, 100, 200, 300, 400, 500 and 600ms. Inter-proton distance 
restraints are important, as frequently more than one low energy geometry is indicated on 
the basis of force field energy calculations alone. For HS dp6-3, the NOE intensities for 
symmetry related cross-peaks corresponding to the following enhancements were 
averaged:  
UA H1 – GlcNS H4, GlcNS H1 – IdoUA(2S) H4, GlcNS H1 – IdoUA(2S) H3, 
IdoUA(2S) H1 – GlcNS H4, IdoUA(2S) H1 – GlcNS H6, GlcNS H1 – GlcUA H4 and 
GlcUA H1 – GlcNAc H4. 
All of the above NOE cross-peaks span glycosidic linkages. It is glycosidic linkage 
geometry that mainly determines the overall 3-dimensional shape of an oligosaccharide 
(see introduction) 
For distance calibration the intra-residue NOE GlcNS H1- GlcNS H2 of both 
glucosamines (residues “b” and “d”) was also assessed. Variations in the distance 
spanned by an intra-residue glucosamine H1-H2 NOE are limited by pyranose ring 
geometry. 
These results are shown in Figure 48. 
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Figure 48        NOE build up curves for all trans-glycosidic NOEs observed within 
oligosaccharide HS dp6-3.  
NOESY spectra were recorded using mixing times of 50, 100, 200, 300, 400, 500 and 
600ms (see experimental procedures). Symmetry related cross-peaks were directly 
integrated using the Mest-ReC NMR analysis program. These volumes were then 
averaged to obtain the final volumes plotted. Error bars correspond to the standard error 
between the two NOE volumes averaged. 
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Figure 48 
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In contrast to the build up curves published by Mikhailov et al. (Mikhailov et al. 1996; 
Mikhailov et al. 1997) a considerable lag phase was observed in the build up profile of all 
the NOEs analysed (see Figure 48). Consequently a two-spin approximation analysis of 
the data was undertaken (see discussion). The build up rate over the initial lag phase, 
corresponding to the first 200ms of each profile (see Figure 48) was calculated and a 
value derived for the distance spanned by each NOE, using the formula 
 
Distance = reference distance x  
 
(Neuhaus and Williamson 2000) 
A theoretical GlcNS H1- GlcNS H2 reference distance of 2.4 Å was used as calibration. 
The calculated approximate distances spanned by each NOE are listed below: 
UA H1 – GlcNS H4    2.58 Å 
GlcNS H1 – IdoUA(2S) H4     2.45 Å 
GlcNS H1 – IdoUA(2S) H3    2.53 Å 
IdoUA(2S) H1 – GlcNS H4    2.66 Å 
IdoUA(2S) H1 – GlcNS H6    2.63 Å 
GlcNS H1 – GlcUA H4     3.0 Å 
GlcUA H1 – GlcNAc H4   2.9 Å 
 
 
 
 
measured build up rate
reference distance build up rate
- 1/6
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22.2 Calculation of potential energy surfaces. 
Potential energy surfaces for each glycosidic linkage were calculated as described under 
experimental procedure. Potential energy surfaces can be used to locate low energy 
glycosidic linkage geometries, which can then be assessed against a set of inter-proton 
distance restraints. Low energy geometries in which a given inter-proton distance exceeds 
a distance restraint can be rejected as unlikely to contribute significantly to the solution 
conformation of a modeled oligosaccharide. The results for HS dp6-3 are presented as 
contour plots in Figure 49.  
NOE derived distances were used to define maximum inter-proton distances that must be 
present in a final proposed model structure. The NOE derived distances were used to 
assess the low energy geometries across each glycosidic linkage, as indicated by the 
potential energy surface calculations. 
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Figure 49 Potential energy surfaces calculated for each glycosidic linkage within 
HS dp6-3.  
Contour lines are shown at the global energy minima (      ) marked with an arrow, and at 
intervals of 3 kJ/mol above this, (      ) global minima +3kJ/mol, (      ) global minima 
+6kJ/mol, (     ) global minima +9kJ/mol, (      ) global minima +12 kJ/mol, (      ) global 
minima +15 kJ/mol, (       ) global minima +18 kJ/mol.  The potential energy was 
evaluated using the glycam04 force field within the AMBER molecular modelling suite 
and partial charge calculation method 1 (see experimental methods). 
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Figure 49  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel A UA 2H1 α– GlcNS 4C1 Panel B UA 1H2 α– GlcNS 4C1
Panel C GlcNS 4C1 α– IdoUA(2S) 1C4 Panel D GlcNS 4C1 α– IdoUA(2S) 2S0
Panel E IdoUA(2S) 1C4 α– GlcNS 4C1 Panel F IdoUA(2S) 2S0 α – GlcNS 4C1
Panel G GlcNS 4C1α– GlcUA 4C1
Panel H GlcUA 4C1 β– GlcNAc α 4C1 Panel I GlcUA 4C1 β– GlcNAc β 4C1
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22.3 Geometry of the UA-GlcNS linkage (monosaccharide “a”-monosaccharide “b”) 
The potential energy surfaces indicated there to be a minimum energy geometry at 
dihedral angles of around Φ= 180˚ and Ψ=0˚, using either starting conformation of the 
uronic acid (see Figure 49, Panels A and B). On inspection of the energy minimised 
structures corresponding to Φ= 180˚ and Ψ=0˚, it was found that the 1H2 conformation of 
UA had made a transition to the 2H1 conformation during the calculation. The minima 
indicated on both maps were therefore the energy result calculated for the same structure 
UA 2H1- GlcNS 4C1 Φ= 180˚ and Ψ=0˚. An overlay of the energy minimised structure 
calculated from the 2H1 and a 1H2 starting conformation of the uronic acid is given in 
Figure 50. The rmsd deviation between the two energy minimised final structures was 
0.22 Å. As with iduronate (see results section 23) this conformational transition validates 
that the glycam force field is able to make correct structural predictions with regard to the 
low energy conformations of unsaturated uronic acid residues. Significantly a transition 
to an intermediate conformation between 1H2 and 2H1 as observed by Mikhailov et al. 
(Mikhailov et al. 1996) (see introduction, section 18.3) was not observed.  This weighs 
further support to the argument that this residue was parameterised incorrectly by 
Mikhailov et al.  
 
 
 
 
 
  
 
 218 
Figure 50  
 
 
 
 
 
 
 
 
 
 
 
Figure 50 Energy minimised structures for the UA-GlcNS glycosidic linkage at 
Φ = 180˚ and Ψ = 0˚.  
An overlay of two final structures is shown, for one structure the UA starting 
conformation was 2H1 for the other 1H2. The distance from proton H1 of the uronic acid 
to proton H4 of the glucosamine was 3.33Å as indicated.  
 
 
 
 
 
3.33Å
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The UA H1 to GlcNS H4 distance of 3.33Å clearly largely exceeds the NOE maximum 
indicated distance of 2.58Å. Additionally, in this geometry a potential NOE between 
these two protons will be obstructed by the C1- glycosidic oxygen bond of the uronic 
acid. For these reasons it was thought unlikely that this geometry contributes significantly 
to the solution conformation across this glycosidic bond. Other low energy geometries 
were sought more consistent with the NOE data. 
At the +3kJ/mol level three other low energy regions are indicated centred around Φ = 
20˚- Ψ =180˚, Φ = 40˚- Ψ = 20˚ and Φ = -40˚- Ψ =-20˚ for a starting conformation of 2H1 
and Φ = 0˚- Ψ = 180˚, Φ = 40˚- Ψ = 20˚ and Φ = -20˚- Ψ = -20˚ for a starting 
conformation of 1H2 (see Figure 49, Panels A and B). For all these geometries the UA 
remained in its starting conformation throughout the calculation. The energy minimised 
structures are shown in Figure 51. 
For both conformations of the uronic acid a significant contribution of the Φ= 20˚- Ψ 
=180˚ geometry (see Figure 49, Panels A and B) to the solution conformation, is not 
supported by the NOE evidence. UA H1 to GlcNS H4 distances of 3.33Å for 1H2 and 
3.35Å for 2H1 are much greater than the 2.58Å distance derived from the intensity of the 
NOE between these two protons. Additionally a potential NOE between these two 
protons in this geometry will again be obstructed, here by the bond between C4 of GlcNS 
and the glycosidic oxygen.  
All other geometries shown in Figure 51 (Panels C-F) can not be ruled out as contributing 
to the solution conformation across the UA-GlcNS glycosidic bond. Movement between 
these geomteries may occur in solution. 
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Figure 51 Energy minimised structures for the UA-GlcNS glycosidic in a 
number of low energy geometries, as indicated by the potential energy surface 
calculations.  
The distance from proton H1 of the uronic acid to proton H4 of the glucosamine is as 
indicated. 
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Figure 51  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel A UA 1H2-GlcNS 4C1 Φ=20˚ Ψ=180˚
Panel C UA 1H2-GlcNS 4C1 Φ=40˚ Ψ=20˚
Panel E UA 1H2-GlcNS 4C1 Φ= -20˚ Ψ= -20˚
Panel B UA 2H1-GlcNS 4C1 Φ=20˚ Ψ=180˚
Panel D UA 2H1-GlcNS 4C1 Φ=40˚ Ψ=20˚
Panel F UA 2H1-GlcNS 4C1 Φ= -40˚ Ψ= -20˚
3.33Å
2.11Å
1.87Å
3.35Å
2.12Å
2.12Å
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22.4 Geometry of the GlcNS-IdoUA(2S) linkage (monosaccharide “b”- 
monosaccharide “c”) 
The potential energy surface calculations indicated there to be a minimum energy 
geometry at dihedral angles of around Φ= -40˚ and Ψ= -20˚ for both IdoUA(2S) in the 
1C4 and 2S0 conformations (see Figure 49, Panels C and D). The energy minimised 
structures at these geometries are shown in Figure 52. 
For both conformations (1C4 and 2S0) of IdoUA(2S) the GlcNS H1 - IdoUA(2S) H4 
distance at the geometries shown in Figure 52 are well within the NOE derived distance 
limit of 2.45Å. For the 1C4 conformation the GlcNS H1- IdoUA(2S) H3 distance is also 
within the NOE limit of 2.53Å. However, this GlcNS H1- IdoUA(2S) H3 NOE derived 
distance is exceeded when IdoUA(2S) is in the 2S0 conformation (see Figure 52, Panel B). 
Other low energy geometries were sought for this glycosidic linkage (see Figure 49, 
Panel D) that more consistent with the NOE data.  
At the first energy level higher than the global minima, the +3kJ/mol level,  the low 
energy structure corresponding to glycosidic dihedral angles Φ= -20˚ and Ψ= -40˚ was 
examined. In this structure the distance actually increases to 3.8Å (data not shown). No 
low energy geometries could be found in which the H1 GlcNS- H3 IdoUA(2S) distance 
was not greater than the NOE derived maximum distance of 2.53Å, when IdoUA(2S) was 
in the 2S0 conformation. This supports the conclusion that this IdoUA(2S) unit 
predominatly occurs in the 1C4 conformation. 
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Figure 52 
 
 
 
 
 
 
 
 
Figure 52 Energy minimised structures for the GlcNS-IdoUA(2S) (1C4 and 2S0) 
glycosidic linkage at Φ= -40˚ and Ψ= -20˚.  
The distance from proton H1 of the glucosamine to proton H4 of the iduronic acid is as 
indicated (→).  The distance from proton H1 of the glucosamine to proton H4 of the 
iduronic acid is as indicated (→). 
 
 
 
 
 
 
 
 
  
Panel A GlcNS 4C1- IdoUA(2S) 1C4
Φ= -40˚ Ψ= -20˚
Panel B GlcNS 4C1- IdoUA(2S) 2S0
Φ= -40˚ Ψ= -20˚
2.11Å
2.35Å
2.11Å
3.0Å
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22.5 Geometry of the IdoUA(2S)-GlcNS linkage (monosaccharide “c”- 
monosaccharide “d”) 
The potential energy surface calculations indicated there to be a minimum energy 
geometry at dihedral angles of around Φ= 40˚ and Ψ= 20˚ for IdoUA(2S) in the 1C4 and 
around  = -40˚ and Ψ= -20˚ for IdoUA(2S) in the 2S0 conformation. The energy 
minimised structures at these geometries are shown in Figure 53. 
For IdoUA(2S) in the 1C4 conformation both the IdoUA(2S) H1- GlcNS H4 and IdoUA 
H1- GlcNS H4 distances are well within the NOE distances of 2.66Å and 2.63Å 
respectively (see Figure 53, Panel A). However, for IdoUA(2S) in the 2S0 conformation, 
while the IdoUA(2S) H1- GlcNS H4 distance is within the NOE distance of 2.63Å, the 
IdoUA(2S) H1- GlcNS H6 distance significantly exceeds the 2.66Å NOE distance (see 
Figure 53, Panel B). Other low energy geometries were sought for this glycosidic linkage 
(see Figure 49, Panel F) more consistent with the NOE data.  
The potential energy surface calculated for IdoUA(2S) 2S0- GlcNS is more complex than 
any of the other maps calculated. The Φ= -40˚ and Ψ= -20˚ minima lies at one end of an 
extended region of low energy structures bounded by a “global minima +3kJ/mol” 
contour. This region extends from around Φ= 20˚ - Ψ= - 40˚ to enclose the global 
mimima at Φ= -40˚ and Ψ= -20˚ (see Figure 49, Panel F). Throughout the whole of this 
region the IdoUA(2S) H1- GlcNS H6 distance exceeds 3.5Å (data not shown).  A second 
region of low energy structures is centred around Φ= 40˚- Ψ= 20˚. For this geometry the 
IdoUA(2S) H1- GlcNS H6 distance falls to 2.25Å and is more compatible with the NOE 
derived distance limit. This structure is shown in Figure 54. 
  
 
 225 
Figure 53  
 
 
 
 
 
 
 
 
Figure 53 Energy minimised structures for the IdoUA(2S)-GlcNS glycosidic 
linkage at Φ = 40˚ and Ψ = 20˚ for IdoUA(2S) in the 1C4 conformation and Φ = -40˚ 
and Ψ = -20˚ for IdoUA(2S) in the 2S0 conformation.  
The distance from proton H1 of the iduronic acid to proton H4 of the glucosamine is as 
indicated (→).  The distance from proton H1 of the iduronic acid to the closest 
glucosamine H6 proton is indicated (→). 
 
 
 
 
 
 
 
 
Panel A IdoUA(2S) 1C4- GlcNS 4C1
Φ= 40˚ Ψ= 20˚
Panel B IdoUA(2S) 2S0- GlcNS 4C1
Φ= -40˚ Ψ= -20˚
2.1Å
2.31Å
2.11Å
4.16Å
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Figure 54         
 
 
 
 
 
 
 
 
 
Figure 54 An energy minimised structure for the IdoUA(2S) 2S0- GlcNS 
glycosidic linkage at Φ = 40˚ and Ψ = 20˚  
The distance from proton H1 of the iduronic acid to proton H4 of the glucosamine is as 
indicated (→).  The distance from proton H1 of the iduronic acid to the closest 
glucosamine H6 proton is indicated (→). 
 
 
 
 
 
 
 
IdoUA(2S) 2S0- GlcNS 4C1 Φ= 40˚ Ψ= 20˚
2.11Å
2.25Å
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22.6 Geometry of the GlcNS- GlcUA linkage (monosaccharide “d”- monosaccharide 
“e”) 
The potential energy surface indicated there to be a minimum energy geometry at 
dihedral angles centred around Φ= -40˚ and Ψ= -20˚ (see Figure 49, Panel G). The energy 
minimised structure at this geometry is shown in Figure 55. The GlcNS H1- GlcUA H4 
distance for the geometry shown in Figure 55 is well within the NOE derived distance 
limit of 3Å. 
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Figure 55 
 
 
 
 
 
 
 
 
 
Figure 55 The energy minimised structure for the GlcNS  4C1- GlcUA  4C1 
glycosidic linkage at Φ = -40˚ and Ψ = -20˚  
The distance from proton H1 of the glucosamine to proton H4 of the glucuronic acid is as 
indicated (→).  
 
 
 
 
 
 
 
 
 
GlcNS 4C1- GlcUA 4C1 Φ= -40˚ Ψ= -20˚
2.11Å
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22.7 Geometry of the GlcUA- GlcNAc (α or β) linkage (monosaccharide “e”- 
monosaccharide “f”) 
The potential energy surface indicated there to be a number of geometries corresponding 
to the global minimal energy configuration of this linkage. As with the UA-GlcNS 
linkage, two global minima energy geometries were indicated centred around Φ = 180˚- 
Ψ = 0˚ and Φ= 20˚- Ψ=180˚ (see Figure 49, Panels H and I). For both anomeric 
configurations and in both of these geometries, the GlcUA H1- GlcNAc H4 inter-proton 
distance significantly exceeds the NOE derived limit of 2.9Å (data not shown).  
Two other global minima energy configurations are indicated centred around Φ = 60˚- Ψ 
= 0˚ and Φ= 0˚- Ψ = -20˚ for GlcNAc α and Φ = 60˚- Ψ = 0˚ and Φ= 20˚- Ψ= -40˚ for 
GlcNAc β (see Figure 49, Panels H and I). The energy minimised structures at these 
geometries are shown in Figure 56. For the geometries shown in Figure 56, in both 
anomeric configurations of GlcNAc the GlcUA H1- GlcNAc H4 distance is well within 
the NOE derived distance limit of 2.9Å (see Figure 56, Panel A-D). None of these 
geometries can be excluded as not occurring across this glycosidic linkage. 
The C5-C6 rotomer conformations of both the GlcNAc α and β- anomers were initiated in 
the gg conformation for all potential energy surface calculations. Comparing the energy 
minimised structures shown in Figure 35, it is clear that a transition has been made during 
the calculation, by the GlcNAc β-anomer, from the starting gg conformation to the gt 
conformation. No such transition is observed for the α-anomer.  
For all structures presented previous to Figure 35, the rotomer conformation remained in 
its initial conformation of gg throughout the calculation (see discussion). 
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Figure 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56 Energy minimised structures for the GlcUA-GlcNAc (α or β) 
glycosidic linkage in a number of low energy geometries, as indicated by the 
potential energy surface calculations.  
The distance from proton H1 of the glucuronic acid to proton H4 of the glucosamine is as 
indicated (→).  Also labelled in each panel is the rotomer conformation of the GlcNAc 
C5-C6 bond (see text).  
 
 
 
Panel A GlcUA 4C1- GlcNAcα 4C1 Φ= 60˚ Ψ= 0˚
Panel C GlcUA 4C1- GlcNAcα 4C1 Φ= 0˚ Ψ= -20˚
Panel B GlcUA 4C1- GlcNAcβ 4C1 Φ= 60˚ Ψ= 0˚
Panel D GlcUA 4C1- GlcNAcβ 4C1 Φ= 20˚ Ψ= -40˚
2.21Å
1.74Å
2.21Å
1.87Å
gg
gt
gg
gt
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22.8 Summary for HS dp6-3 
Selected Φ and Ψ angle combinations resulting in low energy geometries, across each 
glyosidic linkage of HS dp6-3 are given in Table 13. All of these geometries are 
supported by NOE evidence as possibly occurring within the solution conformation of 
this oligosaccharide (see sections 24.1 - 24.7). 
Two static models for HS dp6-3 were constructed. In each the UA monosaccharide was 
modelled in the predominant conformation indicated by the coupling constant analysis 
(see discussion) (2H1). The terminal GlcNAc monosaccharide was modelled in the 
predominant α anomeric configuration. Where more than one possible glycosidic 
geometry was indicated (see Table 10), geometries preferred as a result of the exo-
anomeric effect were modelled (see introduction). Two models were constructed one in 
which the IdoUA(2S) monosaccharide was in the 1C4 conformation and one in which it is 
in the 2S0 conformation. GlcUA always occurs in the 4C1 conformation (see introduction). 
Construction of two models containing alternate IdoUA(2S) conformations, follows the 
modelling procedure adopted by Mulloy et al (Mulloy et al. 1993). These models are 
shown in Figure 57. 
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Table 10  Selected Φ and Ψ dihedral angles across each glycosidic linkage of HS 
dp6-3. All selected dihedral angles result in minimal energy geometries across the 
glycosidic linkage. These angles are also selected on the basis of NOE evidence as 
possibly contributing to the solution conformation of the oligosaccharide (see text, 
sections 24.1 – 24.7). Dihedral angles preferred as a result of the exo-anomeric effect are 
shown in red (see introduction). 
Linkage and monosaccharide conformation Dihedral angles 
  
Φ Ψ 
  
    
a-b 
    
UA 1H2- GlcNS 4C1 40 20 
  -20 -20 
UA 2H1- GlcNS 4C1 40 20 
  -40 -20 
b-c 
    
GlcNS 4C1- IdoUA(2S) 1C4 -40 -20 
GlcNS 4C1- IdoUA(2S) 2S0 -40 -20 
c-d 
    
IdoUA(2S) 1C4- GlcNS 4C1 40 20 
IdoUA(2S) 2S0- GlcNS 4C1 40 20 
d-e 
    
GlcNS 4C1- GlcUA 4C1 -40 -20 
e-f 
    
GlcUA 4C1- GlcNAcα 4C1  60 0 
  0 -20 
GlcUA 4C1- GlcNAcβ 4C1 60 0 
  20 -40 
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Figure 57    
 
 
 
 
 
 
 
   
 
 
 
 
 
                  
Figure 57 Two final proposed model structure of oligosaccharide HS dp6-3.  
The two models differ in the conformation of the IdoUA(2S) monosaccharide at position 
“c”. 
Model A: UA 2H1-GlcNS 4C1-IdoUA(2S) 1C4-GlcNS 4C1-GlcUA 4C1-GlcNAcα 4C1 
Model B: UA 2H1-GlcNS 4C1-IdoUA(2S) 2S0-GlcNS 4C1-GlcUA 4C1-GlcNAcα 4C1  
 
 
 
 
Model A
Model B
UA                 GlcNS IdoUA(2S)    GlcNS GlcUA GlcNAc
a                      b                 c                 d                    e                  f
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23. NOE inter-proton distance restraints in the static molecular modelling of HS 
dp6-2, dp6-5 and dp6-6. 
For the construction of molecular models for HS dp6-2, -5 and -6, trans-glycosidic NOEs 
observed at a 500ms mixing time were taken as occurring over a distance of <3Å (see 
discussion). Low energy geometries on each potential energy surface were then evaluated 
accordingly (see discussion). 
 
23.1 Static molecular modelling of HS dp6-2. 
Potential energy surfaces across many of the glycosidic linkages within HS dp6-2 were 
calculated as part of modelling of HS dp6-3 (see Figure 49). Additional energy surfaces 
were calculated for both GlcNS-IdoUA and IdoUA-GlcNAc(α or β) linkages present in 
HS dp6-2. These are shown in Figure 58. Table 11 lists the Φ and Ψ dihedral angles 
across each glycosidic linkage of HS dp6-2 supported as possible values by an NOE 
derived distance restraint of <3Å (see introduction to section 25 above and discussion).  
In construction of the molecular models, shown in Figure 59, where several possible 
glycosidic geometries were indicated (see Table 11), again those preferred as a result of 
the exo-anomeric effect were modelled. In each model, the UA monosaccharide was 
modelled in the predominant conformation indicated by the coupling constant analysis 
(2H1). The terminal GlcNAc monosaccharide was modelled in the predominant α 
anomeric configuration. Two models were constructed one in which the IdoUA(2S) and 
IdoUA monosaccharides are in the 1C4 conformation and one in which both are in the 2S0 
conformation (see Figure 59).  
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Note, it is entirely possible that these iduronate monosaccharides may be present in 
alternate conformations, i.e. one in the 1C4 conformation and one in the 2S0 conformation. 
There is no experimental evidence to suggest that changes between iduronate 
conformations occur in a concerted fashion along an oligosaccharide chain. The 
construction of only two models, with all iduronates in either one conformation, 1C4 
(Figure 59, model A), or another, 2S0 (Figure 59, model B), follows the modelling 
procedure adopted by Mulloy et al. (Mulloy et al. 1993). The models shown in Figure 59 
can then be directly compared to the previous heparin dodecasaccharide models 
constructed by Mulloy et al. (see introduction, section 17). 
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Figure 58 Potential energy surfaces calculated across the glycosidic linkages 
indicated, within HS dp6-2.  
Contour lines are shown at the global energy minima (      ) marked with an arrow, and at 
intervals of 3 kJ/mol above this, (      ) global minima +3kJ/mol, (      ) global minima 
+6kJ/mol, (     ) global minima +9kJ/mol, (      ) global minima +12 kJ/mol, (      ) global 
minima +15 kJ/mol, (       ) global minima +18 kJ/mol.  The potential energy was 
evaluated using the glycam04 force field within the AMBER molecular modelling suite 
and partial charge calculation method 1 (see experimental methods). 
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Figure 58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel E IdoUA 2S0 α – GlcNAc 4C1 α Panel F IdoUA 2S0 α – GlcNAc 4C1 β
Panel C IdoUA 1C4 α– GlcNAc 4C1 α Panel D IdoUA 1C4 α– GlcNAc 4C1 β
Panel A GlcNS 4C1 α– IdoUA 1C4 Panel B GlcNS
4C1 α– IdoUA 2S0
Φ˚Φ˚
Φ˚ Φ˚
Φ˚ Φ˚
Ψ
˚
Ψ
˚
Ψ
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Table 11  Selected Φ and Ψ dihedral angles across each glycosidic linkage of HS 
dp6-2. All selected dihedral angles result in minimal energy geometries across the 
glycosidic linkage. These angles are also selected on the basis of an NOE derived inter-
proton distance restraint of <3Å, as possibly contributing to the solution conformation of 
the oligosaccharide. Dihedral angles preferred as a result of the exo-anomeric effect are 
shown in red (see introduction). 
Linkage and monosaccharide conformation Dihedral angles 
  
Φ  Ψ 
  
    
a-b 
    
UA 1H2- GlcNS 4C1 40 20 
  -20 -20 
UA 2H1- GlcNS 4C1 40 20 
  -40 -20 
b-c 
    
GlcNS 4C1- IdoUA(2S) 1C4 -40 -20 
GlcNS 4C1- IdoUA(2S) 2S0 -40 -20 
c-d 
    
IdoUA(2S) 1C4- GlcNS 4C1 40 20 
IdoUA(2S) 2S0- GlcNS 4C1 40 20 
d-e 
    
GlcNS 4C1- IdoUA 1C4 -40 -20 
GlcNS 4C1- IdoUA 2S0 -40 -20 
e-f 
    
IdoUA 1C4- GlcNAcα 4C1 40 -40 
IdoUA 1C4- GlcNAcβ 4C1 50 10 
  0 40 
IdoUA 2S0- GlcNAcα 4C1 50 10 
  40 -40 
  -40 -20 
IdoUA 2S0- GlcNAcβ 4C1  50 10 
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Figure 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59 Two final proposed model structure of oligosaccharide HS dp6-2.  
The two models differ in the conformation of the IdoUA(2S) monosaccharide at position 
“c” and in the conformation of the IdoUA monosaccharide at position “e”. 
Model A: UA 2H1-GlcNS 4C1-IdoUA(2S) 1C4-GlcNS 4C1-IdoUA 1C4-GlcNAcα 4C1 
Model B: UA 2H1-GlcNS 4C1-IdoUA(2S) 2S0-GlcNS 4C1-IdoUA 2S0-GlcNAcα 4C1  
 
UA                 GlcNS IdoUA(2S)    GlcNS IdoUA GlcNAc
Model B
Model A
a                      b                 c           d                   e            f
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23.2 Static molecular modelling of HS dp6-5. 
Potential energy surfaces were calculated across the UA-GlcNAc(6S), GlcNAc(6S)-
GlcUA, GlcUA-GlcNS and IdoUA-GlcNAc (α or β) glycosidic linkages. The potential 
energy surface across the GlcNS-IdoUA linkage was previously calculated when 
modelling HS dp6-2. These results are shown in Figure 60. The subsequent table (Table 
12) lists potential Φ and Ψ dihedral angles across each glycosidic linkage, supported as 
possible values by an NOE derived distance restraint of <3Å (see the previous 
introduction to section 25 and discussion).  
For construction of the molecular models, shown in Figure 61, where several possible 
glycosidic geometries were indicated (see Table 12), again those preferred as a result of 
the exo-anomeric effect were modelled. In each model the UA monosaccharide was 
modelled in the predominant conformation indicated by the coupling constant analysis 
(see discussion) (2H1). The terminal GlcNAc monosaccharide was modelled in the 
predominant α anomeric configuration. Two models were constructed one in which the 
IdoUA monosaccharides is in the 1C4 conformation and one in which it is in the 2S0 
conformation (see Figure 61). 
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Figure 60 Potential energy surfaces calculated across the glycosidic linkages 
indicated, within HS dp6-5.  
Contour lines are shown at the global energy minima (      ) marked with an arrow, and at 
intervals of 3 kJ/mol above this, (      ) global minima +3kJ/mol, (      ) global minima 
+6kJ/mol, (     ) global minima +9kJ/mol, (      ) global minima +12 kJ/mol, (      ) global 
minima +15 kJ/mol, (       ) global minima +18 kJ/mol.  The potential energy was 
evaluated using the glycam04 force field within the AMBER molecular modelling suite 
and partial charge calculation method 1 (see experimental methods). 
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Figure 60  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel A UA 2H1 α– GlcNAc(6S) 4C1 Panel B UA 1H2 α– GlcNAc(6S) 4C1
Panel C GlcNAc(6S) 4C1α– GlcUA 4C1 Panel D GlcUA 4C1 β– GlcNS 4C1
Φ˚ Φ˚
Φ˚ Φ˚
Ψ
˚
Ψ
˚
Ψ
˚
Ψ
˚
Panel F IdoUA 1C4 α– GlcNAc(6S) 4C1 β
Φ˚
Ψ
˚
Panel E IdoUA 1C4 α– GlcNAc(6S) 4C1 α
Φ˚
Ψ
˚
Ψ
˚
Φ˚
Panel H IdoUA 2S0 α – GlcNAc(6S) 4C1 β
Ψ
˚
Ψ
˚
Panel G IdoUA 2S0 α – GlcNAc(6S) 4C1 α
Φ˚
Ψ
˚
Ψ
˚
Ψ
˚
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Table 12  Selected Φ and Ψ dihedral angles across each glycosidic linkage of HS 
dp6-5.  
All selected dihedral angles result in minimal energy geometries across the glycosidic 
linkage. These angles are also selected on the basis of an NOE derived inter-proton 
distance restraint of <3Å, as possibly contributing to the solution conformation of the 
oligosaccharide. Dihedral angles preferred as a result of the exo-anomeric effect are 
shown in red (see introduction). 
Linkage and monosaccharide conformation Dihedral angles 
  
Φ  Ψ 
  
    
a-b 
    
UA 1H2- GlcNAc(6S) 4C1 60 0 
UA 2H1- GlcNAc(6S) 4C1 60 0 
b-c 
    
GlcNAc(6S) 4C1- GlcUA 4C1 -60 -40 
  -20 10 
c-d 
    
GlcUA 4C1- GlcNS 4C1 40 20 
  0 -40 
d-e 
    
GlcNS 4C1- IdoUA 1C4 -40 -20 
GlcNS 4C1- IdoUA 2S0 -40 -20 
e-f 
    
IdoUA 1C4- GlcNAc(6S)α 4C1 40 20 
  40 -40 
  -20 -20 
IdoUA 1C4- GlcNAc(6S)β 4C1 50 10 
IdoUA 2S0- GlcNAcα 4C1 40 20 
IdoUA 2S0- GlcNAcβ 4C1  60 0 
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Figure 61 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61 Two final proposed model structure of oligosaccharide HS dp6-5.  
The two models differ in the conformation of the IdoUA monosaccharide at position “e”. 
Model A: UA 2H1-GlcNAc(6S) 4C1-GlcUA 4C1-GlcNS 4C1-IdoUA 1C4-GlcNAc(6S)α 4C1 
Model B: UA 2H1-GlcNAc(6S) 4C1- GlcUA 4C1 -GlcNS 4C1-IdoUA 2S0-GlcNAc(6S)α4C1  
 
 
Model A
Model B
UA            GlcNAc(6S)    GlcUA GlcNS IdoUA GlcNAc(6S)
a                      b                 c                d                    e            f
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23.3 Static molecular modelling of HS dp6-6. 
Potential energy surfaces were calculated across the IdoUA(2S)-GlcNS(6S) and 
GlcNS(6S)-IdoUA linkages. The potential energy surfaces across all other linkages were 
calculated when modelling HS dp6-2 and dp6-3 (see Figure 49, Panels A-B and Figure 
58, Panels C-F). These results are shown in Figure 62. The subsequent table (Table 13) 
lists potential Φ and Ψ dihedral angles across each glycosidic linkage, supported as 
possible values by an NOE derived distance restraint of <3Å (see the previous 
introduction to section 25 and discussion). 
For construction of the molecular models, shown in Figure 63, where several possible 
glycosidic geometries were indicated, again those preferred as a result of the exo-
anomeric effect were modelled. In each model the UA monosaccharide was modelled in 
the predominant conformation indicated by the coupling constant analysis (see 
discussion) (2H1). The terminal GlcNAc monosaccharide was modelled in the 
predominant α anomeric configuration. Two models were constructed, one in which the 
IdoUA(2S) monosaccharide and the IdoUA monosaccharide are in the 1C4 conformation, 
and one in which both are in the 2S0 conformation (see note in section 25.1, on the 
reasoning behind the construction of only two models). 
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Figure 62  
 
 
 
 
 
 
 
 
 
 
Figure 62 Potential energy surfaces calculated across the glycosidic linkages 
indicated, within HS dp6-6.  
Contour lines are shown at the global energy minima (      ) marked with an arrow, and at 
intervals of 3 kJ/mol above this, (      ) global minima +3kJ/mol, (      ) global minima 
+6kJ/mol, (     ) global minima +9kJ/mol, (      ) global minima +12 kJ/mol, (      ) global 
minima +15 kJ/mol, (       ) global minima +18 kJ/mol.  The potential energy was 
evaluated using the glycam04 force field within the AMBER molecular modelling suite 
and partial charge calculation method 1 (see experimental methods). 
 
 
 
Panel A IdoUA(2S) 1C4 α– GlcNS(6S) 4C1 Panel B IdoUA(2S) 2S0 α – GlcNS(6S) 4C1
Panel C GlcNS(6S) 4C1 α– IdoUA 1C4 Panel D GlcNS(6S) 4C1 α– IdoUA 2S0
Φ˚ Φ˚
Φ˚ Φ˚
Ψ
˚
Ψ
˚
Ψ
˚
Ψ
˚
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Table 13  Selected Φ and Ψ dihedral angles across each glycosidic linkage of HS 
dp6-6.  
All selected dihedral angles result in minimal energy geometries across the glycosidic 
linkage. These angles are also selected on the basis of an NOE derived inter-proton 
distance restraint of <3Å, as possibly contributing to the solution conformation of the 
oligosaccharide. Dihedral angles preferred as a result of the exo-anomeric effect are 
shown in red (see introduction). 
Linkage and monosaccharide conformation Dihedral angles 
  
Φ  Ψ 
  
    
a-b 
    
UA 1H2- GlcNS 4C1 40 20 
  -20 -20 
UA 2H1- GlcNS 4C1 40 20 
  -40 -20 
b-c 
    
GlcNS 4C1- IdoUA(2S) 1C4 -40 -20 
GlcNS 4C1- IdoUA(2S) 2S0 -40 -20 
c-d 
    
IdoUA(2S) 1C4- GlcNS(6S) 4C1 40 20 
IdoUA(2S) 2S0- GlcNS(6S) 4C1 40 20 
d-e 
    
GlcNS(6S) 4C1- IdoUA 1C4 -40 -20 
GlcNS(6S) 4C1- IdoUA 2S0 -40 -40 
e-f 
    
IdoUA 1C4- GlcNAcα 4C1 40 -40 
IdoUA 1C4- GlcNAcβ 4C1 50 10 
  0 40 
IdoUA 2S0- GlcNAcα 4C1 50 10 
  40 -40 
  -40 -20 
IdoUA 2S0- GlcNAcβ 4C1  50 10 
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Figure 63  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63 Two final proposed model structures of oligosaccharide HS dp6-6.  
The two models differ in the conformation of the IdoUA(2S) monosaccharide at position 
“c” and the conformation of the IdoUA monosaccharide at position “e”.. 
Model A: UA 2H1-GlcNS 4C1-IdoUA(2S) 1C4-GlcNS(6S) 4C1-IdoUA1C4-GlcNAcα 4C1 
Model B: UA 2H1- GlcNS 4C1-IdoUA(2S) 2S0-GlcNS(6S) 4C1-IdoUA 2S0-GlcNAcα 4C1 
 
 
UA               GlcNS IdoUA(2S)      GlcNS(6S)     IdoUA GlcNAc
a                    b                  c             d                   e           f
Model A
Model B
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24. Molecular dynamic modelling 
In reality molecules are not static structures and are constantly tumbling and moving in 
solution. As mentioned in the introduction, NMR derived structures represent an average 
of many structures that occur in solution. Throughout its lifetime in solution, for short 
periods of time a molecule may change shape and adopt or ‘sample’ an alternate 
conformation away from the average structure seen on its NMR analysis. This is 
particularly the case with oligosaccharide structures, which are known to be particularly 
flexible in solution (Imberty and Perez 2000). An idea can be gained as to the extent a 
modelled structure may deviate from its static structure, through the use of molecular 
dynamic modelling techniques. It was thought that dynamic simulations may also offer a 
new insight into any possible structural influences on oligosaccharide dynamics. 
In contrast to the construction of potential energy surfaces, molecular dynamic 
simulations are more reliant on how through space interactions between atoms are 
modelled (Leach 2001). Partial charge values assigned to each atom play a crucial role in 
determining these through space interactions. As mentioned in the introduction, partial 
charges can not be measured experimentally but may be calculated using any number of 
computational techniques, reviewed in (Leach 2001). Therefore different partial charge 
sets assigned to the same molecular system, while equally valid, may produce different 
dynamic results. Using existing glycam04 force field parameters an evaluation of three 
different partial charge sets was made on HS dp6-2 and -3 structural models.   
Variations of the two torsion angles Φ and Ψ were monitored over the course of a 1ns 
explicit water molecular dynamics simulation (see experimental procedures). For both 
oligosaccharides, static model A was dynamically modelled. Results for HS dp6-2 are 
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shown in Figure 64, and results for HS dp6-3 in Figure 65. Simulations on HS dp6-5 and 
-6 were carried out using solely charge set 1. These results are shown in Figures 66 and 
67. 
All iduronates and terminal uronic acid residues remained in their starting conformation 
throughout the course each simulation (data not shown). For iduronate residues this is in 
contrast to the molecular dynamic results obtained when modelling their monosaccharide 
structures in isolation (see results section 23). This result lends support to the hypothesis 
that the movement of C1 and C4 is severely restricted by the addition of flanking 
monosaccharide units to an otherwise free to move iduronate monosaccharide (Forster 
and Mulloy 1993). Hinderance of free motion at C1 and C4, severely decreasing the rate 
at which iduronate ring conformational transitions occur (Forster and Mulloy 1993). 
Angulo et al. (Angulo et al. 2003) ran 2ns dynamic simulations on a hexasaccharide 
structure, double the duration of the 1ns simulations undertaken in this study, and still 
observed no major iduronate conformational transitions.  
 
24.1 HS dp6-2, -3, -5 and  -6 molecular dynamics 
With HS dp6-2 and -3, except for one notable exception, see panel C2 Figure 64 and 
discusion, all non-terminal glycosidic linkages over all charge sets remained close to their 
starting geometry. Several terminal glycosidic linkages moved to sample alternate 
geometries that where also suggested by the NMR structural refinement process (see 
Figures 64 and 65). For example A3 (Figure 64) was initiated at dihedral angles Φ = 40, 
Ψ = 20 but also moved to sample the Φ = -40, Ψ = -20 geometry (see Table 11). This 
involves a re-orientation of the terminal UA residue with respect to the rest of the 
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molecule; the shape of the rest and majority of the molecule remaining consistent. The 
results of these dynamic simulations were to some extent dependent on the partial charge 
model; compare Figure 65 panels 2A and 3A.  
It is notable that only when intramolecular hydrogen bonds are dis-allowed in the 
calculation of partial charges, partial charge model 3, that the UA-GlcNS bond samples 
an alternate geometry; compare Figures 64 and 65 panels 3A with panels 1A and 2A. 
This suggests hydrogen bonds play a significant role in the stabilisation of the Φ = 40˚, Ψ 
= 20˚ geometry. Hydrogen bond strength is effectively lowered by using partial charge 
calculation method 3. Therefore hydrogen bonding within the UA-GlcNS- disaccharide, 
appears to have a stronger influence in determining glycosidic linkage geometry than it 
does for other disaccharide structures. It is hard to determine if this is functionally 
significant or a modelling artefact. Futher studies will need to address this issue. 
Also notable, are dynamic differences across the reducing terminal IdoUA-GlcNAc and 
GlcUA-GlcNAc glycosidic linkages of HS dp6-2 and -3 respectively. For the IdoUA-
GlcNAc linkage for all charge models (Figure 64, column E) the geometry of this linkage 
remains close to its initial value, with Φ at around 40˚. In contrast, for the GlcUA-
GlcNAc linkage a starting geometry of Φ = 60˚, Ψ = 0˚ and an alternate geometry of Φ = 
0˚, Ψ = -20˚ are sampled using partial charge set 1 (Figure 65, panel E1) and partial 
charge set 3 (Figure 65, panel E3). It may be that the GlcUA-GlcNAc linkage has a 
higher degree of conformational flexibility over that of a IdoUA-GlcNAc linkage. 
However, perhaps the key observation from these dynamic studies is the suggestion that 
6-O-sulphate groups are able to exert an influence on the dynamics of adjacent glycosidic 
linkages. This is suggested by the fact that within HS dp6-6, the terminal IdoUA–GlcNAc 
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linkage appears to sample two additional conformationas to the one in which the dynamic 
simulation was initiated. The simulation was initiated with IdoUA-GlcNAc glycosidic 
torsion angles at Φ = 40˚, Ψ = -40˚ (see Table 13) and during the course of the simulation 
moves to sample a region of the potential energy surface around Φ = -20˚, Ψ = -20˚ and 
Φ = -45˚, Ψ = -45˚ (see Figure 67, panel E). A similarly modelled IdoUA–GlcNAc within 
HS dp6-2 (see Figure 64 panel E1) makes no such conformational transitions. Possibly 
the monosaccharide to which the IdoUA is linked on the opposite side, GlcNS(6S) for HS 
dp6-6 or GlcNS for HS dp6-2, is the main cause of this (see discussion).  
With regard to the use of different partial charge set in the dynamic modelling of HS dp6-
2 and HS dp6-3, these results represent in good start in the attempt to develop a new force 
field for the modelling of HS and heparin oligosaccharides. It was suspected that it may 
be the case that dynamics may vary as a result of charge model and for a number of 
glycosidic linkages this is indeed the case. A next step in the development of this force 
field may be to establish how well the new partial charges reproduce the quantum 
mechanical properties of a molecule in combination with the existing glycam04 torsion 
parameters. See discussion section 10, for the differences beteen quantum and mechanical 
molecular modelling.  Quantum mechanical calculations take an extreme amount of 
computational time, however these calculations are currently underway both as a 
continuation of this thesis work and in the laboratory of Dr. Dupradeau, at the university 
of Amien, France.  
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Figure 64 Variations in Φ and Ψ torsion angles over the course of a 1ns explicit 
water molecular dynamic simulation of HS dp6-2.  
Structures were sampled every picosecond over the course of a 1ns TP5 explicit water 
molecular dynamic simulation (see experimental procedures). Φ and Ψ torsion angles 
across each glyosidic linkage for each of the 1000 structures sampled are plotted and 
connected in chronological order (   ). Also plotted are contour lines representing the 
potential energy surface of each glyosidic linkage indicated (see Figure 49). 
Results on line 1 were calculated using partial charge set 1, results on line 2 using partial 
charge set 2, and results on line 3 using partial charge set 3 (see experimental 
procedures). 
Column A, UA 2H1 α – GlcNS 4C1 
Column B, GlcNS 4C1 α – IdoUA(2S) 1C4 
Column C, IdoUA(2S) 1C4 α – GlcNS 4C1 
Column D, GlcNS 4C1 α – IdoUA 1C4 
Column E, IdoUA 1C4 α – GlcNAc 4C1 α 
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Figure 64 
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Figure 65 Variations in Φ and Ψ torsion angles over the course of a 1ns explicit 
water molecular dynamic simulation of HS dp6-3.  
Structures were sampled every picosecond over the course of a 1ns TP5 explicit water 
molecular dynamic simulation (see experimental procedures). Φ and Ψ torsion angles 
across each glyosidic linkage for each of the 1000 structures sampled are plotted and 
connected in chronological order (   ). Also plotted are contour lines representing the 
potential energy surface of each glyosidic linkage indicated (see Figures 49 and 58). 
Results on line 1 were calculated using partial charge set 1, results on line 2 using partial 
charge set 2, and results on line 3 using partial charge set 3 (see experimental 
procedures). 
Column A, UA 2H1 α – GlcNS 4C1 
Column B, GlcNS 4C1 α – IdoUA(2S) 1C4 
Column C, IdoUA(2S) 1C4 α – GlcNS 4C1 
Column D, GlcNS 4C1 α – GlcUA 1C4 
Column E, GlcUA 1C4 α – GlcNAc 4C1 α 
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Figure 65 
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Figure 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66 Variations in Φ and Ψ torsion angles over the course of a 1ns explicit 
water molecular dynamic simulation, HS dp6-5, model A. 
Structures were sampled every picosecond over the course of a 1ns TP5 explicit water 
molecular dynamic simulation (see experimental procedures). Φ and Ψ torsion angles 
across each glyosidic linkage for each of the 1000 structures sampled are plotted and 
connected in chronological order (    ). Also plotted are contour lines representing the 
potential energy surface of each glyosidic linkage indicated (see Figures 58 and 60)
Panel A UA 2H1 α– GlcNAc(6S) 4C1 Panel B GlcNAc(6S) 4C1α– GlcUA 4C1
Panel C GlcUA 4C1 β– GlcNS 4C1 Panel D GlcNS 4C1 α– IdoUA 1C4
Panel E IdoUA 1C4 α– GlcNAc(6S) 4C1 α
Φ˚ Φ˚
Φ˚ Φ˚
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Figure 67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67 Variations in Φ and Ψ torsion angles over the course of a 1ns explicit 
water molecular dynamic simulation, HS dp6-6, model A. 
Structures were sampled every picosecond over the course of a 1ns TP5 explicit water 
molecular dynamic simulation (see experimental procedures). Φ and Ψ torsion angles across 
each glyosidic linkage for each of the 1000 structures sampled are plotted and connected in 
chronological order (     ). Also plotted are contour lines representing the potential energy 
surface of each glyosidic linkage indicated (see Figures 49, 58 and 62). 
Panel A UA 2H1 α– GlcNS 4C1 Panel B GlcNS 4C1 α– IdoUA(2S) 1C4
Panel C IdoUA(2S) 1C4 α– GlcNS(6S) 4C1 Panel D GlcNS(6S) 4C1 α– IdoUA 1C4
Panel E IdoUA 1C4 α– GlcNAc 4C1 α
Φ˚ Φ˚
Φ˚ Φ˚
Φ˚
Ψ
˚
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˚
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˚
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˚
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DISCUSSION  
1. Initial studies into the degradation of HS by the heparinase III enzyme. 
Many previous studies have used the heparinase III enzyme to degrade polymeric HS into 
shorter chain length oligosaccharides for structural and/or functional analysis (see 
introduction, NMR section). Frequently, the minimum quantity of enzyme required to 
bring about complete digestion of a know quantity of HS is not addressed. 
Heparinase III cleavage of HS is through a β-eliminative mechanism, and generates 
oligosaccharides terminating at their non-reducing end in a ∆4, 5 unsaturated uronic acid 
(see introduction). This absorbs U.V. light at a wavelength of 232nm and allows the 
progression of a heparinase III digest to be monitored. Typically, digestion is assumed to 
be complete when no further increase in absorbance at 232nm is detected (Pervin et al. 
1995; Hileman et al. 1997). Due to the long incubation times used in the initial studies 
detailed in this study (see results section 1) spectrometer readings were subject to severe 
drift (data not shown). Therefore the progress of digestion was monitored through 
changes in the gel filtration profile of the sample.  
A quantity of 40mU of heparinase III added in 10mU aliquots over the course of 88 hours 
was found sufficient to digest 200 mg of HS (100mg/ml) to completion (see Figure 20, 
panel E) 
 
2. SAX-HPLC chromatography of sized HS oligosaccharides 
SAX-HPLC analysis of the dp4 and dp6 oligosaccharide pools showed them to be 
considerably less heterogeneous in nature than the Heparinase III generated pools 
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analysed by Hileman et al. (Hileman et al. 1997) (see Figure 23). This could be due to 
three reasons:  
1) Possible variations in HS start material, although porcine mucosal HS purchased from 
Celsus laboratories was used in this and the Hileman et al. study;  
2) Improved gel filtration chromatography. There is a high probability that the samples 
analysed by Hileman et al. contain contaminating oligosaccharides of both a shorter and 
longer chain length. The presence of these contaminants in addition to the authentic chain 
length oligosaccharides increase sample heterogeneity; 
3) The extent of enzyme digestion. Great care was taken in this thesis work to ensure all 
heparinase III enzyme digests were complete. A partial digest may result in a 
considerable increase in sample heterogeneity and more complicated SAX-HPLC 
profiles. 
 
3. SAX-HPLC and PAGE analysis 
It has been shown that the detection of a single peak on SAX-HPLC does not always 
correspond to the presence of a single oligosaccharide species (Vives et al. 2001; 
Goodger 2003). Likewise a split peak of the types labelled 1, 2 and 3 in Figure 23, Panel 
B, does not necessarily correspond to the presence of 2 oligosaccharide species. K5 
polysaccharide derived oligosaccharides that are composed entirely of -GlcUA-GlcNAc- 
disaccharide units elute as similar split peaks on SAX-HPLC (Murphy 2003). For these 
reasons PAGE analysis was carried out on a number of dp6 and dp8 SAX-HPLC peaks. 
A smear, rather than a number of clearly resolved bands was observed on PAGE analysis 
of dp6-1 (see Figure 24). It is thought that this peak may be composed of saccharide units 
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which remain covalently linked to a protein core amino acid sequence (see introduction, 
section 6.2, page 47, chain initiation).  
The presence of two alternately charged oligosaccharides in dp6-2 and dp-3, suggested by 
their split SAX-HPLC peaks, was not supported by the PAGE analysis. Both stained for a 
single oligosaccharide band. Dp6-5 and dp6-6 also stained for a single band, however 
these peaks were not split on HPLC analysis.  
On the basis of the dp6-5 and -6 results it might have been assumed that HS dp6-4 also 
contained a single oligosaccharide species. Likewise on the basis of the HS dp6-2 and -3 
results it might have been assumed that dp6-7, a split peak, also contains one 
oligosaccharide species. However, at least two major species were detected in both of 
these samples. This demonstrates that each individual SAX-HPLC peaks must be 
assessed independently and that for a number of oligosaccharides, chromatographic 
separation is not achievable on the basis of charge by SAX-HPLC alone. This also 
applies to a number of dp8 oligosaccharides (see Figures. 23 and 24). 
Split peaks of the type observed for dp6-2 and dp6-3, may be due to the presence of both 
α- and β-anomeric configurations for the reducing end terminal unit. With dp6-2 and -3 
both α- and β-anomeric configurations were detected on NMR analysis for their terminal 
N-acetyl glucosamine residues (see Figure 33). It may be that one configuration (α or β) 
results in a slight increase in the affinity of the oligosaccharide for the HPLC stationary 
phase, possibly brought about by differences in the predominant rotamer conformations 
of GlcNAcα and GlcNAcβ (discussed later). 
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4. PAGE and disaccharide analysis 
The disaccharide analysis of HS dp6-2, -3, -5 and -6 supported the evidence from PAGE 
analysis (see Figure 24) that each is mainly composed of a single hexasaccharide 
structure (see Table 2).  The disaccharide analysis of the dp8 subfractions -1, -3 and -7 
however, did not support their PAGE analysis. Each was found to contain varying 
proportions of six different disaccharide units (see Table 2).  
The probable reason for this discrepancy may be due to the quantity of dp8 subfractions 
material analysed by PAGE. In addition to the major oligosaccharide species stained, the 
disaccharide analysis results suggest these samples to also contain multiple additional 
oligosaccharides at low concentrations. In support of this, on overloading the lanes with 
dp8 material, a number of minor bands were also stained (data not shown). On the basis 
of the dp8 disaccharide and PAGE analyses, dp8 subfractions were not taken on for 
further NMR characterisation and remain stored for future study. 
 
5. Variation between SAX-HPLC profiles 
The reasons behind the observation of varying proportions of dp6-5 and -6 
oligosaccharides in pooled dp6 material from the preparative size-exclusion column are 
unclear (see figure. 25). All digests were carried out on the same batch of HS purchased 
from Celsus laboratories, prior to addition to the size exclusion column. Several different 
batches of heparinase III enzyme were used, and initially it was thought that this may be 
the reason for variations. Slight variations did occur occasionally between batches, but 
frequently greater variations occurred when using the same batch of enzyme.  
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One possible explanation may be that for any one digest a particular ‘selection’ of 
polymeric heparan sulphate chains are present within the 200mg of material taken for 
digestion. Structural variations within this selection may then have an effect on the 
proportions of the various oligosaccharide sequences that result. In support of this, 
variations were also seen in the levels of dp6-2 and -3 however the most dramatic 
differences were observed with dp6-5 and -6. 
An alternative explanation may be that subtle variations exist in the digestion rate of 
some disaccharide linkages. While a majority of susceptible disaccharide linkages have 
been cleaved by 40 mU of hep III over an 88 h period, a variable number of some 
resistant, but cleavable linkages may remain intact. It is possible that one of these 
linkages is present within HS dp6-5, leading to variations in the proportions of this 
oligosaccharide detected on apparent digestion completion. This may well be the result of 
the unusual –GlcNAc(6S)–GlcUA-GlcNS- trisaccharide sequence at the centre of HS 
dp6-5 (discussed later). 
 
6. PAGE purification of dp6-5 and dp6-6 
The further purification of dp6-5 and -6 by PAGE, resulted in significant sample losses. 
Approximately half the original material was lost on further purification. This was mainly 
due to the number of chromatographic steps that were then necessary to remove 
contaminating Azure A stain and polyacrylamide from these samples (see experimental 
procedures).  
An alternative to Azure A staining may be the reverse staining technique as detailed by 
Hardy and Castellanos-Serra (Hardy and Castellanos-Serra 2004). A preliminary 
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evaluation of this technique towards the end of this study demonstrated that it could be 
used to clearly stain heparin derived oligosaccharides (data not shown). Bands could then 
be extracted from the gel without the presence of the difficult to remove Azure A organic 
dye.  
The finding that polyacrylamide was present in these samples was unexpected as this was 
assumed to become efficiently chemically cross linked and insoluble on gel formation. 
Polyacrylamide itself is not thought to be toxic (King and Noss 1989), however the 
acrylamide monomer is a potent neurotoxin (Kupperman 1958; McCollister et al. 1964) 
and probable human carcinogen (Bull et al. 1984; Johnson et al. 1986). Vives et al. 
(Vives et al. 2001), reported that contaminants were a problem when gel-extracted 
oligosaccharides were tested for biological activity. Residual acrylamide monomer is 
likely an impurity in most polyacrylamide preparations, ranging from <1 ppm to 600 ppm 
(King and Noss 1989). Its removal by the HPLC method described by Vives et al., or by 
the DEAE method described in this thesis, is crucial if gel purified oligosaccharides are to 
be tested for biological activity (Goodger 2003). 
 
7. 13C DEPT-135 and 13C HSQC experiments. 
Following assignment of a majority of the protons within all oligosaccharides, using 
COSY, TOCSY and NOESY spectra, additional 13C DEPT-135 and 13C HSQC spectra 
were recorded (where sample quantities permited). A large amount of material is required 
for 13C NMR studies (>1mg) due to the low natural presence of the 13C nuclei. Spectra 
were recorded for HS dp6-2 and -3 and hep dp6-1 and -2 (see Appendix II, Figures 103-
106). This was done because using COSY and TOCSY data, H6 glucosamine protons 
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proved particularly difficult to assign. Frequently very weak or no cross-peaks could be 
detected to these protons on TOCSY analysis. This was thought to be due to a splitting of 
the signal intensity between each of the two H6 protons, effectively halving each of their 
signal intensities.  
A DEPT-135 pulse sequence results in a characteristic pattern of signal intensities for 13C 
coupled to one, two or three hydrogens, CH, CH2 or CH3. The CH2 bonded carbons have 
negative signal intensity, while CH and CH3 carbons have positive signal intensity 
(Becker 2000). Simply, HSQC spectra reveal which protons are coupled to which 13C 
atoms through the occurrence of 13C-1H cross-peaks (Becker 2000). The 13C at 
glucosamine carbon position 6 is a CH2 bonded carbon and has a negative DEPT-135 
signal intensity. This negative intensity can easily be identified against the background of 
predominantly positive signals in all DEPT-135 recorded spectra (see appendix II). The 
large number of positive signals are the result of the large number of CH bonded carbons 
present in each oligosaccharide. On identifying signals arising from C6 carbons, HSQC 
spectra were then used to establish where the chemical shifts occured for the two H6 
protons.  
Where sample quantities did not permit the recording of 13C spectra, a lack of TOCSY 
cross-peaks to a particular proton was assumed to indicate a H6 proton. This assumption 
was always confirmed by COSY analysis. H6-H5 COSY cross-peaks did not appear to 
suffer from the same loss in signal intensity as TOCSY cross-peaks (see Figure 69, panel 
A, in a later section of this discussion). Frequently it was possible to assign ring systems 
from H1-H5 using TOCSY and COSY spectra. Additional COSY cross-peaks from H5, 
i.e. not to the H4 resonance, were assigned to H5-H6. 
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8. Evidence for the conservation of HS monosaccharide sequences across species 
barriers   
The three monosaccharide sequences, HS dp6-2, -3 and -6, have previously been isolated 
and sequenced from the cell surface of a cultured murine 3T3 fibroblast cell line (Merry 
et al. 1999). HS dp6-3 and -6 have also previously been isolated and sequenced from an 
alternate source of porcine HS (Vives et al. 1999). In the field of protein structure and 
functional studies, amino acid sequences are often found to be conserved across species 
and form domains within larger protein structures (Whitford 2005). These domains often 
have a conserved evolutionary function. It seems remarkably co-incidental that 3 out of 
the 4 HS oligosaccharides characterised in this study, and two from the study of Vives et 
al. (Vives et al. 1999) should be homologous with oligosaccharides isolated from a 
murine cell line (Merry et al. 1999). It is speculated that in common with amino acid 
sequence conservation, conservation of HS monosaccharide sequences may also occur 
across species barriers, to confer conservation of function.  
 
9. HS dp6-5, a novel monosaccharide sequence 
HS dp6-5 represents a unique unpublished monosaccharide sequence. However, it is very 
similar in sequence to a hexasaccharide previously characterised by Hileman et al. 
(Hileman et al. 1997) (see below). 
                                                 1          2                  3           4         5           6 
HS dp6-5   UA-GlcNAc(6S)-GlcUA-GlcNS-IdoUA-GlcNAc(6S) 
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Hileman et al. dp6   UA-GlcNAc(6S)-IdoUA-GlcNS-GlcUA-GlcNAc(6S)  
The two sequences differ only in the order in which the internal GlcUA and IdoUA 
monosaccharides (underlined) occur within the sequence. For HS dp6-5, correctly 
establishing this order is key to marking this oligosaccharide out as containing a new, 
novel monosaccharide sequence. The NMR evidence for the positioning of GlcUA at 
position 3 and IdoUA at position 5 is clear and un-ambiguous.  
A characteristic pattern of NOE cross-peaks within the NOESY spectrum of HS dp6-5 
identifies the presence of a -GlcNS-IdoUA- disaccharide linkage (see Figure 68). 
Analyses of the 2D-COSY and TOCSY spectra recorded for HS dp6-5 clearly establish 
that the non-reducing terminal UA unit is linked to a GlcNAc(6S) monosaccharide (see 
Figure 69). This places GlcNAc(6S) at position 2. Consequently, the only 
monosaccharide positions available for which a –GlcNS-IdoUA- disaccharide sequence 
can occur are at positions 4 and 5. The analyses presented in Figures 68 and 69 confirm 
the results of a full sequential assignment of this saccharide, undertaken as detailed in the 
results section, for HS dp6-2 and -3. 
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Figure 68 
 
 
 
 
 
 
 
 
 
Figure 68 An enlargement of a section from a 2D-NOESY spectrum (500ms 
mixing time) recorded for HS dp6-5.  
Circled in red are a pattern of three NOE cross-peaks that indicate the presence of the 
disaccharide sequence –GlcNS-IdoUA-. This same pattern of cross-peaks was detected in 
each of HS dp6-1 and -2 each containing a –GlcNS-IdoUA(2S)- disaccharide sequence.  
Also circled in green is an NOE cross-peak between H1 of the terminal uronic acid unit 
and a proton in the proceeding ring system, speculatively assigned as H6. This 
proceeding ring system on this initial analysis may be either a GlcNAc(6S) 
monosaccharide or GlcNS monosaccharide unit. 
.
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Figure 69 Enlargements of sections from 2D- COSY and TOCSY spectra 
recorded for HS dp6-5.  
In the TOCSY spectrum no through bond connectivity’s could be detected to the 
proton(s) speculatively assigned as H6, (see discussion main text, on H6 assignments).  
In the COSY spectrum (panel A) two through bond connectivitys were detected to 
protons at 4.219 ppm and 4.098 ppm, both were assigned as H5. In the TOCSY spectrum 
(panel B) through bond connectivity’s could be detected to two anomeric protons at 5.459 
ppm and 5.248 ppm.  
As highlighted by the circled area in panel B, no cross-peaks where detected to the 
previously assigned GlcNS anomeric proton (see Figure 68). This clearly established 
positions 1 and 2 of this oligosaccharide sequence to be UA and GlcNAc(6S) 
respectively. 
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Figure 69 
Panel A 
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10. Molecular modelling GlcNAcβ, gg to gt transitions 
All low energy geometries calculated for the GlcNAcβ anomeric configuration contained 
the gt rotamer of GlcNAcβ. This was despite its initiation in the gg conformation (see 
Figure 56). No other N-glucoamine monosaccharides made such transitions and remained 
in the gg rotamer state throughout the energy minimisation process. To investigate this, 
new quantum mechanical modelling calculations were carried out. Quantum mechanical 
techniques explicitly take into account the movement of electrons during calculations. 
Molecular modelling techniques e.g. the glycam04 forcefield, assume that adjustments in 
the movement of electrons in response to changes in the positioning of the atomic nuclei, 
are so rapid that they can be discounted from any modelling calculations. Geometry 
optimisation at the HF/6-31G* level of theory was performed on both GlcNAcβ and 
GlcNAcα structures using the GAMESS quantum mechanical modelling program (data 
not shown). Simply, HF/6-31G* is quantum mechanical shorthand to describe how the 
energy of the system was calculated and is known as a ‘basis set’. For its contribution to 
this discussion it is not thought necessary to unravel the complicated nomenclature of 
quantum mechanical basis sets. For such an explanation see (Leach 2001). HF/6-31G* is 
a well known and respected basis set with which to calculate quantum mechanical 
properties (Leach 2001). As with the molecular mechanical modelling calculations 
GlcNAcβ made a gg to gt transition on quantum mechanical structure optimisation 
(equivalent to molecular mechanical energy minimisation). Similarly geometry optimised 
GlcNAcα remained in the gg rotamer state. Geometry optimisation using quantum 
mechanical modelling techniques ruled out the gg to gt transition as simply being a 
molecular mechanical partial charge effect. 
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It is possible that a gg to gt transition (see introduction, Figure 1 for a diagram of gg and 
gt conformational states) is the consequence of going against the endo-anomeric effect 
(see introduction). The β-anomeric configuration of GlcNAc (see introduction, Figure 19 
for diagram) may be more energetically favoured by the gt rotamer state. Similar 
transitions have not been reported however for glucose monosaccharides. Suggesting the 
gg to gt transition may somehow involve the N-acetyl group. 
It was noticeable that for all molecular and quantum mechanical energy minimised 
GlcNAcβ structures, a hydrogen bond was present between the N-acetyl group oxygen 
and the hydroxyl group proton attached to carbon position 1. This was deduced on the 
basis of the distance and the angle between these two atoms upon completion of the 
modelling calculations (a distance of less than 2Å and an angle of less than 60˚). Due to 
the change in C1 geometry, in the α anomeric configuration, formation of such a 
hydrogen bond is not possible. How or why this then results in a rotation from gg to gt 
around the C5-C6 bond is not clear. Computational predictions that the GlcNAcβ anomer 
has a preference to exist in the gt rotamer state are an interesting apparently un-reported 
phenomenon. The possible biological implications of this discovery now remain for 
future study. 
 
11. Derivation of molecular modelling inter-proton distance restraints 
In theory, a full relaxation matrix analysis of NOE data can be used in order to account 
for multispin effects and derive more accurate interproton distances. Such an analysis was 
employed by Mulloy et al. through use of their NOEMOL program (Mulloy et al. 1993) 
  
 
 273 
and by Mikhailov et al. using the MARDIGRAS program (Mikhailov et al. 1996; 
Mikhailov et al. 1997).  
The severe lag phase observed in the build up curves of all NOEs analysed (see Figure 
48) indicates that spin diffusion from other protons, additional to the two directly 
involved in the NOE, contributes significantly to the intensity observed. Spin diffusion is 
the result of NOE enhancements being transmitted along a chain of spin systems. The 
pyranose ring of each monosaccharide unit is just such a chain of spin systems. Indirect 
intensity enhancements as a result of spin diffusion, in-fact dominate all cross-relaxation 
pathways (see Figure 48). It has been shown that in cases such as this a full relaxation 
matrix analysis of the data, does not yield any more accurate inter-proton distances than a 
simple two-spin approximation analysis (Clore and Gronenborn 1989). Hence a full 
relaxation matrix analysis of the data was not undertaken. A simple two spin 
approximation analysis was used in the derivation of inter-proton distance restraints for 
HS dp6-3.  
The NOE build up curves shown in Figure 48 are in marked contrast to the near perfect 
build up curves published by Mikhailov et al (Mikhailov et al. 1996; Mikhailov et al. 
1997). Possibly the increased sulphation level of the heparin derived hexasaccharides 
analysed by Mikhailov et al. reduces the effect of spin diffusion. However no evidence 
could be found for this in the literature and why this should be the case is unclear. The 
NOE kinetics observed by Mikhailov et al. are unusual, in that no evidence for the 
phenomenon of spin diffusion can be seen at all. Even at the shortest mixing time of 
100ms used by them these data points form part of a text book perfect NOE build up 
curve. Given that all protons are part of a pyranose ring system, at least partial evidence 
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might be expected for the existence of spin diffusion. Of course, it is entirely possible that 
a lag phase is only observed in the NOE build up kinetics of heparin derived 
oligosaccharides at mixing times of less than 100ms. Again why this difference should 
occur between HS and heparin derived NOE kinetics is unclear. NOE build up curves 
were not produced for the heparin derived oligosaccharides produced as part of this thesis 
work, mainly because of the NMR instrument time involved. 
Practically, construction of a NOE build up curves takes a considerable amount of NMR 
instrument time. Yamada et al. have previously stated that significant NOE connectivities 
were only observed over distances of less than 3Å within a range of 8 HS/heparin and 
chondroitin sulphate derived disaccharides (Yamada et al. 1992). Although how they 
arrived at this conclusion is not stated. An analysis of the molecular models constructed 
for HS dp6-3 confirms this is also the case with this hexasaccharide. On this basis a 
maximum inter-proton distance of 3Å was used to evaluate all low energy geometries in 
the construction of models for HS dp6-2, -5 and -6. NOE build up curves for these 
saccharides were not constructed. 
Given the broad low energy regions of each potential energy surface, no advantage in the 
refinement process is gained using a ‘build up rate’ derived inter-proton distance over a 
value of 3Å. By ‘broad low energy region’ it is meant that the area bounded by low 
energy contour lines on each potential energy surface are not restricted to only a very 
tight range of Φ and Ψ values. The opposite, and an example of a narrow set of low 
energy regions would be seen if a potential energy surface were calculated for a 
individual H-C-C-H torsion angle in ethane. Three different very narrow ranges of Φ and 
Ψ values would be low energy, conforming to the three possible staggered conformations 
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of ethane. In all cases for HS dp6-3 refinement using the ‘build up rate’ derived distance 
and a distance of 3Å placed glycosidic linkages in the same low energy geometries. No 
3Å geometries could be discounted on the use of the more accurate distance. 
 
12. SAX-HPLC elution position, modelling insights and biological implications 
Given their high negative charge density, electrostatic interactions between the positively 
charged stationary phase of the HPLC column and N- and O- sulphate groups of an 
oligosaccharide will be primarily responsible for determining its binding affinity. 
Secondary to this, electrostatic interactions between the less electro-negative carboxyl 
and acetyl groups may also play a role. It can also be imagined that interactions with the 
stationary phase of the HPLC column may to some extent also mimic binding interactions 
with the positively charged HS binding site of many protein ligands.  
For the forthcoming sections of this discussion, the static models produced for each HS 
oligosaccharide in results sections 24-25 have been reformatted using the VMD 
molecular graphics viewer (Humphrey et al. 1996). Reformatting was done in order to 
empthasize the positioning of electronegative groups within each HS oligosaccharide. By 
comparing these re-formatted models, a number of new insights can be gained into how 
the positioning of electronegative groups may influence SAX-HPLC elution position. 
These insights, and biological implications where appropriate, are discussed in the 
forthcoming sections.  
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13. HS dp6-2 
Reformatted models for HS dp6-2 (UA-GlcNS-IdoUA(2S)-GlcNS-IdoUA-GlcNAc) are 
shown in Figures 70 to 72. For Figures 70 and 71, to produce model E, model D was re-
orientated so that the maximum number of electronegative groups are positioned along 
the visible surface of the molecule. It is probable that it is this surface that interacts with 
the stationary-phase of the HPLC column and HS binding sites at the surface of a protein 
ligand. In this orientation a total of 5 groups may contribute to a binding affinity for the 
stationary phase (labelled 1-5 in Figures 70-72). 
The superimposition model (Figure 72) reveals that the positioning of electronegative 
groups 4 and 5 are largely unaffected by iduronate conformational changes. However, the 
positioning of electronegative groups 1 to 3 are re-organised. Similar re-orientations were 
reported by Mulloy et al. (Mulloy et al. 1993). 
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Figure 70 HS dp6-2 molecular models.  
All internal iduronates are modelled in the 1C4 conformation. 
Model A, whole model, line representation,  
Model B, whole model, solid surface representation,  
Model C, whole model, wireframe surface representation,  
Model D, as model C with N- and O-sulphate groups, carboxyl groups and acetate 
oxygens in Van der Waals representation (red);  
Model E, a re-orientation of model D. 
X, Y, Z, relative coordinate axis are shown for models B-D 
A number of electronegative groups are numbered 1-5 in model E 
1. UA, carboxyl group 
2. GlcNS, N-sulphate group 
3. IdoUA(2S), 2-O-sulphate group 
4. IdoUA, carboxyl group 
5. GlcNAc, N-acetate group 
All models were formatted using the VMD molecular graphics program (Humphrey et al. 
1996). 
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Figure 70 
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Figure 71 HS dp6-2 molecular models.  
All internal iduronates are modelled in the 2S0 conformation. 
Model A, whole model, line representation,  
Model B, whole model, solid surface representation,  
Model C, whole model, wireframe surface representation,  
Model D, as model C with N- and O-sulphate groups, carboxyl groups and acetate 
oxygens in Van der Waals representation (yellow);  
Model E, a re-orientation of model D. 
X, Y, Z, relative coordinate axis are shown for models B-D 
A number of electronegative groups are numbered 1-5 in model E 
1. UA, carboxyl group 
2. GlcNS, N-sulphate group 
3. IdoUA(2S), 2-O-sulphate group 
4. IdoUA, carboxyl group 
5. GlcNAc, N-acetyl group 
All models were formatted using the VMD molecular graphics program (Humphrey et al. 
1996).
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Figure 71 
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Figure 72 A superimposition model of HS dp6-2. 
Two models of HS dp6-2, one in which both internal iduronates are in the 1C4 
conformation (model A), and one in which both internal iduronates are in the 2S0 
conformation (model B), have been superimposed to form model C.  
Superimposition alignment was carried out using the rmsd extension of the VMD 
molecular graphics program (Humphrey et al. 1996). Model representations and colours 
are as in Figures 70 and 71. 
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Figure 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N- and O-sulphate groups, carboxyl groups and acetate oxygens in Van der Waals 
representation (red); UA-GlcNS-IdoUA(2S)1C4-GlcNS-IdoUA1C4-GlcNAc  
N- and O-sulphate groups, carboxyl groups and acetate oxygens in Van der Waals 
representation (yellow); UA-GlcNS-IdoUA(2S)2S0-GlcNS-IdoUA2S0-GlcNAc  
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14. HS dp6-3, differences to HS dp6-2 and possible biological implications 
Reformatted models for HS dp6-3 are shown in Figure 73. In the orientation shown in 
Figure 73, as with HS dp6-2, again a total of 5 electronegative groups may contribute to a 
binding affinity for the stationary phase to the SAX column (labelled 1-5). Positional 
rearrangements are again observed on iduronate conformational changes within the 
oligosaccharide. 
Both individual models, and superimposition models for HS dp6-2 and -3, are very 
similar, compare Figures 73 and 72, and it is not immediately clear why HS dp6-3 should 
have an increased binding affinity for the SAX-HPLC column. HS dp6-2 and HS dp6-3 
are almost identical in their 3-dimensional shape and in the positioning of their 
electronegative substituents. If it can be understood why these two molecules interact 
differently with the stationary phase of the SAX-HPLC column, a greater insight may be 
gained into similar interactions at the protein surface.  
Differences in their HPLC binding affinities may be due to a subtle conformational 
change that occurs between the two molecules around electronegative group 5. Models 
for both HS dp6-2 and -3 have been produced with the whole of each reducing terminal 
GlcNAc residue, containing group 5, in a Van der Waals representation, see Figure 74. In 
model B it can clearly be seen that the methyl group obscuring the acetyl oxygen (group 
5) in model A is rotated. This places the acetyl oxygen in the same plane as 
electronegative groups 1-4, possibly now allowing it to interact with the SAX-HPLC 
stationary phase. Due to the steric hinderance of the methyl group in model A it is 
doubtful if the acetyl oxygen interacts with the HPLC stationary phase in the same plane 
as groups 1-4. The increased affinity of HS dp6-3 may therefore be due to a contribution 
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of the electronegative acetyl oxygen to electrostatic interactions with the HPLC stationary 
phase. 
Acetyl oxygen groups are often overlooked as significant contributors to electrostatic 
interactions between oligosaccharides and proteins. This is perhaps because many 
binding studies use heparin or HS S-domain structures which contain few, if any, 
GlcNAc monosaccharide units. It is believed that the modelling and SAX-HPLC data 
presented in this thesis, represent the first evidence for the involvement of HS N-acetyl 
groups in oligosaccharide electrostatic interactions. Given that GlcNAc containing 
disaccharide units typically make up >50% of all disaccharide units in standard HS 
preparations, this observation may be of significant biological relevance. Previously, it 
has been suggested that the role of N-acetyl and NA/NS domains within HS is merely to 
space the S-domains correctly, so that more than one S-domain may make contact with 
more than one HS binding site at the protein surface (Mulloy and Forster 2000). It may 
also be that N-acetyl groups in the regions between the S-domains may also make 
additional stabilising electrostatic interactions with the protein surface. 
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Figure 73 A superimposition model of HS dp6-3. 
Two models of HS dp6-3, one in which the internal iduronate is in the 1C4 conformation 
(model A), and one in which the internal iduronate is in the 2S0 conformation (model B), 
have been superimposed to form model C.  
Superimposition alignment was carried out using the rmsd extension of the VMD 
molecular graphics program (Humphrey et al. 1996). Model representations and colours 
are as in Figures 70 and 71. 
A number of electronegative groups are numbered 1-5 
1. UA, carboxyl group 
2. GlcNS, N-sulphate group 
3. IdoUA(2S), 2-O-sulphate group 
4. GlcUA, carboxyl group 
5. GlcNAc, N-acetate group 
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Figure 73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N- and O-sulphate groups, carboxyl groups and acetate oxygens in Van der Waals 
representation (red); UA-GlcNS-IdoUA(2S)1C4-GlcNS-GlcUA-GlcNAc 
N- and O-sulphate groups, carboxyl groups and acetate oxygens in Van der Waals 
representation (yellow); UA-GlcNS-IdoUA(2S)2S0-GlcNS-GlcUA-GlcNAc 
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Figure 74 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 74 HS dp6-2 and HS dp6-3 molecular models.  
HS dp6-2 is modelled with all internal iduronates in the 1C4 conformation (Model A). HS 
dp6-2 is also modelled with its lone internal iduronate in the 1C4 conformation (Model 
B). 
Model representations and colours are as in Figures 72 and 73 with the addition that the 
whole reducing terminal GlcNAc residue of each model is also shown in a Van der Waals 
representation. 
All models were formatted using the VMD molecular graphics program (Humphrey et al. 
1996).
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15. A molecular re-orientation for HS dp6-5 
Reformatted models for HS dp6-5 are shown in Figure 75. In model A the 
oligosaccharide is shown in the same orientation as oligosaccharides dp6-2 and -3 in 
Figures 70-74. However, it is doubtful if the molecular surface shown here constitutes the 
binding surface for this oligosaccharide to the SAX-HPLC stationary phase, or to the 
surface of a potential protein ligand. Only two electronegative groups are present. It is 
more likely that the stationary phase binding surface occurs on the opposite side of the 
molecule as shown in model B, consisting of 4 electronegative groups. A superimposition 
model for HS dp6-5 in the orientation of model B is shown in Figure 76. From the 
superimposition model it can be seen that in this proposed binding orientation only 4 
electronegative groups constitute the binding surface. Four electronegative groups are in 
contrast to the 5 electronegative groups potentially forming the binding surface of HS 
dp6-2 and -3. The increased SAX-HPLC binding affinity for HS dp6-5 may be due to the 
type of electronegative group rather than the number present at the binding surface. The 
proposed binding surface for HS dp6-5 is composed of three O-sulphate groups (groups 
1, 3 and 4) and a single carboxyl group (group 2). The additional O-sulphate group may 
add an additional degree of affinity that outweighs the contributions from the carboxyl 
and acetyl groups of HS dp6-2 and -3.  
The molecular re-orientation of HS dp6-5 relative to all other models demonstrates that 
ligand binding sites do not necessarily occur on the same side of a HS polymer, in a so 
called ‘cis’ binding orientation (Gallagher and Lyon 2000). It could be imagined that if 
the nonreducing terminal of HS dp6-5 were linked to the reducing terminal of HS dp6-3, 
where each then to bind a protein ligand, these ligands would be positioned on opposite 
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sides of the oligosaccharide chain, in a so called ‘trans’ binding orientation (Gallagher 
and Lyon 2000). The possibility for this ‘trans’ mode of binding was implied by regions 
of high electronegativity, formed by closely positioned N-, 2-O- and 6-O-sulphate 
groups, occurring consecutively on opposite sides of the dodecasaccharide chain in the 
heparin dodecasaccharide models of Mulloy et al. (Mulloy et al. 1993) (see introduction, 
Figure 17). Two proteins binding to two such consecutive regions of high 
electronegativity would then be positioned on opposite sides of the oligosaccharide chain. 
This mode of binding actually exists in the Pellegrini crystal structure of an 
FGF1:FGFR2c:heparin complex (Pellegrini et al. 2000) (see introduction, Figure 14). 
The molecular modelling and SAX-HPLC evidence in this study for the protein binding 
surface of HS dp6-5 to be on the opposite side of the molecule to HS dp6-2, -3 and -6, 
further re-inforces the existence of both ‘trans’ and ‘cis’ ligand binding modes within HS 
oligosaccharides.
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Figure 75 HS dp6-5 molecular models.  
HS dp6-5 is modelled with the internal iduronate in the 1C4 conformation in both cases. 
Model B is a re-orientation of model A (see text). 
X, Y, Z, relative coordinate axis are shown for both models.  
A number of electronegative groups are numbered 1-4 in both models. 
1. UA, carboxyl group (model A), GlcNAc(6S), 6-O- sulphate group (model B), 
2. IdoUA carboxyl group (model A), GlcUA carboxyl group (model B) 
3. GlcNS, N-sulphate group,  
4. GlcNAc(6S), 6-O-sulphate group, 
Model representations and colours are as in Figures 70 and 71. 
All models were formatted using the VMD molecular graphics program (Humphrey et al. 
1996)
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Figure 75 
 
 
 
 
 
 
 
 
 
 
 
UA-GlcNAc(6S)-GlcUA-GlcNS-IdoUA1C4-GlcNAc(6S) 
1
2
1 2
3
4
A B
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Figure 76 A superimposition model of HS dp6-5. 
Two models of HS dp6-5, one in which the internal iduronate is in the 1C4 conformation 
(model A), and one in which the internal iduronate is in the 2S0 conformation (model B), 
have been superimposed to form model C.  
Superimposition alignment was carried out using the rmsd extension of the VMD 
molecular graphics program (Humphrey et al. 1996). Model representations and colours 
are as in Figures 70 and 71. 
A number of electronegative groups are numbered 1-4 
1. GlcNAc(6S), 6-O- sulphate group, 
2. GlcUA, carboxyl group, 
3. GlcNS, N-sulphate group,  
4. GlcNAc(6S), 6-O-sulphate group, 
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Figure 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N- and O-sulphate groups, carboxyl groups and acetate oxygens in Van der Waals 
representation (red); UA-GlcNAc(6S)-GlcUA-GlcNS-IdoUA1C4-GlcNAc(6S)     
N- and O-sulphate groups, carboxyl groups and acetate oxygens in Van der Waals 
representation (yellow); UA-GlcNAc(6S)-GlcUA-GlcNS-IdoUA2S0-GlcNAc(6S)     
 
1 1
2 2
3 3
44
A B
C
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16. De-2-O-sulphation analysis 
The main purpose of generating de-2-O-sulphated oligosaccharides was to examine more 
closely the role 2-O-sulphation plays in influencing conformational equilibrium. An 
unexpected finding of the NMR analysis of the de-2-O- sulphated heparin 
hexasaccharides was the resistance of their terminal uronic acid residues to de-2-O-
sulphation.  
Iduronate chemical de-2-O-sulphation (see experimental procedures) is brought about by 
a base induced intramolecular displacement by the hydroxyl oxygen attached to carbon 
position 3, of the O-sulphate group attached to carbon position 2. The result of this 
displacement is the formation of an epoxide, 2,3-epoxigulonic acid. How this epoxide 
then decomposes determines the end product of de-2-O-sulphation (Jaseja et al. 1989; 
Piani et al. 1993). On lyophilisation to dryness the epoxide decomposes to leave a de-2-
O-sulphated iduronate residue. It may be that the presence of a C4-C5 double bond within 
terminal uronate residues disrupts the efficient formation of the epoxide intermediate. 
The results presented in sections 20 and 21 show that terminal uronates are not totally 
resistant to de-2-O-sulphation with on average 14.5% of the original total number of 2-O-
sulphates removed on each treatment. It was shown that simulating multiple treatments 
by increasing the concentration of sodium hydroxide, does not increase the efficiency 
with which de-2-O-sulphation of these residues occurs. It is suggested that 7 passes of the 
procedure detailed under experimental procedures may be enough to totally remove all 
UA(2S) 2-O-sulphate groups. Four passes of the de-2-O- sulphation procedure was the 
maximum number undertaken as part of this thesis study. After 4 passes >40% of the 
UA(2S) 2-O-sulphate groups still remained in-situ. 
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16.1 Biological implications 
A great number of studies have been published in which chemically de-2-O-sulphated 
polymeric heparin have been used in functional analyses. The following are just a 
selection (Maccarana et al. 1993; Coltrini et al. 1994; Ishihara et al. 1994; Ono et al. 
1999; Chuang et al. 2000; Lundin et al. 2000; Lyon et al. 2000; Ostrovsky et al. 2002; 
Yabushita et al. 2002; Ricard-Blum et al. 2004; Robinson et al. 2005). More recently 
chemically de-sulphated polymeric HS has also been used (Robinson et al. 2006). The 
aim of many of these studies is to try and establish a minimal oligosaccharide sulphation 
requirement for ligand binding or biological activity. UA or UA(2S) residues at the non-
reducing end of an oligosaccharide are usually the result of a deliberate heparinase or 
chemical β-eliminative degradation of a longer saccharide chain. Of the twelve studies 
cited above, all produced chemically de-2-O-sulphated heparin/HS for their functional 
studies from polymeric commercial grade heparin/HS. In no study had this material been 
deliberately treated with heparanase or undergone chemical β-eliminative degradation. 
Given this, it might be expected that the de-2-O-sulphated material used may contain 
none of the de-2-O-sulphation resistant UA(2S) monosaccharides. However, Jandik et al. 
(Jandik et al. 1996) have shown that under extreme conditions of high pH (1M sodium 
hydroxide) and elevated temperature (60˚C) heparin may be degraded. Note that Jandik et 
al. specifically examined only the chemical stability of heparin, not HS. Given the strong 
structural similarity between HS and heparin it is probable that HS is also degraded under 
similar extreme conditions. Jandik et al. detected an appreciable increase in the number 
of non-reducing terminal UA(2S) residues present in a heparin sample incubated at 60˚C 
in 1M sodium hydroxide over a 10h period (Jandik et al. 1996), (as detected by a rise in 
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the absorbance of the sample at 232nm). The original animal source for most 
commercially purchased heparin/HS is bovine lung or porcine intestine (Linhardt and 
Gunay 1999). Extraction and purification of commercial grade heparin/HS from these 
tissues involves just such an exposure to high temperatures and alkaline pH for prolonged 
periods of time (Linhardt and Gunay 1999). In the light of the stability study by Jandik et 
al. it is thought likely that all commercial heparin/HS preparations may contain variable 
quantities of UA(2S) residues, the precise number of which varying between suppliers as 
a result of differing manufacturing conditions. In support of this a number of resonances 
at around 105 ppm were detected in the 13C spectra of porcine mucosal heparin samples, 
recorded separately by both Desai et al. and Guerrini et al. (Desai and Linhardt 1995; 
Guerrini et al. 2001). One of these resonances may correspond to the C4 resonance of a 
terminal UA(2S) residue (see Table 5). However, neither study assigned a UA(2S) C4 
resonance. Guerrini et al. also recorded a 1H spectrum for both porcine and bovine tissue 
extracted heparin. In these spectra a number of resonances can be seen that may 
correspond to chemical shifts for UA(2S) H1, H2 and H3 (see Table 5). This was not 
commented on by Guerrini et al. (Guerrini et al. 2001).  
A key role for terminal residues and in particular UA(2S) residues in establishing 
biological activity is suggested by the crystal structure of an FGF2:FGFR1:heparin 
complex produced by Schlessinger et al. (Schlessinger et al. 2000) (see introduction). In 
the Schlessinger crystal complex, two terminal UA(2S) residues lie at the centre of a 
negatively charged cleft that runs between the two receptor molecules (see introduction). 
In this position, the 2-O-sulphate and carboxyl groups of both UA(2S) residues may 
make extensive stabilising electrostatic contacts wth both receptor molecules. When it is 
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considered that a single HS chain may extend for up to more than 50 disaccharide units in 
length, it seems remarkable that the crystal complex of Schlessinger involves the ends of 
two different oligosaccharide molecules. Within polymeric HS/heparin, by far the 
majority of sequences do not involve any terminal units. Without the crystallographic 
evidence, a more logical FGF2:FGFR1:heparin complex might be expected not to involve 
terminal monosaccharide units at all. It may be that an FGF2:FGFR1 signalling complex, 
and possibly other biological signalling complexes, have a preference for formation 
around sequences containing a terminal monosaccharide residue such as the UA(2S). In 
further support of this it has been reported that only after its enzymatic degradation does 
polymeric HS gain the ability to activate FGF-2 mitogenicity (Kato et al. 1998). This 
may be correlated to an increase in the number of terminal oligosaccharide units around 
which active complexes may form. If this is the case the biological influence of a small 
number of unremoved 2-O-sulphate groups at the non-reducing end of oligosaccharide 
may be more exaggerated when it is assayed for biological activity. Therefore, great care 
needs to be taken in the interpretation of results from studies were it has been shown that 
de-2-O-sulphation of a saccharide does not influence its biological activity. The specific 
studies of (Ono et al. 1999; Ostrovsky et al. 2002; Robinson et al. 2006) are discussed 
further below. However, without any additional experimental evidence, solely using 
chemically de-2-O-sulphated heparin, Yabushita et al. (Yabushita et al. 2002), have 
concluded that 2-O-sulphate groups are not important for the biological activity of the 
chlamydial major outer membrane protein. In this case and in others, it may be that 
internal 2-O-sulphate groups are not important for biological activity but that terminal 
UA(2S) sulphate groups are.  
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The heparan sulphate 2-O-sulphotransferase enzyme (HS2ST) is responsible for the 2-O-
sulphation of HS during its biosynthesis (see introduction). An alternative to chemical de-
2-O-sulphation, is to produce cell lines in which this gene has been knocked out, so called 
HS2ST-/- mutant cell lines. HS extracted from these cell lines when grown in culture 
contains absolutely zero 2-O-sulphte groups (Merry et al. 2001). A number of 
contradictions now exist in the literature on the requirements for 2-O-sulphate groups 
when studied using either chemically de-2-O-sulphated heparin/HS or HS extracted from 
HS2ST-/- cell lines. Ostrovsky et al. (Ostrovsky et al. 2002) have shown that de-2-O-
sulphated heparin is still biologically active in an FGF-1, FGFR2IIIb mitogenesis assay. 
However, Merry et al. (Merry et al. 2001) have shown using HS2ST-/- HS, that 2-O-
sulphate groups are required for the FGF-1 ligand to bind HS. This contradiction may be 
explained by the presence of none reducing terminal UA(2S) monosaccharides in the de-
2-O-sulphated material prepared by Ostrovsky et al.  In support of this, Guerrini et al. 
have reported a role for none reducing terminal monosaccharides in the formation of 
FGF-1 heparin complexes (Guerrini et al. 2002).   
Ono et al. (Ono et al. 1999) have shown using de-2-O-sulphated heparin, that 2-O-
sulphate groups are not required for the biological activity of the VEGF isoform 165 
(VEGF165). In support of this Robinson et al. (Robinson et al. 2006) have shown that 
HS2ST-/- material does not have a reduced affinity for VEGF165 when compared to 
normal HS. However, Robinson et al. also reported that chemically de-2-O-sulphated HS 
was able to compete with polymeric HS for binding interactions with VEGF165. These 
two results by Robinson et al. seem contradictory as to the role of 2-O-sulphate groups in 
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VEGF165 interactions. This contradiction may be explained by the presence of UA(2S) 
monosaccharides in the de-2-O-sulphated material prepared by Robinson et al.  
The identified resistance of UA(2S) to chemical de-sulphation should cause a re-think on 
the use of chemically de-2-O-sulphated heparin/HS in ligand binding or biological 
assays. Most studies report 2-O-sulphate levels as being reduced by >80% after one 
round of sodium hydroxide treatment. However, it now cannot be ruled out that the 
critical positioning of the remaining 2-O-sulpahte groups, a majority of which will form 
UA(2S) units are not an important factor in influencing ligand binding interactions and 
ultimately biological activity when assayed for. 
 
17. The influence of sulphation pattern on iduronate and terminal uronic acid 
equilibria 
The coupling constant reviews of Ferro et al. (Ferro et al. 1990) and Ragazzi et al. 
(Ragazzi et al. 1993) were expanded to also include all data published subsequent to 1990 
and 1993 respectively. Using the theoretical coupling constants given in Table 9 for 
iduronate monosaccharides, and theoretical coupling constants taken from Ragazzi et al. 
for terminal uronic acid monosaccharides, Table 14 was constructed. Also included in 
Table 14 are populational data for HS dp6-2, -3, -5, de-2-O-HS dp6-3, Hep dp6-1 and de-
2-O-hep dp6-1. A comparison of all data shown in Table 14 reveals new insights into the 
influence of sulphation pattern on conformational equilibria.  
Structure A (see Table 14) was previously analysed as the terminal unit of an extended 
K5 polysaccharide (Ragazzi et al. 1993).  The previous conclusion, drawn by Ragazzi et 
al., that the attachment of a polysaccharide chain to the UA-GlcNAc disaccharide unit 
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(structure C in Table 14), causes a shift towards the 2H1 conformation from the 1H2 
conformation, is confirmed by analysis of HS dp6-1 and HS dp6-2 (compare HS dp6-1, -
2, and structures A to C in Table 14). The two additional disaccharide units added to UA-
GlcNAc disaccharide in HS dp6-1 and -2, in contrast to the polymeric structure analysed 
by Ragazzi et al, do not constitute a polysaccharide chain. By comparing structure C (see 
Table 14) to structure B (see Table 14) it can be concluded that rather than a 
polysaccharide chain, the addition of a single disaccharide unit is able to exert the same 
shift towards 2H1. 
Comparing structures C and E (see Table 14), N-sulphation as opposed to N-acetylation, 
to the reducing side of a terminal uronic acid has little influence on its conformational 
equilibrium. Structure D (see Table 14) is included to demonstrate the influence of 
solvent. Stucture D was analysed by Bazin et al. (Bazin et al. 1998) at 25˚C in 
deuterochloroform. All other analyses cited in Table 14 were carried out at 25˚C in 
buffered D2O. 
Comparing structures C and F, 6-O-sulphation of a linking glucosamine causes a shift 
towards 1H2, addition of an N-sulphate group as in structure G has little further influence.  
None of the coupling constant data produced since 1993, or as part of this thesis work 
contradict the previous conclusions drawn by Ragazzi et al. (Ragazzi et al. 1993), that by 
far the greatest influence towards the 1H2 conformation is 2-O-sulphation of UA itself 
(compare structures C, E, F and G to H). A shift back towards 2H1 as seen for a UA-
GlcNAc disaccharide is not seen when UA(2S)-GlcNS(6S) becomes part of a more 
extended oligosaccharide chain (compare structures H to I). 
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For non-sulphated iduronate monosaccharides, using structure J with which to make a 
comparison, neither N-sulphation of the reducing side glucosamine or 6-O-sulphation of 
the non-reducing side glucosamine is able to exert a significant conformational influence 
(compare structures J and K). It is only when the non-reducing side glucosamine becomes 
N-sulphated as in HS dp6-2 that a significant influence towards 1C4 is exerted (compare 
HS dp6-2 to structures J and K).  
Comparing HS dp6-2 and HS dp6-5 suggests that 6-O-sulphation of the non-reducing 
glucosamine exerts influence back towards 2S0, by 8%. However, comparison of HS dp6-
5 to structure L and de-2-O-sulphated HS dp6-3 suggests it may exert a slight influence 
more towards 1C4, by 3% and 2% respectively.  This highlights the issue that there is a 
limit at which coupling constants can be measured accurately, therefore little should be 
read into population differences of less than 10%. For this reason it is concluded that the 
main influence on non-sulphated iduronate conformation is N-sulphation of the non-
reducing side glucosamine. This is present in all of saccharides HS dp6-5 through to 
structure N. None of these saccharides show a significant alteration in conformational 
balance above 10% when compared to HS dp6-2. 
 
Ferro et al. (Ferro et al. 1990) concluded that 2-O-sulphation alters the balance of 
iduronate conformational equilibrium more towards 1C4.  This is indeed the case when 
comparing HS dp6-3 (76% 1C4, see Table 14) and de-2-O-sulphated HS dp6-3 (51% 1C4, 
see Table 14). However, this is not the case when comparing Hep dp6-1 (51% 1C4, see 
Table 14) and de-2-O-sulphated Hep dp6-1 (57% 1C4, see tabe 14). This suggests that 
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flanking 6-O-sulphation plays a major influence in altering IdoUA(2S) conformational 
equilibrium.  
Comparing HS dp6-2, -3, structure O and structure P (see Table 14) it is only when both 
N-sulphation and 6-O-sulphation are present at the non-reducing side glucosamine that a 
significant influence towards the 2S0 conformation is exerted, by an average of 18.6%. 
Comparing structure P to structure Q suggests that N-sulphation and 6-O-sulphation 
flanking IdoUA(2S) exert the same influence as N- and 6-O-sulphation solely occurring 
to the non-reducing side (see Table 14). A significant role is not suggested for a non-
reducing side N-sulphate group. In all saccharides Hep dp6-1 through to structure U a 
non-reducing side N-sulphate group and a flanking and/or same side 6-O-sulphate group 
are present.  
Structures S through to U also demonstrate that a 3-O-sulphate group positioned on either 
side of IdoUA(2S) is able to exert significant conformational influence towards 2S0. The 
same influence is not seen with IdoUA, compare the influence of 3-O-sulphation within 
structures S to U with that between structures M and N (see Table 14). 
 
For structures V and W the 4C1 conformation was calculated to contribute significantly to 
the conformational equilibrium of the two iduronates indicated. Iduronates within 
structures V and W occur within a synthetic oligosaccharide and it may be that the 
synthetic process used in its production has left a lasting contribution of the 4C1 
conformation (Lucas et al. 2003). 
  
 
 303 
Table 14 Conformational distributions of iduronate and terminal uronic acid 
monosaccharides within oligosaccharides characterised in this study and a number 
of previously published studies. 
Theoretical coupling constants for iduronates were taken from Table 9, and theoretical 
coupling constants for terminal uronic acids from Ragazzi et al. (Ragazzi et al. 1993)  
For iduronates, a three conformational least squares fit was performed to derive estimated 
conformer populations, for terminal uronic acids a two conformational least squares fit 
(see introduction). 
The residual value for the sum of square differences after parameters a, b and c (or a, b 
for UA) had been optimised is given as a guide to fit accuracy (see introduction). Better 
fitting population estimates having a value closer to zero. 
Where more than one residue of the type analysed exists within a sulphation sequence, 
the residue(s) analysed are indicated by arrows. 
Symbols:   
 
 ∆UA  GlcUA  IdoUA  IdoUA(2S)  GlcNAc 
 
    
 GlcNS  GlcNAc(6S)  GlcNS(6S)  GlcNS(3S,6S)   
 
 
 O-methyl  O-isopropyl  O-polysaccharide chain 
  
 
NS
S
NS
S
NA
S
NS
S
NA
R
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∆UA 1H2 2H1 J 1,2 J 2,3 J 3,4 J 4,5 Residual sum of Reference for coupling
square differences constants
HS dp6-2 27 73 6.9 6.3 3.1 - 0.22 this thesis 
HS dp6-3 31 69 6.6 6.0 3.4 - 0.03 this thesis
A 31 69 6.59 6.01 3.36 - 0.01 Ragazzi et al. (1993)
B 29 71 5.9 6.8 3.0 0.76 Hileman et al . (1997)
C 43 57 5.96 5.4 3.58 - 0.06 Ragazzi et al. (1993)
D 16 84 7.2 6.5 3 - 0.2 Bazin et al. (1998)
E 41 59 6.03 5.47 3.56 - 0.02 Ragazzi et al. (1993)
F 51 49 5.48 4.93 3.75 - 0.04 Ragazzi et al. (1993)
G 53 47 5.36 4.81 3.79 - 0.06 Ragazzi et al. (1993)
H 92 8 3.28 2.77 4.52 - 0.04 Ragazzi et al. (1993)
I 100 0 2.0 2.0 4.8 0.25 Pervin et al . (1995)
Non-sulphated IdoA 1C4 4C1 2S0 J 1,2 J 2,3 J 3,4 J 4,5
J 37 0 63 3.9 6.6 3.6 3.2 0.93 van_Boeckel et al . (1987)
K 34 1 65 3.5 6.6 4.5 3.3 0 Ojeda et al . (2002)
HS dp6-2 57 0 43 2.5 5.0 3.3 2.8 0.34 this thesis
HS dp6-5 49 0 51 2.5 5.3 4.1 3.4 0.76 this thesis
(Hz)(%)
(%) (Hz)
 
NS NANSS
NS NANSS
NA
R
NS
NA
NA
NA
S
NS
S
NS
S
S
NANA
NS NANSS
NANS NSS S
S
NA NS NA
S S
NA NA
NS NSS
S S
S
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L 52 0 48 3.3 5.4 3.6 2.4 0.25 van_Boeckel et al . (1987)
de-2-O-HS dp6-3 51 1 48 2.5 5.3 4.4 2.8 0.55 this thesis
de-2-O-Hep dp6-1 57 0 43 1.6 5.3 3.4 2.8 1.87 this thesis
M 52 0 48 2.1 5.4 4.2 2.5 0.98 Lucas et al . (2003)
N 52 0 48 3.3 5.4 3.6 2.4 0.25 Ferro et al . (1990)
Sulphated IdoA 1C4 4C1 2S0 J 1,2 J 2,3 J 3,4 J 4,5
HS dp6-2 74 0 26 1.6 4.1 3.15 2.2 0.76 this thesis
HS dp6-3 76 0 24 1.6 4.1 3.15 1.5 0.99 this thesis
O 83 0 17 1.4 3.2 2.8 2.1 0.77 van_Boeckel et al . (1987)
P 59 0 41 2.8 5.4 3.1 2.5 1.07 van_Boeckel et al . (1987)
Q 50 0 50 3 5.8 4 2.8 0.21 Ojeda et al . (2002)
Hep dp6-1 51 0 49 2.5 5.6 4.1 3.2 0.29 this thesis
R 59 0 41 2.8 5.4 3.1 2.5 1.07 van_Boeckel et al . (1987)
S 33 0 67 3.9 7.3 3.9 3.3 1.98 van_Boeckel et al . (1987)
T 26 0 74 3.5 8.3 4.2 3 2.8 Ferro et al . (1990)
(%) (Hz)
 
NS NS
NS
S
NS NS
SS
NSNSNS
S S S
NSNSNS
S S
NS NANSS
NS NANSS
NA
S
S NS
NS
S
S NS
NANS NSS S
S
NS
S
NS NS
SS
SS
S
NS
S
S NS
NSSNS
S
NSSNS
S S
NS NS NA
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U 6 0 96 5.3 9.4 4.4 4.4 5.4 van_Boeckel et al . (1987)
V 64 18 18 3.6 4.2 3.6 3.5 1.72 Lucas et al . (2003)
W 60 28 12 3.6 4.3 4.5 3.7 1.25 Lucas et al . (2003)
 
 
SNSNS
S S
NS
S
SNS NS NSS S
SNS NS NSS S
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17.1 Biological implications 
One biological implication is with regard to the conformational equilibrium of iduronate 
residues in the alternating NA/NS domains of HS (see introduction, section 8.2, page 65). 
Iduronates in the following sequence: 
             
1C4                        2S0                           1C4                             2S0 
   1          2            3             4          5         6          7           8 
-GlcNS-IdoUA-GlcNAc-IdoUA-GlcNS-IdoUA-GlcNAc-IdoUA- 
 
could be expected to be in predominantly different conformations; iduronates 2 and 6 
predominantly in the 1C4 conformation, iduronates 4 and 8 predominantly in the 2S0 
conformation, as indicated. Even with the addition of 6-O-sulphate groups to the 
glucosamines in this sequence, it can be concluded from the data presented in Table 14 
that this pattern would not be expected to alter significantly.   
NA/NS domains have been implicated in a number of ligand binding interactions (see in 
particular the discussion on endostatin in the introduction, section 12, page 77). This 
pattern of alternating iduronate conformations may be an important structural feature for 
biological activity. 
 
Another important implication is with regard to the positioning of 6-O-sulphate groups. 
Within HS S-domains, 6-O-sulphation appears to be under tight regulatory control and 
either centrally positioned or positioned at the reducing terminal (Merry et al. 1999; 
Vives et al. 1999; Goodger 2003). Centrally positioned this will have the effect of 
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influencing the conformational equilibria of both proceeding and preceeding IdoUA(2S) 
residues. For example, in the following sequence (sequence 10c (Merry et al. 1999)): 
 
  1       2           3                4            5                 6                 7                 8          9 
UA-GlcNS-IdoUA(2S)-GlcNS-IdoUA(2S)-GlcNS(6S)-IdoUA(2S)-GlcNS-IdoUA- 
  10 
GlcNAc 
  
iduronates 5 and 7 may be expected to be present at 50% 1C4, 50% 2S0, whereas iduronate 
3 will be predominantly present in the 1C4 conformation (approx 75% 1C4).  
It could be suggested that the shift in the conformational equilibria of iduronates 5 and 7, 
towards 2S0, may be important for the potential biological activity of this oligosaccharide. 
A similar shift has been shown to be important within iduronate 5 of an antithrombin III 
binding synthetic pentasaccharide (see introduction, section 14.1, page 94).  However, it 
may be that changes in the conformational equilibrium of the iduronate at 
monosaccharide position 3, towards the 1C4 conformation that are biologically relevant, 
as detailed below. 
All decasaccharides, sequenced and tested for biological activity by Goodger, are given 
in Figure 77. Also shown in Figure 77 are the predominant conformations of all 
iduronates in these sequences, as deduced from Table 14. Where no conformation 
predominates these iduronates are marked as 50/50 (50%1C4, 50%2S0). The biological 
activity of a decasaccharide almost identical in monosaccharide sequence to the one 
shown above was tested for biological activity by Goodger (Goodger 2003), 
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decasaccharide D, Figure 77. The only difference between the two saccharides being that 
Goodger was not able to establish the epimeric identity of the monosaccharide at 
sequence position 9, this may have been either IdoUA or GlcUA (see Figure 77). The 
decasaccharide assayed by Goodger was able to elicit a mitogenic response from FGF-2 
in combination with the FGFR1 IIIc receptor. A similar decasaccharide (decasaccharide 
F, Figure 77) shown below was not able to elicit a biological response with FGF-2 in the 
same assay system. 
 
Decasaccharide D, biologically active (see Figure 77) 
1       2           3                4            5                 6                 7                 8          9 
UA-GlcNS-IdoUA(2S)-GlcNS-IdoUA(2S)-GlcNS(6S)-IdoUA(2S)-GlcNS-HexUA- 
  10 
GlcNAc 
Decasaccharide F, biologically inactive (see Figure 77)  
1       2           3                4            5                 6                 7                 8          9 
UA-GlcNS-IdoUA-GlcNS-IdoUA(2S)-GlcNS(6S)-IdoUA(2S)-GlcNS-HexUA- 
  10 
GlcNAc(6S) 
 
Note that the 2-O-sulphate group at monosaccharide position 3 is absent from the 
biologically inactive decasaccharide shown above. The 6-O-sulphate group added at 
monosaccharide position 10, may or may not promote biological activity. Both inactive 
and active decasaccharides were found by Goodger that contained this terminal 6-O-
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sulphate group (Goodger 2003), see Figure 77. It could be argued that the 2-O-sulphate 
group itself, removed from monosaccharide position 3, rather than the conformation of 
the iduronate is important for biological activity. However, out of the total of 4 
biologically active decasaccharides identified by Goodger two did not contain a 2-O-
sulphate group at monosaccharide position 3, see Figure 77. These same two 
decasaccharides also had a GlcUA at monosaccharide position 3; GlcUA being stable in 
the 4C1 conformation. The possible significance of this is not clear until the sequence of 
the other two biologically active decasaccharides is examined. Both contain IdoUA(2S) 
at monosaccharide position 3 flanked by two solely N-sulphated glucosamines. 
IdoUA(2S) in such a sequence could be predicted to be at >70% 1C4 (see Table 14). It 
may be that the presence of a chair conformation (either 4C1 or 1C4) at monosaccharide 
position 3 of the decasaccharides tested by Goodger, is one of the key features that 
bestow biological activity. 
An analysis of the monosaccharide sequences shown in Figure 77 for conserved patterns 
of sulphate group positioning identifies that all active decasaccharides carry N-sulphate 
groups at all non-terminal glucosamine sugars. A conserved 2-O-sulphate group also 
occurs at monosaccharide position 5. However, these two conserved features are also 
present in the two non-biologically active decasaccharides ‘E’ and ‘F’, see Figure 77. 
This suggests other structural features contained within the active oligosaccharides may 
also be important for biological activity. In all active decasaccharides, 6-O-sulphation at 
monosaccharide positions 5 and/or 10 in combination with a predominance of either the 
1C4 or 4C1 conformation at monosaccharide position 3 also appears to be conserved. 
Given this, the question then arises as to why decasaccharide E is not biologically active. 
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6-O- sulphation at monosaccharide position 8 within decasaccharide E appears to knock 
out the biological activity of what otherwise could be assumed to be an active saccharide 
(compare biological activities of decasaccharides E and D). Yet the same 6-O-sulphation 
at monsaccharide position 8 within decasaccharide A does not inactivate this 
oligosaccharide. The influence of 6-O-sulphation at position 8 to render some 
decasaccharide sequences inactive, whilst leaving the biological activity of others intact, 
implies that there may be another as yet unknown structural feature at work within these 
oligosaccharides. Discussed in the forthcoming sections are work that was done in order 
to try and establish other structural features that may play a role in influencing the 
biological activity of the Goodger decasaccharides.  
  
 
 312 
Figure 77 The monosaccharide sequences of 4 biologically active and 2 
biologically inactive decasaccharides. 
The decasaccharide sequences shown were assayed for activity in a FGF-2, FGFR1 IIIc 
Baf cell mitogenesis assay. This Figure was adapted from a similar Figure shown in the 
PhD thesis of Goodger (Goodger 2003). Monosaccharide positions within the 
decasaccharide are numbered 1-10. Also labelled, as deduced from Table 14, are the 
dominant conformation of each iduronate monosaccharide. The conformation of each 
glucuronic acid is also labelled as 4C1 although this does not vary. For iduronates, were 
no conformation predominates this monosaccharide is labelled 50/50 (50%1C4, 50%2S0) 
Symbols codes are as in Table 14, with the addition of the symbol           to signify a 
hexuronic acid (HexUA) of an unknown epimeric identity (either IdoUA or GlcUA). 
I/G
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Figure 77 
Active with FGF-2 and FGFR1 IIIc  Inactive with FGF-2 and FGFR1 IIIc 
1     2    3     4    5     6    7    8    9     10  1      2    3    4    5     6    7     8    9     10 
NS NSS S
SS
NS NS
I/G
SS
NA NS NSS S
S
NS NS
I/G
S
NA
NS NSS
S
NS NS
I/G
S
NA NS NSS S
S
NS NS
I/G
S
NA
NS NSS SNS NS
I/G
S
NAS
NS NSS SNS NS
I/G
S
NAS
4C1 50/50 50/50
4C1 50/50 50/50
4C1 50/50 50/50
1C4 1C4 1C4
1C4 50/50 50/50
50/50 50/50 50/50
A
B
C
D
E
F
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18. Structural features in additional to sulphation pattern and iduronate 
conformation may influence biological activity 
In order to explain variations in the biological activity of the Goodger decasaccharides, 
the structures of all HS dp6 models were investigated in detail. For the purposes of this 
investigation, features such as the presence or absence of a particular sulphate group or a 
preference for iduronate in one conformation or another were dis-regarded, although they 
are undoubtably important. It was thought that any additional structural features that 
occur within these dp6 oligosaccharides may also occur within the dp10 oligosaccharides 
of Goodger. The oligosaccharides of Goodger could not be modelled and studied directly 
as NMR data does not exist for these oligosaccharides with which to support possible 
structural conclusions. 
 
19. A Comparison of HS dp6 structural models  
It was thought that the differences in biological activity may be due to differences in the 
overall three dimensional shape of an oligosaccharide, changing as monosaccharide 
sequence changes. Figure 78 was constructed in order to assess the extent of such 
structural differences within the HS dp6 structural models. As can be seen in Figure 78, 
apart from obvious variations due to a presence or lack of a particular sulphate group and 
structural variations around the reducing terminal N-acetyl group of HS dp6-3 
(previously discussed, see section 14), very little differences occur within the overall 
three dimensional shape of each oligosaccharide. This lead to the idea that molecular 
dynamic differences may exist between these oligosaccharides.  
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Figure 78 A comparison of of the molecular shape of all HS dp6 structural 
models. 
Models in which electronegative groups are shown in red contain all iduronates in the 1C4 
conformation (models A-D). Models in which electronegative groups are shown in 
yellow contain all iduronates in the 2S0 conformation (models E-H) 
Models A and E, HS dp6-2, 
Models B and F, HS dp6-3, 
Models C and G, HS dp6-5, 
Models D and H, HS dp6-5 
Model representations are as in Figures 70 and 71. 
All models were formatted using the VMD molecular graphics program (Humphrey et al. 
1996).
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Figure 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C D
E F G H
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20. Molecular dynamic studies 
The construction of static models based on NMR data represents an average structure. 
This static structure does not allow for the fact that for a proportion of its time in solution, 
a molecule may exist or ‘sample’ a number of alternate conformations. As detailed in the 
results section, most dynamically modelled glycosidic linkage geometries remained close 
to their starting values or moved to ‘sample’ values that were also suggested by the 
structural refinement process. However, in one case glycosidic linkage geometries 
sampled an additional area of their potential energy surface that had previously been 
ruled out by the structural refinement process, see panel C2, Figure 64 (note, the 
structural refinement process only took into consideration IdoUA(2S) H1 NOE cross-
peaks). The results from this panel show that when using charge set 2, the IdoUA(2S)–
GlcNS internal disaccharide unit of HS dp-2, moves away from its initial geometry of 
Φ= 40, Ψ= 20 to sample an an area of its potential energy surface around the torsion 
angle Φ= -10, Ψ= -20. For the purposes of this discussion the initial Φ= 40, Ψ= 20 
geometry is termed geometry ‘a’ and the Φ= -10, Ψ= -20 geometry ‘b’. If a molecular 
model is constructed for HS dp6-2 with the internal IdoUA(2S) –GlcNS linkage in 
geometry ‘b’ (Φ= -10, Ψ= -20),  all that seems to occur on a first analysis is a minor re-
positioning of the carboxyl group at the non-reducing terminal (arrowed in Figure 79). If 
however, this hexasaccharide is extended in length, to a dodecasaccharide similar to that 
as modelled by Mulloy et al. (Mulloy et al. 1993), the supposed non trivial nature of this 
change becomes apparent. See Figure 80. A minor change in the local conformation of 
the oligosaccharide around the IdoUA(2S)-GlcNS linkage, arrowed in Figure 80, causes a 
small deviation or kink in the oligosaccharide chain away from its usual conformation. 
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As the chain increases in length away from the glycosidic linkage at which the kink 
occurs, its effects become more and more dramatic. Raman et al. have previously 
reported on the existence of such a chain kink within the trisaccharide sequence –
GlcNS(6S)-IdoUA(2S)-GlcNS(6S)- present within all x-ray crystallography determined 
heparin-FGF1 and FGF-2 complexes. Given its occurrence in all complexes studied, 
Raman et al. speculated that this kink may be an essential feature of heparin/HS-FGF 
interactions (Raman et al. 2003). Raman et al. also concluded that after the occurrence of 
a kink the chain is restored to its original helical conformation, Figure 80 generally 
supports this conclusion. However, if no compensatory adjustments are made in the 
geometry of subsequent glycosidic linkages, the original course of this helical structure 
through three dimensional space, is altered by the occurrence of a chain kink. This has 
important consequences for the relative positioning of disaccharide units at opposite ends 
of an oligosaccharide chain. This may be an important piece of structural/functional 
information previously overlooked by Raman et al.  
Experimental proof for the existence of geometry b is present in the NOESY spectra of 
HS dp6-2 and HS dp6-3. If geometry ‘b’ were to exist in solution IdoUA(2S) H2-GlcNS 
H6 and/or H4 NOE cross-peak(s) should be clearly detectable. On examination of the HS 
dp6-2 and HS dp6-3 NOESY spectra just such NOE cross-peaks are detected, see Figure 
81. It was thought that similar kinks may occur within the decasaccharide structures of 
Goodger.
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Figure 79 
 
 
 
 
 
 
 
 
 
 
Figure 79 A second superimposition model of HS dp6-2. 
Two models of HS dp6-2 are superimposed. In both models all internal iduronates are in 
the 1C4 conformation. In one model (Van der Waals representations in red) the internal in 
IdoUA(2S) –GlcNS linkage is in a Φ= 40, Ψ= 20 geometry. In the second model (Van 
der Waals representations in yellow) the internal in IdoUA(2S) –GlcNS linkage is in a 
Φ= -10, Ψ= -20 geometry (geometry b).  
Superimposition alignment was carried out using the rmsd extension of the VMD 
molecular graphics program (Humphrey et al. 1996).  
  320 
Figure 80 An extended dodecasaccharide superimposition model of HS dp6-2. 
The terminal UA unit of the two dp6-2 models superimposed in Figure 79 were removed 
and the oligosaccharides extended by the addition of the sequence -IdoUA(2S)1C4-
GlcNS-IdoUA(2S)1C4-GlcNS-IdoUA(2S)1C4-GlcNS-UA2H1. All geometries for these 
linkages were taken from Table 11 and as such are consistent with NOE data. The two 
models were then superimposed, with structural alignment based on the first five residues 
of the original hexasaccharide models. In one model (Van der Waals representations in 
red, model A, whole molecule in red, model B) the internal IdoUA(2S) –GlcNS linkage 
arrowed in model B is in a Φ= 40, Ψ= 20 geometry. In the second model (Van der Waals 
representations in yellow, model A, whole molecule in yellow, model B) the internal  
IdoUA(2S) –GlcNS linkage is in a Φ= -10, Ψ= -20 geometry.  
Superimposition alignment was carried out using the rmsd extension of the VMD 
molecular graphics program (Humphrey et al. 1996). 
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Figure 80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
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Figure 81 Enalarged sections from the NOESY spectra (500ms mixing time) of 
HS dp6-2 and HS dp6-3. 
In both spectra trans-glycosidic NOE cross-peaks can be detected from both the anomeric 
proton of the IdoUA(2S) residue and proton H2 of this same ring system. For HS dp6-2 
(panel A) a H2 cross-peak is only observed to a H6 proton of the proceeding 
glucosamine. For HS dp6-3 (panel B) cross-peaks are observed between the H2 proton a 
H6 proton and a H4 proton of the same proceeding glucosamine. 
The colours and annotation scheme are as in results sections 10-11   
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Figure 81 
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21. Molecular dynamic evidence that internal 6-O-suphation may cause an increased 
sampling rate of geometry ‘b’ 
The molecular dynamic data was studied to try and establish structural features which may 
induce kink formation. Here after when oligosaccharides are refered to as containing a kink, it 
should be understood that this kink is a dynamic feature of the chain and that oligosaccharides 
may move in and out of this kinked conformation with differing frequencies in solution. 
Given that all heparin-FGF complexes contain a chain kink (Raman et al. 2003) (discussed in 
section 20), it may be the ability of certain structural features to increase the conformational 
lifetime of the kinked conformation over the conformational lifetime of the straight 
conformation that may be biologically relavant.   
During dynamic simulations on HS dp6-6 the terminal IdoUA–GlcNAc linkage appeared to 
sample two glycosidic linkage geometries that would lead to a kinked oligosaccharide chain, 
geometry ‘b’ (Φ = -10˚, Ψ = -20˚) and an additional geometry termed geometry ‘c’ Φ = -45˚, 
Ψ = -45˚ (see Figure 67, panel E). A similarly modelled IdoUA–GlcNAc within HS dp6-2 
(see Figure. 64 panel E1) made no such conformational transitions. The IdoUA-GlcNAc 
disaccharide forms part of a different terminal trisaccharide sequence in both HS dp6-6 and 
HS dp6-2, as shown below: 
  
-GlcNS-IdoUA-GlcNAc  HS dp6-2 
-GlcNS(6S)-IdoUA-GlcNAc  HS dp6-6 
 
All molecular dynamic calculations carried out as part of this thesis work were deliberately set 
up so that each monosaccharide was only influenced by charges from its immediate neighbour 
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monosaccharides. This was done by using an electrostatic cut-off value of 6Å (see 
experimental procedures). Given this, the 6-O-sulphate group present in the trisaccharide 
sequence of HS dp6-6 is a strong candidate for altering the IdoUA-GlcNAc dynamics within 
HS dp6-6 when compared to HS dp6-2. The influence of this internal 6-O-sulphate group may 
indeed be direct, by through space interactions with atoms involved in the –IdoUA-GlcNAc 
linkage. However, given that all dynamics calculations were carried out with explicit water 
molecules, it may also interrupt local hydrogen bonding networks between the water 
molecules and the –IdoUA-GlcNAc disaccharide unit that may stabilise the Φ = 40˚, Ψ = -40˚ 
conformation. 
Unfortunately, due to the low amount of sample material available for HS dp6-6, it is not 
possible to verify if the alternate geometries exist experimentally. An IdoUA H2-GlcNAc H6 
and/or H4 NOE should be clearly detectable for these geometries. 
  
22. PAGE evidence for a link between internal 6-O-sulphation and a chain kink 
Vives et al. have previously purified HS dp6-6 and HS dp6-2 from an alternate source of 
porcine HS (Vives et al. 2001). The migration position on PAGE anlysis for both of these 
oligosaccharides was found to be significantly different, HS dp6-6 migrating at a slower rate 
through the gel than HS dp6-2. Similar results were obtained as part of this thesis work, see 
results, Figure 24. 
The sequences of HS dp6-6 and HS dp6-2 are given below  
                         1        2            3               4                   5        6 
HS dp6-6  UA-GlcNS-IdoUA(2S)-GlcNS(6S)-IdoUA-GlcNAc  
HS dp6-2 UA-GlcNS-IdoUA(2S)-GlcNS-IdoUA-GlcNAc 
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Ignoring the influence of molecular shape in the general theory of PAGE electrophoresis 
given in a standard biochemistry text such as (Mathews and van_Holde 1990), HS 
oligosaccharides with more negative charge density migrate through the gel at a faster rate 
than oligosaccharides with less charge density, the more negatively charged molecule 
experiencing a stronger pull towards the anode electrode. In this modified theory, it is a puzzle 
as to why HS dp6-6 migrates at a slower rate than HS dp6-2, HS dp6-6 does after all have a 
higher negative charge density. Bringing back in the influence of molecular shape on PAGE 
theory, asymmetric molecules encounter a higher degree of frictional resistance as they move 
through the gel than symmetrical molecules (Mathews and van_Holde 1990). The molecular 
dynamic data suggest that for a proportion of its conformational lifetime HS dp6-6 may 
contain a kink. This kink may then hinder its progress through the pores of the polyacrylamide 
gel. The NMR and computational data suggest HS dp6-2 may also kink but at a significantly 
reduced rate to that of the HS dp6-6 molecule. As a consequence of this, HS dp6-2 is able to 
migrate at a faster rate through the pores in the polyacrylamide gel. Interestingly, if ‘kink-rate’ 
can be related to PAGE migration distance in this way it can be predicted from Figure 24 that 
HS dp6-5 kinks at a much slower rate than either of HS dp6-2 or HS dp6-6 (compare Figure 
24 migration distances for each oligosaccharide). This implies that the –GlcUA-GlcNS- 
disaccharide unit centrally positioned within HS dp6-5 may act as a stabilising feature against 
chain kinks induced by 6-O-sulphation.  
 
 
 
  327 
23. Implication of the link between chain kinks and 6-O-sulphation for the biological 
activity of the Goodger decasaccharides 
From Figure 77, the fact that oligosaccharide ‘C’ is biologically active suggests an increased 
‘kink-rate’ in free solution is not an essential feature for biological activity. Oligosaccharide 
‘C’ does not contain an internal 6-O-sulphate group. With regard to the observation made by 
Raman et al., that all heparin oligosaccharides in complex with FGF molecules contain a 
chain kink, the fact that oligosaccharide ‘C’ is biologically active suggests chain kinks, 
additional to their occurence in free solution, may also be induced on protein binding. The 
question then is ‘could a raised ‘kink-rate’ in the wrong part of an oligosaccharide chain prior 
to protein binding knock out its biological activity?’ The prime target for such a kink to occur 
is between monosaccharides 9 and 10 of all the Goodger decasaccharides. The 6-O-sulphation 
of monosaccharide 8 as in the inactive oligosaccharide ‘E’ may be expected to increase the 
rate at which a kink may occur in free solution between these two residues. However, 6-O-
sulphation also occurs at monosaccharide 8 within decasaccharide ‘A’ but yet this 
oligosaccharide is still biologically active. Two reasons are suggested for this 
1) The reducing terminal unit (unit 10) of decasaccharide ‘A’ carries a 6-O-sulphate group. 
In free solution, when this unit is 6-O-sulphated, it may be that 6-O-sulphation of 
monosaccharide 8 is able to exert less of a conformational influence on the dynamics of 
the glycosidic bond between monosaccharides 9 and 10. Further molecular dynamic 
studies will be able to ascertain if this is the case. 
2) The epimeric identity of monosaccharide 9 has not been identified. It may be that this is a 
glucuronic acid residue. Implied evidence from the migration position of HS dp6-5 on 
PAGE suggests a –GlcUA-GlcNAc(6S) terminal disaccharide may display different 
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dynamic properties to a terminal –IdoUA-GlcNAc(6S) disaccharide. Again further 
molecular dynamic studies will ascertain if this is the case. 
 
24. Experimental evidence for kinked heparin oligosaccharides in free solution? 
Given the experimental evidence for the existence of kinks in free solution within HS 
oligosaccharides, the NOESY spectra of all heparin hexasaccharides produced as part of this 
thesis work were also examined for similar experimental evidence. Due to severe spectral 
overlap in the area of the spectrum where IdoUA(2S)-H2 protons and GlcNS(6S)-H6/H4 
protons occur, it was not possible to establish if geometry ‘b’ exists within the heparin 
hexasaccharides produced as part of this study. Spectral overlap can be expected to be a 
problem for all heparin or heparin derived oligosaccharides where glucosamines are 6-O-
sulphated. 6-O-sulphation shifts all glucosamine H6 and H5 proton resonances downfield to 
an area of the spectrum where the H2 resonance of IdoUA(2S) occurs. Perhaps for this reason 
experimental evidence for the existence of geometry ‘b’ and kinked heparin chains in free  
solution has never previously been shown. Trans-glycosidic NOEs where not analysed in the 
de-6-O-sulphated heparin study of Mulloy et al. (Mulloy et al. 1994). If they were this study 
may have picked up the existence of IdoUA(2S) H2- GlcNS H6/H4 cross peaks before they 
were detected within HS dp6-2 and -3 as part of this thesis work. 
 
25. Overall summary 
It is felt that the original aims of this study have been met and surpassed. It has been 
demonstrated that the considerable experimental difficulties encountered when working with 
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incredibly heterogeneous HS samples can be overcome and valuable structural data gathered 
for authentic HS derived oligosaccharides, in addition to heparin equivalents.  
The NMR and molecular modelling data, has enabled significant new insights to be gained 
into the role sulphation patterns may play in influencing oligosaccharide conformation and 
more importantly function. For the first time a role has also been suggested for N-acetyl 
groups in HS-protein electrostatic interactions. N-acetyl groups are normally overlooked as a 
contributor to electrostatic interactions due to their low electronegativity in comparison to 
sulphate and carboxyl groups. The modelling studies undertaken as part of this study suggest 
they may be overlooked in error and appropriately positioned N-acetyl groups may also be an 
important contributor to HS-protein electrostatic interactions and biological activity.  
It has been known for some time that the balance of terminal uronic acid and internal 
iduronate equilibria are influenced by the sulphation state of their neighbouring N-
glucosamine residues. However, a number of significant gaps were present in the literature 
concerning the analysis of iduronate residues in sequences such as –GlcNS-IdoUA-GlcNS- 
and –GlcNS-IdoUA-GlcNS(6S)- and –GlcNS-IdoUA(2S)-GlcNS-. These are common 
saccharide sequences found within HS but not heparin. Iduronate conformational information 
gathered as part of this thesis work has now filled these gaps. Using Table 14 it is now 
possible for the first time to predict the probable conformational balance of iduronate residues 
within almost all sulphation sequences in which they may occur. Using a library of 
decasaccharide structures tested for biological activity (Goodger 2003), it has been shown 
how this knowledge can lead to new insights into iduronate conformation and oligosaccharide 
functional relationships. 
  330 
Molecular dynamic modelling studies have revealed that glycosidic linkages may not be fixed 
permanently in geometries favoured as a result of the exo-anomeric effect. Static molecular 
modelling has shown that when alternate geometries occur the effect is to ‘kink’ the chain 
away from its usual 3-dimensional topology. NOE data supports the existence of just such a 
kink within HS dp6-2 and HS dp6-3. Molecular dynamic studies suggest that the rate at which 
kink formation occurs at a particular glycosidic bond can be related to the presence of a 
nearby 6-O-sulphate group. Finally and most importantly, it has been suggested how the 
existence of such kinks may be tolerated in certain parts of an oligosaccharide chain and not 
in others if an oligosaccharide is to possess biological activity. 
  
 
APPENDIX I 
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Figure 82 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 82 Two-dimensional 500 mHz 1H-NMR COSY spectrum, HS dp6-2.
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Figure 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 83 Two-dimensional 500 mHz 1H-NMR COSY spectrum, HS dp6-3. 
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Figure 84 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 84 Two-dimensional 500 mHz 1H-NMR TOCSY spectrum, HS dp6-2. Mixing time 120ms. 
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Figure 85  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 85 Two-dimensional 500 mHz 1H-NMR TOCSY spectrum, HS dp6-3. Mixing time 120ms. 
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Figure 86 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 86 Two-dimensional 500 mHz 1H-NMR NOESY spectrum, HS dp6-2. Mixing time 500ms. 
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Figure 87 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 87 Two-dimensional 500 mHz 1H-NMR NOESY spectrum, HS dp6-3. Mixing time 500ms. 
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Figure 88  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 88 Two-dimensional 500 mHz 1H-NMR COSY spectrum, HS dp6-5.
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Figure 89  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 89 Two-dimensional 500 mHz 1H-NMR COSY spectrum, HS dp6-6. 
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Figure 90  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 90 Two-dimensional 500 mHz 1H-NMR TOCSY spectrum, HS dp6-5. Mixing time 80ms 
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Figure 91  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 91 Two-dimensional 500 mHz 1H-NMR TOCSY spectrum, HS dp6-6. Mixing time 80ms 
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Figure 92  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 92 Two-dimensional 500 mHz 1H-NMR NOESY spectrum, HS dp6-5. Mixing time 500ms 
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Figure 93  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 93 Two-dimensional 500 mHz 1H-NMR NOESY spectrum, HS dp6-6. Mixing time 500ms 
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Figure 94 Two-dimensional 500 mHz 1H-NMR COSY spectrum, hep 6-1. 
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Figure 95 Two-dimensional 500 mHz 1H-NMR COSY spectrum,  hep 6-2. 
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Figure 96 Two-dimensional 500 mHz 1H-NMR TOCSY spectrum,  hep 6-1. Mixing time 120ms  
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Figure 97 Two-dimensional 500 mHz 1H-NMR TOCSY spectrum,  hep 6-2. Mixing time 120ms  
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Figure 98 Two-dimensional 500 mHz 1H-NMR NOESY spectrum,  hep 6-1. Mixing time 500ms  
3.03.54.04.55.05.56.0
6.0
ppm
3.0
3.5
4.0
4.5
5.0
5.5
p
p
m
3 . 0 03 . 5 04 . 0 04 . 5 05 . 0 05 . 5 06 . 0 0
3 . 0 0
3 . 5 0
4 . 0 0
4 . 5 0
5 . 0 0
5 . 5 0
6 . 0 0
  
 
 
 
 
 348 
Figure 99  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 99 Two-dimensional 500 mHz 1H-NMR NOESY spectrum,  hep 6-2. Mixing time 500ms 
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Figure 100 Two-dimensional 500 mHz 1H-NMR COSY spectrum, HS 6-3 after chemical de-2-O-sulphation.
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Figure 101 Two-dimensional 500 mHz 1H-NMR COSY spectrum, hep 6-1 after chemical de-2-O-sulphation. 
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Figure 102  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 102 Two-dimensional 500 mHz 1H-NMR COSY spectrum, hep 6-2 after undergoing two rounds of the chemical de-
2-O-sulphation procedure
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Figure 103 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 103 Two-dimensional 500 mHz HSQC  spectrum, HS dp6-2. The vertical 1D spectrum was recorded using a DEPT-135 
pulse sequence.
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Figure 104 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 104 Two-dimensional 500 mHz HSQC  spectrum, HS dp6-3. The vertical 1D spectrum was recorded using a DEPT-135 
pulse sequence.
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Figure 105 Two-dimensional 500 mHz HSQC  spectrum, hep dp6-1. The vertical 1D spectrum was recorded using a DEPT-135 
pulse sequence. 
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Figure 106 Two-dimensional 500 mHz HSQC  spectrum, hep dp6-2. The vertical 1D spectrum was recorded using a DEPT-135 
pulse sequence
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